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ABSTRACT 
 
Self-Reported Physician Prescribing Behavior and Factors Related to 
Antidepressant Prescribing to Children and Adolescents with Major Depressive 
Disorder  
 
Andrea R. Pfalzgraf, MPH 
 
     Major depressive disorder is a serious public health problem and impacts 
approximately 2% of children and 4-8% of the adolescents in the United States (Birmaher 
et al., 1996).  There are risks associated with untreated major depressive disorder and no 
sound epidemiological basis for treating children and adolescents with this disorder 
(Brent, 2005).  The purpose of this study was to examine physician treatment preferences   
for children and adolescents with major depressive disorder and to examine the factors 
which impact these choices.      
     The study was conducted in two phases.  Phase I involved identifying pediatricians 
who treat child and adolescents for major depressive disorder and who were willing to 
participate in the larger Phase II survey, regarding specific treatment practices.    
Survey methodology was utilized in both phases and a national random sample of 
pediatricians (n= 2,000) and child psychiatrists (n= 2,250) was employed.   
     Approximately 40.00% of the pediatricians who returned surveys indicated they treat 
children and/or adolescents.  Of those 163 pediatricians who treat children and/or 
adolescents, only 67.48% (n=110) were willing to participate in the Phase II survey. 
Phase II of this study determined the majority of the child psychiatrists indicated they 
utilize a combination of antidepressants and counseling to treat children (52.19%) and 
adolescents (76.95%) with major depressive disorder.  A preponderance of pediatricians   
also use a combination of antidepressants and counseling to treat children (63.46%) and 
adolescents (87.72%) with major depressive disorder.  In the event physicians utilize an 
antidepressant medication for the first-line of treatment for children or adolescents, they 
indicated they most commonly prescribe medication was either Prozac® or Zoloft®. 
     It was found that child psychiatrists and pediatricians monitor both children and 
adolescents significantly less (p=0.000) than the U.S. FDA recommendations during the 
first and second months of antidepressant therapy.  During month three, pediatricians still 
monitor children and adolescents significantly less (p=0.000) than the U.S. FDA 
recommendations.  However, the frequency with which child psychiatrists monitor 
children (p=0.098) and adolescents (p=0.101), who are on antidepressant treatment, 
during the third month of treatment, does not differ significantly from the U.S. FDA 
recommendations  
     It was found the type of physician, age of the physician, and geographic region in 
which the physician practiced was associated with prescribing antidepressant medication 
for a child with major depressive disorder.  Exploratory factor analysis revealed four 
underlying factors; socio-economic status of patient, disease severity, medication cost, 
and drug profile.  Based on this analysis, it was concluded that these four factors 
influence child psychiatrists’ decision of whether or not to prescribe antidepressant 
medication to a child or adolescent who had been newly diagnosed with major depressive 
disorder.   
     In the absence of empirical research to guide the selection of treatment of children and 
adolescents with major depressive disorder this study determined physicians prefer to 
treat children and/or adolescents with a combination of antidepressants and counseling.  
Physicians reported an adequate course of treatment to help prevent relapse of depressive 
symptoms.  However, physicians need to increase the amount of monitoring to be in line 
with U.S. FDA monitoring recommendations.  Limitations to the study are those inherent 
with any research utilizing survey methodology.  The rationales behind physician 
preferences for treatment and monitoring choices for children and adolescents with major 
depressive disorder were not studied and are subject to future research.  Further 
investigation is also warranted to better understand the associations between physician 
characteristics (specialty, age, and geographic location) and the treatment prescribed.  
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 1 
CHAPTER ONE: INTRODUCTION 
     Chapter one provides an introduction for this dissertation.  The statement of the research 
problem and the specific research objectives follow.  The chapter concludes with a discussion of 
the significance and limitations of the study.   
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     Major depressive disorder in children and adolescents is a serious public health problem in 
the United States (U.S.).  Studies indicate that between ten and 15 percent (%) of all children and 
adolescents in the U.S. show at least some symptoms of depression (United States Department of 
Health and Human Services-SAMHSA, 2004).  Major depressive disorder in children under the 
age of six years is rare, but does occur (American Academy of Child and Adolescent Psychiatry, 
2007; National Alliance for the Mentally Ill, 2004).  However, as age increases so does the 
prevalence of major depressive disorder.  Approximately, two percent of all children between the 
ages of six and 12 years have been diagnosed with major depressive disorder, while between four 
and 8.3% of adolescents (13-18 years) in the U.S. are affected by major depressive disorder 
(Birmaher, Ryan, & Williamson, 1996; National Alliance for the Mentally Ill, 2004).  Before 
children reach puberty, the rates of depression among males and females indicate that they are 
equally impacted by the disorder (American Academy of Child and Adolescent Psychiatry, 2007; 
Costello, Mustillo, Erkanli, Keeler, & Angold, 2003).  Once an individual reaches adolescence, 
females are twice as likely as males to have major depressive disorder (American Academy of 
Child and Adolescent Psychiatry, 2007; Costello et al., 2003).  It is estimated that 14-25% of 
children and adolescents will experience at least one episode of major depressive disorder before 
adulthood (Lewinsohn, Rohde, & Seeley, 1998; Ryan, 2005).        
     Globally, depression is among the leading cause of disability (World Health Organization, 
2007).  Although the cost in children and adolescents is unknown, the economic cost of 
depression in adults is large (Haby, Tonge, Littlefield, Carter, & Vos, 2004; Lynch & Clarke, 
2006; World Health Organization, 2007).  Researchers calculated the economic burden of 
depression in the U.S. in 2000 to be $83.1 billion (Greenberg et al., 2003).  This amount included 
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$26.1 billion in direct medical costs and $51.5 billion in associated workplace costs (Greenberg 
et al., 2003).   
     Major depressive disorder is diagnosed in both adults and youth by utilizing the criteria (See 
Table 2.1) set forth by the American Psychiatric Association’s Diagnostic and Statistical Manual 
of Mental Disorders (DSM).  A diagnosis of major depressive disorder is made if the patient has 
at least five of the nine symptoms specified in the DSM, for a period of at least two weeks 
(American Psychiatric Association, 2000).   
     There are risks associated with untreated major depressive disorder.  Studies indicate that 
major depressive disorder in children and adolescents tends to be a chronic and recurring 
disorder, which may persist into adulthood (Costello et al., 2002; Emslie et al., 1997; Lewinsohn, 
Rohde, Klein, & Seeley, 1999).  Additionally, children and adolescents with major depressive 
disorder have a greater risk for drug abuse, difficulties in school, impaired functioning, and even 
suicide (Lewinsohn et al., 1999; Weissman et al., 1999).  Given that there are serious 
consequences associated with major depressive disorder, treatment of children and adolescents 
with this disorder becomes crucial.     
Statement of the Problem   
     Unfortunately, for physicians the optimal treatment for children and adolescents who have 
major depressive disorder is not a clear decision.  There is no sound epidemiological basis for 
choosing antidepressant treatment in children and adolescents with major depressive disorder 
(Brent, 2005).  Even the most recently updated Practice Parameters published by the American 
Academy of Child and Adolescent Psychiatry are intended to provide physicians with some 
guidelines for their treatment decisions (American Academy of Child and Adolescent Psychiatry, 
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2007).  These Practice Parameters are not meant to serve as or define the standard of care for 
children and adolescents with major depressive disorder (American Academy of Child and 
Adolescent Psychiatry, 2007).     Only in the last several decades has major depressive disorder 
in children and adolescents been recognized as a problem in the scientific community (Costello 
et al., 2002).  Thus, the scientific literature demonstrating efficacy of antidepressant treatment in 
children and adolescents with major depressive disorder is limited and physicians have a limited 
number of positive controlled trials upon which to base antidepressant treatment (Ryan, 2005).  
Currently, only one antidepressant, Prozac®, is approved by the U.S. Food and Drug 
Administration (FDA) to treat major depressive disorder in children and adolescents, but much, 
off-label use of other antidepressants occurs (Brent, 2005).  Furthermore, all antidepressant 
treatments, even those demonstrating efficacy, have been the subject of debate because of a U.S. 
FDA Public Health Advisory (U.S. FDA, 2004b).    
     On October 15, 2004 the U.S. FDA directed manufacturers of antidepressants to revise the 
labels of these medications (U.S. FDA, 2004b).  It was recommended that a black-box warning 
indicating that the use of antidepressant medications increased the risk of suicidality (suicidal 
thinking and suicidal behavior) in children and adolescent patients (U.S. FDA, 2004b).  In 
addition to the warning, the U.S. FDA has suggested certain monitoring should accompany 
antidepressant treatment (U.S. FDA, 2005).  Ideally, a child or adolescent receiving 
antidepressant treatment should be seen by the physician one time per week for the first four 
weeks of treatment (U.S. FDA, 2005).  During the second and third months of treatment, the 
patient should be seen biweekly and at week 12, respectively (U.S. FDA, 2005). 
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     However, scientific evidence is not the only factor that impacts physicians’ antidepressant 
prescribing decisions to children and adolescents with major depressive disorder.  Other factors 
impacting physicians’ prescribing decisions include, patient-related (e.g., patient’s age), 
physician-related (e.g., physician’s specialty), marketing-related (e.g., advertisements), and drug-
related (e.g., drug cost) factors (Benson, 1983; Cates, 2001; Eisenberg, 1979).       
        The majority of the scientific literature which examines prescribing patterns of medication 
to children and adolescents encompass all psychotropic medications (Elfron, 2003; Goodwin, 
Gould, Blanco, & Olfson, 2001; Haapasalo-Pesu, Erkolahti, Saarijarvi, & Aalberg, 2004; 
Harpaz-Rotem & Rosenheck, 2006; Hugtenburg, Heerdink, & Tso, 2005; Hong & Shepherd, 
1996; Jensen et al., 1999; Kaplan & Busner, 1997; Lekhwani, Nair, Nikhinson, & Ambrosini, 
2004; Najjar et al., 2004; Olfson, Gameroff, Marcus, & Waslick, 2003; Rushton & Whitmire, 
2001; Safer, 1997; Zito et al., 2000; Zito et al., 2003), all mental illness diagnoses (Elfron, 2003; 
Goodwin et al., 2001; Haapasalo-Pesu et al., 2004; Harpaz-Rotem & Rosenheck, 2006; 
Hugtenburg et al., 2005; Hong & Shepherd, 1996; Jensen et al., 1999; Kaplan & Busner, 1997; 
Lekhwani et al., 2004; Najjar et al., 2004; Rushton & Whitmire, 2001; Safer, 1997; Zito et al., 
2000; Zito et al., 2003), and examine prescribing trends over time (Goodwin et al., 2001; 
Haapasalo-Pesu et al., 2004; Hong & Shepherd, 1996; Lekhwani et al., 2004; Najjar et al., 2004; 
Olfson et al., 2003; Rushton & Whitmire, 2001; Safer, 1997; Zito et al., 2000; Zito et al., 2003).  
These studies have limited generalizability because of geographic limitations (Elfron, 2003; 
Haapasalo-Pesu et al., 2004; Hugtenburg et al., 2005; Kaplan & Busner, 1997; Lekhwani et al., 
2004; Najjar et al., 2004; Rushton & Whitmire, 2001; Safer, 1997).  For example, the Rushton & 
Whitmire (2001) study was limited to the state of North Carolina.  Several other studies are not 
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generalizable to the U. S. because they examine prescribing trends in European countries or 
Australia (Elfron, 2003; Haapasalo-Pesu et al., 2004; Hugtenburg et al., 2005; Kaplan & Busner, 
1997).   
     Fewer studies focus only on antidepressant prescribing to children and adolescents (Bramble, 
1995; Fegert, Kolch, Zito, Glaeske, & Janhsen, 2006; Kurian et al., 2007; Murray, deVries, & 
Wong, 2004; Murray, Thompson, Santosh, & Wong, 2005; Nemeroff et al., 2007; Rushton, 
Clark, & Freed, 2000; Vitiello, Zuvekas, & Norquist, 2006; Zito et al., 2002).  These studies do 
limit their analysis to only antidepressant medications but no studies were located that limited the 
patient diagnosis to major depressive disorder.  The majority of the scientific literature, which 
examines the prescribing of antidepressants to children and adolescents, has utilized large 
databases.  The exception being three studies, Bhatia et al., 2008, Bramble, 1995, and Rushton, 
Clark, & Freed, 2000, which used surveys to obtain prescribing information directly from 
physicians who prescribe antidepressants to children and adolescents.  Thus, most of these 
studies capture information about antidepressant utilization, and not data regarding the decision-
making process.  A few studies examined antidepressant use in relation to the demographic 
characteristics of patients (Fegert et al., 2006; Rushton et al., 2000; Vitiello et al., 2006; Zito et 
al., 2002).  No studies were located which examined predictors of antidepressant prescribing in 
the U.S. after the 2004 FDA warning, however a few studies did examine the impact of the 2004 
warnings on the number of prescriptions for antidepressants to children and adolescents (Bhatia 
et al., 2008;  Kurian et al., 2007; Nemeroff et al., 2007).  
     In the absence of empirical research to guide the selection of antidepressant treatment 
additional research needs to be conducted to examine:  1) what physicians consider to be the 
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most appropriate antidepressant treatment, 2)  physicians’ recommended course of treatment, and 
3) the factors which impact physicians’ decisions to treat major depressive disorder in children 
and adolescents with antidepressants.  Thus, the purpose of this study is designed to examine 
physician antidepressant choices for children and adolescents with major depressive disorder and 
to examine the factors which impact these choices.        
Study Objectives 
     The study will be conducted in two phases.  Phase I will consist of a national survey to 
determine the proportion of pediatricians who treat children and adolescents with major 
depressive disorder, in the U.S.  These physicians will also be asked to participate in phase II of 
this study.  The specific objectives of phase I are as follows:   
Phase I Objectives: 
Objective 1:  To determine the proportion of pediatricians who treat children and adolescents 
with major depressive disorder. 
 
Objective 2:  To determine the proportion of pediatricians who refer children and adolescents 
with major depressive disorder.  
     
Objective 3:   To determine the health care provider to whom pediatricians refer a child or 
adolescent with major depressive disorder. 
    
Objective 4:  To determine geographic differences in pediatricians’ willingness to treat versus 
referral of children and/or adolescents with major depressive disorder.    
 
Null Hypothesis 4.0:  There is no difference in the geographic locations of pediatricians who 
treat versus refer children and/or adolescents for major depressive disorder.   
         
 
     Phase II of this study will survey the pediatricians identified in phase I plus a random sample 
of child psychiatrists.  This phase is designed to ascertain information about physicians’ 
treatment and prescribing patterns of antidepressants to both newly diagnosed children (five 
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through 12 years of age) and adolescents (13 through 18 years of age) with major depressive 
disorder.  The specific objectives address each age category separately.    
 Phase II Objectives:  
          Objectives 5 through 13 focus on the treatment and prescribing patterns of children (five 
through 12 years of age) with major depressive disorder.   
 
Objective 5:  To determine the demographic characteristics of physicians who treat newly 
diagnosed children with major depressive disorder. 
 
Objective 6:  To determine physicians’ first line of treatment for newly diagnosed children with 
major depressive disorder by: a) type of treatment, b) drug category, and c) specific 
antidepressant prescribed. 
 
Objective 7:  To determine physicians’ second and third lines of treatment for newly diagnosed 
children with major depressive disorder by:  a) drug category, and b) specific  antidepressant 
prescribed.  
 
Objective 8: To determine the difference in first, second, and third lines of antidepressant 
treatment prescribed by physicians to newly diagnosed children with major depressive disorder 
by a) the pharmacotherapy category and b) specific antidepressant prescribed. 
 
Null Hypothesis 8.a:  There is no difference in the pharmacotherapy category prescribed by 
physicians for first, second, and third lines of antidepressant treatment for newly diagnosed 
children with major depressive disorder. 
 
Null Hypothesis 8.b:  There is no difference in the specific antidepressant prescribed by 
physicians for first, second, and third lines of treatment for newly diagnosed children with major 
depressive disorder.  
 
Objective 9:  To predict which physician characteristics effect the treatment prescribed for 
children with major depressive disorder. 
     
Objective 10:  To determine the average length of antidepressant treatment for newly diagnosed 
children with major depressive disorder. 
 
Objective 11:  To determine the types of pharmacotherapy monitoring in newly diagnosed 
children with major depressive disorder. 
  
Objective 12:  To determine differences in antidepressant monitoring for newly diagnosed 
children with major depressive disorder and the U.S. FDA recommendations for monitoring 
children treated with antidepressants. 
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Null Hypothesis 12.0:  There is no difference in pharmacotherapy monitoring for newly 
diagnosed children with major depressive disorder and the U.S. FDA recommendations for 
monitoring children treated with antidepressants.   
  
Objective 13:  To determine whether there are differences, by physician type, in the average 
number of times per month physicians monitor children with major depressive disorder. 
 
Null Hypothesis 13.0:  There is no difference, by physician type, in the average number of times 
per month physicians monitor children with major depressive disorder.  
 
 
     Next, Objectives 14 through 22 address these same issues but in the adolescents (13 through 
18 years of age) population. 
 
Objective 14:  To determine the demographic characteristics of physicians who treat newly 
diagnosed adolescents with major depressive disorder. 
 
Objective 15:  To determine physicians’ first line of treatment for newly diagnosed adolescents 
with major depressive disorder by: a) type of treatment, b) drug category, and c) specific 
antidepressant prescribed. 
 
Objective 16:  To determine physicians’ second and third lines of treatment for newly diagnosed 
adolescents with major depressive disorder by:  a) drug category, and b) specific antidepressant 
prescribed.  
  
Objective 17: To determine the difference in first, second, and third lines of antidepressant 
treatment prescribed by physicians to newly diagnosed adolescents with major depressive 
disorder by a) the pharmacotherapy category and b) specific antidepressant prescribed. 
 
Null Hypothesis 17.a:  There is no difference in the pharmacotherapy category prescribed by 
physicians for first, second, and third lines of antidepressant treatment for newly diagnosed 
adolescents with major depressive disorder. 
 
Null Hypothesis 17.b:  There is no difference in the specific antidepressant prescribed by 
physicians for first, second, and third lines of treatment for newly diagnosed adolescents with 
major depressive disorder.  
 
Objective 18:  To predict which physician characteristics effect the treatment prescribed for 
adolescents with major depressive disorder. 
     
Objective 19:  To determine the average length of antidepressant treatment for newly diagnosed 
adolescents with major depressive disorder. 
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Objective 20:  To determine the types of pharmacotherapy monitoring in newly diagnosed 
adolescents with major depressive disorder. 
 
Objective 21:  To determine differences in antidepressant monitoring for newly diagnosed 
adolescents with major depressive disorder and the U.S. FDA recommendations for monitoring 
adolescents treated with antidepressants. 
 
Null Hypothesis 21.0:  There is no difference in pharmacotherapy monitoring for newly 
diagnosed adolescents with major depressive disorder and the U.S. FDA recommendations for 
monitoring children treated with antidepressants.   
  
Objective 22:  To determine whether there are differences, by physician type, in the average 
number of times per month physicians monitor adolescents with major depressive disorder. 
 
Null Hypothesis 22.0:  There is no difference, by physician type, in the average number of times 
per month physicians monitor adolescents with major depressive disorder.  
 
     Phase II of this study also utilizes survey methodology to determine factors which influence 
child psychiatrists’ decisions to prescribe antidepressant therapy to children and adolescents who 
have been diagnosed with major depressive disorder.  The relative importance of the factors, 
which influence these physicians’ decisions regarding antidepressant treatment, will also, be 
determined.  The specific objectives for this portion of the study are listed below.   
Objective 23:   To determine the relative importance which physicians place on each factor prior 
to prescribing antidepressants to newly diagnosed children and adolescents with major 
depressive disorder. 
 
Objective 24:  To determine the factors associated with physicians’ antidepressant prescribing 
behavior for children and adolescents newly diagnosed with major depressive disorder.   
 
Significance of the Study 
     The current study will be a valuable addition to the literature because it will be the first study, 
in the U.S. to determine, on a national scale, which factors physicians consider when making 
decisions to treat children and adolescents with major depressive disorder.  This will also be the 
first U.S. study to determine physicians’ first, second, and third-lines of antidepressant treatment 
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by category and specific drug; the length of treatment; and monitoring practices in the treatment 
of newly diagnosed children and adolescents with major depressive disorder.   
     Additionally, little is known about the variables which influence child psychiatrists’ decision 
to prescribe antidepressant medication to children and adolescents with major depressive 
disorder.  Thus, by examining the variables which influence child psychiatrists’ antidepressant 
prescribing decisions, the results may be utilized as the basis for future studies to research 
prescribing decisions in greater detail. 
     The results of the current study will also be beneficial to health care organization and 
pharmaceutical manufactures in the creation of marketing and educational strategies aimed at 
physicians who utilize antidepressants to treat children and adolescents with major depressive 
disorder.  By taking into consideration what physicians deem important in the prescribing 
decision, newly created marketing, promotional, and educational materials may incorporate this 
information and create advertising and educational messages which better appeal to physicians. 
     Another benefit of this study is the identification of the most appropriate treatment for 
children and adolescents with major depressive disorder.  Child psychiatrists are the experts in 
treating children and adolescents for major depressive disorder.  According to the American 
Academy of Child and Adolescent Psychiatry, child psychiatrists undergo two years of 
specialized training beyond that of an adult psychiatrist (American Academy of Child and 
Adolescent Psychiatry, 2001).  Although other physicians may treat children and adolescents 
with major depressive disorder child psychiatrists should be the experts based on their training.  
Thus, the information gleaned from this study will not only provide guidance to other physician 
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specialties, but also to parents about the best treatment options for children and adolescents with 
major depressive disorder.  
Limitations of the Study 
       Limitations to the current study are similar to other studies that employ survey methodology.  
These limitations include errors such as sampling error, measurement error, and non-response 
error.  Sampling error will be minimized by conducting a national survey and utilizing the most 
comprehensive mailing lists of physicians available.  Non-response error should be minimized 
by repeated mailings and the identification of pediatricians who treat children and adolescents in 
Phase I of the study.   Chapter two will discuss the literature reviewed for the basis of this study.     
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CHAPTER TWO:  LITERATURE REVIEW 
     Chapter two discusses the treatment of major depressive disorder in children and adolescents.  
The chapter begins with the topic of diagnosis, clinical course of major depressive disorder, and 
the risk factors associated with untreated major depressive disorder. Next, the stages of major 
depressive disorder treatment are described.  This is followed by a discussion of the different 
classes of antidepressant treatment, their mechanism of action, and their efficacy for the 
treatment of major depressive disorder in children and adolescents.  Efficacy of psychotherapy 
and the combination of antidepressant treatment and psychotherapy are then reviewed.  An 
examination of the factors which influence physicians’ prescribing decisions, with specific 
attention given to the scientific literature regarding antidepressant prescribing to children and 
adolescents follows.  The chapter concludes with a summary of these factors and additional 
factors which have been found to influence other prescribing decisions.    
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Diagnosis of Major Depressive Disorder   
     The Diagnostic and Statistical Manual of Mental Disorders (DSM) is a standard classification 
of mental disorders and is written and published by the American Psychiatric Association.  The 
American Psychiatric Association is an organization that represents United States (U.S.) 
psychiatrists (American Psychiatric Association, 2006a).  The last revisions to the DSM were 
made when the DSM-IV-TR edition was published in July 2000 (American Psychiatric 
Association, 2006c).  The DSM is utilized by mental health professionals to help diagnose 
mental disorders.  It contains a list of psychiatric disorders, diagnostic criteria, text describing the 
disorder and its epidemiology, and a diagnostic code that corresponds to each of these disorders 
(American Psychiatric Association, 2006c). Institutions, agencies, and researchers may use these 
codes for data collection and billing purposes (American Psychiatric Association, 2006c). These 
diagnostic codes have been derived from the International Statistical Classification of Diseases 
and Related Health Problems (ICD) (American Psychiatric Association, 2006c).  No information 
about treatment is included in the DSM (American Psychiatric Association, 2006c). 
     According to the DSM-IV-TR a patient can be diagnosed with major depressive disorder if 
five or more of the nine specified symptoms have been present during the same two-week period 
and represent a change from previous functioning (American Psychiatric Association, 2000).  
These nine symptoms are described in Table 2.1.  
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Table 2.1:  Nine Symptoms from DSM-IV-TR Utilized to Diagnose Major Depressive 
Disorder
a 
 
1.   Depressed mood most of the day, nearly every day, as indicated by either  
      subjective report (e.g., feels sad or empty) or observation made by others (e.g., 
      appears tearful).  Note: In children and adolescents, can be irritable mood. 
 
2.   Markedly diminished interest or pleasure in all, or almost all, activities most of 
      the day, nearly every day (as indicated by either subjective account or observation 
      made by others) 
 
3.   Significant weight loss when not dieting or weight gain (e.g. a change of more 
      than 5% of body weight in a month) or decrease or increase in appetite nearly 
      every day.  Note:  In children, failure to make expected weight gains 
 
4.   Insomnia or hypersomnia nearly every day 
 
5.   Psychomotor agitation or retardation nearly every day (observable by others, no 
      merely subjective feelings of restlessness or being slowed down) 
 
6.   Fatigue or loss of energy nearly every day 
 
7.   Feelings of worthlessness or excessive or inappropriate guilt (which may be 
      delusional) nearly every day (not merely self-reproach or guilt about being sick) 
 
8.   Diminished ability to think or concentrate, or indecisiveness, nearly every day 
      (either by subjective account or as observed by others) 
 
9.   Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation 
      without a specific plan, or a suicide attempt or a specific plan or committing 
      suicide.  
                                                   
a
 Adapted from DSM-IV-TR(American Psychiatric Association, 2000)                 
 
     It should be noted the DSM-IV-TR requires that either depressed mood or loss of interest or 
pleasure in activities be a present symptom for the patient to be diagnosed with major depressive 
disorder (American Psychiatric Association, 2000).  Additionally, the DSM-IV-TR requires that 
certain symptoms may not be utilized to make a diagnosis of  major depressive disorder.  These 
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symptoms are as follows:  any symptom that is due to a general medical condition, mood-
incongruent delusions, or hallucinations (American Psychiatric Association, 2000).  The DSM 
indicates that for children and adolescents the irritable mood symptom may replace the depressed 
mood symptom, which is usually present in adults who are diagnosed with major depressive 
disorder (American Psychiatric Association, 2000).  Also, children may fail to make expected 
weight gains when they have major depressive disorder (American Psychiatric Association, 
2000). 
Clinical Course of Major Depressive Disorder  
     A major depressive episode is defined by utilizing the diagnostic criteria set forth by the 
American Psychiatric Association and are listed in Table 2.1 (American Psychiatric Association, 
2000).  It is estimated that between 14-25% of children and adolescents experience at least one 
episode of major depressive disorder before adulthood (Lewinsohn, Rhode, & Seeley, 1998; 
Ryan, 2005).  The median duration of a major depressive episode for youth is between seven to 
nine months (American Academy of Child and Adolescent Psychiatry, 1998; Kovacs, Obrosky, 
Gatsonis, & Richards, 1997).  Several terms have been frequently utilized by clinicians and 
researchers to describe the clinical course of an episode of major depressive disorder.  
Unfortunately, these terms have not always been utilized in a standardized manner.  Frank et al. 
(1991) proposed standard definitions for these terms so that research results regarding the 
clinical course of major depressive disorder in children and adolescents might be compared.  The 
American Academy of Child and Adolescent Psychiatry has adapted these terms and utilized 
them in their 1998 practice parameters (American Academy of Child and Adolescent Psychiatry, 
1998).  The terms and definitions can be found in Table 2.2. 
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Table 2.2:  Terms and Definitions Describing the Clinical Course of Major Depressive 
Disorder
a  
Term: Definition: 
1.  Response Significant improvement of depressive 
symptoms during the initial or acute 
treatment phase. In general, response 
coincides with the onset of remission. 
2.  Remission   A period of at least two weeks and less 
than two months with no more than one 
clinically significant symptom.   
3.  Partial remission   A period of at least two weeks and less 
than two months with more than one 
clinically significant symptom but fewer  
symptoms than the full syndrome. 
4.  Recovery An asymptomatic period of more than two 
months. 
5. Relapse  An episode of depression during the period 
of remission. 
6. Recurrence   The emergence of symptoms of major 
depressive disorder during the period of 
recovery (a new episode).                          
a  Adapted from Frank et al., 1991                                                                                                                                     
Emslie et al. (1997) assessed remission, recovery, and recurrence of major depressive disorder in 
hospitalized children and adolescents, utilizing the definitions established by Frank et al. (1991).  
The average time to remission was 59.5 days with a range of 14 to 246 days (Emslie et al, 1997).  
Recovery was achieved in 98% of the patients within one year and recurrence occurred in 61% 
of the children and adolescents (Emslie et al, 1997).  Of those with a recurrence of major 
depressive disorder, 47.2% had the recurrence within the first year, while another 22.2% (a total 
of 69.4%) had the recurrence of major depressive disorder by the end of year two (Emslie et al., 
1997).    
     Other studies have indicated that depression is chronic and most children and adolescents who 
have experienced an episode of major depressive disorder will have a recurrence of the disorder 
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within five years (Kovacs et al., 1984; Ryan, 2005).  Additionally, depressed youth have 
recurrences of depression into adulthood at rates of 30%-50% (Angst, Gamma, Sellaro, Lavori, 
& Zhang, 1990; Costello et al., 2002; Lewinsohn, Rhode, Klein, & Seeley, 1999).  Since major 
depressive disorder can be chronic and recur, treatment of this disorder in children and 
adolescents becomes important.  Treatment is also important as there are various risk factors 
associated with major depressive disorder in children and adolescents.  The next section 
discusses some of the risk factors associated with major depression in children and adolescents.     
Risk Factors Associated with Major Depressive Disorder 
     Major depressive disorder in children and adolescents is associated with a high degree of 
morbidity and mortality.  Children and adolescents with major depressive disorder, compared to 
normal controls are at greater risk for drug and alcohol abuse, tend to experience significantly 
greater difficulty in school and work, and have greater impairment in overall functioning 
(Lewinsohn et al., 1999; Weissman et al., 1999).  Left untreated, major depressive disorder is 
likely to recur in children and adolescents (Lewinsohn et al., 1999).  Research indicates that 
untreated depression, which began during childhood or adolescence, tends to persist into 
adulthood (Lewinsohn et al., 1999; Weissman et al., 1999).            
     Left untreated major depressive disorder can a have serious impact on the lives of children 
and adolescents.  Major depressive disorder is associated with a higher risk of substance abuse, 
impaired functioning, and even suicide. Although not all depressed youth commit suicide, it has 
been estimated that between 40-80% of youth with depression have experienced thoughts of 
suicide (American Psychiatric Association & American Academy of Child and Adolescent 
Psychiatry, 2004). As age increases so does the risk of suicide, from 1.3/100,000 for youth aged 
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10-14 years to 8.2/100,000 for adolescents aged 15-19 years (National Institute of Mental Health, 
2004).  Furthermore, research indicates that over 50% of those children and adolescents 
diagnosed with depression will attempt suicide, and at least 7% will take their lives as a result of 
depression (Ringold, 2005).   
     Untreated major depressive disorder tends to recur in youth and continue into adulthood.  
Furthermore, there are serious risks related to untreated major depressive disorder.  Therefore, it 
is imperative that this disorder be treated in children and adolescents.   
Stages of Major Depressive Disorder Treatment 
     Treatment is commonly referred to in the literature as being divided into three stages or 
phases (Agency for Health Care Policy and Research, 1993).  The Agency for Healthcare 
Research and Quality (AHRQ), formerly the Agency for Healthcare Policy and Research 
(AHCPR) defined the three phases for the treatment of major depressive disorder (Karasu, 
Gelenberg, Merriam, & Wang, 2000; Agency for Health Care Policy and Research, 1993).  The 
aim of each phase is the “attainment of a stable, fully asymptomatic state and full restoration of 
psychosocial function” (Agency for Health Care Policy and Research, 1993).  The first or initial 
phase of treatment is the acute treatment phase.  This phase uses formal procedures to reduce or 
remove the symptoms and signs of depression and helps to restore the patient’s psychosocial 
function (Agency for Health Care Policy and Research, 1993).  The patient is considered a 
responder and remission is induced when the patient improves with the use of treatment.  The 
next phase is the continuation phase of treatment.  The purpose of the continuation phase of 
treatment is to prevent a relapse and maintain remission (Agency for Health Care Policy and 
Research, 1993).  Based on the AHRQ definition, the continuation phase continues until the 
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patient has maintained remission for six months (Agency for Health Care Policy and Research, 
1993).  Some physicians may discontinue treatment at the end of the continuation phase; 
however treatment may be continued into the maintenance phase of treatment (Agency for 
Health Care Policy and Research, 1993).  The purpose of maintenance treatment is to prevent a 
recurrence or a new episode of major depressive disorder in the patient (Agency for Health Care 
Policy and Research, 1993).         
Treatment of Major Depressive Disorder in Children and Adolescents  
     Antidepressant medication and psychotherapy have each been found to be beneficial in the 
treatment of major depressive disorder.  The research on the efficacy of major depressive 
disorder treatments for children and adolescents has only been conducted in the more recent 
years and literature in this area is limited when compared to the literature in the treatment of 
major depressive disorder in the adult population.  Additionally, some of the treatments that have 
proved helpful in the adult population are not efficacious when treating children and adolescents 
with major depressive disorder.  Therefore, the adult research results should not be generalized to 
the child and adolescent population and additional research needs to be conducted in this area.   
     The following two sections of this dissertation will be devoted to antidepressant treatments 
for children and adolescents with major depressive disorder.  First, each class of antidepressant 
medication will be reviewed.  Second, the randomized clinical trials of antidepressant medication 
for major depressive disorder in children and adolescents will be examined.   
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Antidepressant Treatment of Major Depressive Disorder  
Mechanism of Action   
     Although the mechanism of antidepressants is not completely understood, the general action 
of these medications is believed to be the following: Neurotransmitters, including 
norepinephrine, serotonin, and dopamine, are released from one neuron or the presynaptic 
neuron into the synapse, or space between two neurons (Lieberman, 2003; Trujillo & Chinn, 
1996).  Once in the synapse neurotransmitters can be deactivated by being reabsorbed by the 
presynaptic neuron or by being broken down by an enzyme called monoamine oxidase (Trujillo 
& Chinn, 1996). It is thought that depression results from a decrease in the concentration of 
neurotransmitters within the synapse.  Therefore, antidepressants act to increase concentrations 
of neurotransmitters within the synapse by either blocking the reuptake or re-absorption of 
neurotransmitters from the synapse or by preventing the enzymatic action of monoamine oxidase 
with the synapse.     
     Each class of antidepressants, their mechanism of action, and their side effects will be 
discussed in the following section.  Randomized controlled trials related to each class of 
antidepressant will be discussed later in this chapter.   
Monoamine Oxidase Inhibitors (MAOIs) 
    Monoamine Oxidase Inhibitors (MAOIs) are a class of antidepressant medication and include 
the drugs Marplan® (isocarboxazid), Nardil® (phenelzine sulfate), and Parnate® (tranlcypromine 
sulfate).  These medications were among the first antidepressants to be synthesized and their 
utilization began in the early 1950’s (Lieberman, 2003; Plestscher, 1991; Trujillo & Chinn, 
1996).      
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     The MAOIs operate by inhibiting the action of the enzyme, monoamine oxidase which breaks 
down neurotransmitters, including norepinephrine, serotonin, and dopamine, within the synaptic 
cleft (Lieberman, 2003; Plestscher, 1991; Trujillo & Chinn, 1996).  Because the MAOIs block 
the action of monoamine oxidase these neurotransmitters are not destroyed and they build up in 
the synapse.  It is thought that the decreased levels of neurotransmitters are associated with 
depression.  Therefore, MAOIs increase neurotransmitter concentrations, and this higher 
concentration is believed to relieve depressive symptoms.       
     Although, MAOIs can be effective in treating depression these medications have the potential 
for serious side effects and numerous drug and food interactions.  Side effects range from 
dizziness, blurred vision, and weight gain to hypertensive crisis (National Institutes of Health, 
2005).  Patients taking MAOIs must avoid foods and drugs that have a high tyramine content 
including cheeses, poultry, alcoholic beverages, coffee, tea, and chocolate (National Institutes of 
Health, 2005).  This trend seems to be related to the potentially serious side effects and 
dangerous interactions with any food or drug which contains tyramine (McCrabe, 1986).  
Tyramine aids in regulating blood pressure (Mayo Clinic, 2004).  MAOIs prevent the normal 
destruction of tyramine, which results in a high level of this amino acid to build up in the human 
body (Mayo Clinic, 2004).  Higher than normal levels of tyramine may cause a severe increase in 
blood pressure and the results can be fatal (Mayo Clinic, 2004).               
     It has been noted in the literature that MAOIs have not been widely utilized in the child and 
adolescent population (Emslie, Walkup, Pliszka, & Ernst, 1999).  In fact due to the potential for 
side effects and interactions some psychiatrists never prescribe MAOIs (Fiedorowicz & Swartz, 
2004).           
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Tricyclic Antidepressants (TCAs) 
     Concurrent to the development and utilization of the MAOIs was the synthesis and use of the 
class of antidepressants known as TCAs (Lieberman, 2003; Pletscher, 1991).  The first TCA to 
be synthesized was Tofranil® (imipramine HCl) (Lieberman, 2003; Pletscher, 1991; Trujillo & 
Chinn, 1996).  By the 1960’s other TCAs, including Norpramin® (desipramine HCl) and Elavil® 
(amitriptyline HCl), were developed (Lieberman, 2003). These newer TCAs were relatively safer 
and better tolerated by patients than the older Tofranil® (Lieberman, 2003; Pletscher, 1991).  
     The TCAs act by blocking the reuptake of neurotransmitters into neurons (Pletscher, 1991).  
The disadvantage of this class of antidepressants is that they are associated with undesirable side 
effects including dry mouth, dizziness, and weight gain (Hazell, O’Connell, & Heathcote, 1995).  
Additionally, the TCAs may cause more serious adverse effects including cardiovascular events 
and the potential for overdose (Hazell et al., 1995).   
Tetracyclic Antidepressants 
     In 1980, the U.S. Food and Drug Administration (FDA) approved Ludiomil® (maprotiline 
HCl) for use in the treatment of depression (United States Food and Drug Administration, 2007).  
The other tetracyclic antidepressant Remeron® (mirtazpine) was not approved by the U.S. FDA 
until 1996 (MedicineNet.com, 1999; United States Food and Drug Administration, 2007).  
Tetracyclic antidepressants increase the amount of the neurotransmitters, norepinephrine and 
serotonin (MedicineNet.com, 1999).  Like the MAOIs and TCAs, the tetracyclic antidepressants 
have relatively more side effects than some of the other antidepressants developed in the last two 
decades.  The more prominent side effects of the tetracyclic antidepressants include sedation and 
risk of overdose (HealthyPlace, 2006).  
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Selective Serotonin Reuptake Inhibitors (SSRIs) 
     The next major class of antidepressants to be developed was the SSRIs (Pletscher, 1991).  In 
1987, Prozac® (fluoxetine HCl), was the first SSRI to be approved and launched in the 
U.S.(United States Food and Drug Administration, 2007).  It should be noted that Prozac® is the 
only antidepressant that has been approved for use in the child and adolescent population, and 
the U.S. FDA granted this approval in 2003 (United States Food and Drug Administration, 
2007).  The 1990’s and early 2000’s brought the development and launch of other SSRIs 
including Celexa® (citalopram HBr), Lexapro® (escitalopram oxalate), Paxil® (paroxetine HCl), 
Luvox ® (fluvoxamine maleate), and Zoloft® (sertraline HCl) (United Stated Food and Drug 
Administration, 2007).  As their name suggests, the SSRIs act by selectively inhibiting the 
reuptake of the neurotransmitter serotonin (Pletscher, 1991).  This results in an increase in 
serotonin levels which helps to treat depressive symptoms (Pletscher, 1991).      
     This class of antidepressants has the advantage of an improved safety and tolerability profile, 
relative to the MAOIs or TCAs (Emslie et al., 1999; Lieberman, 2003; Pletscher, 1991).  
Additionally, the SSRIs have the advantage of being safer to the patient if taken in excess, such 
as in an attempt at a drug overdose (Emslie et al., 1999).  Common side effects of the SSRIs 
include agitation, sleep difficulties, and gastrointestinal upset (Emslie et al., 1999).    
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)      
     The SNRIs were developed during the same time period as the SSRIs.  By 1993, the U.S. 
FDA approved, the first SNRI, Effexor® (venlafaxine HCl) for the treatment of depression 
(United States Food and Drug Administration, 2007).  Cymbalta® (duloxetine HCl) was 
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approved in 2004, in the U.S., for use in the treatment of depression (United States Food and 
Drug Administration, 2007).  
     The SNRIs have an action similar to that of the TCAs, as these antidepressants block the 
reuptake of both norepinephrine and serotonin.  However, SNRIs have an improved side effect 
profile compared to TCAs including less risk of cardiovascular events and less potential for 
overdose (United States Food and Drug Administration, 2007).     
Norepinephrine and Dopamine Reuptake Inhibitors (NDRIs) 
     Wellbutrin® (buproprion HCl) is an NDRI and is unique as its mechanism of action mainly 
affects the neurotransmitter dopamine (GlaxoSmithKline, 2006).  However, this NDRI inhibits 
the reuptake of serotonin, norepinephrine, and dopamine (GlaxoSmithKline, 2006).  Wellbutrin® 
was initially approved by the U.S. FDA for use in the treatment of depression in 1985 (United 
States Food and Drug Administration, 2007).  Since that time two other dosage forms of 
Wellbutrin® have gained approval for the treatment of depression.  In 1996 Wellbutrin SR® was 
approved and in 2003 Wellbutrin XL® gained approval (United States Food and Drug 
Administration, 2007).  The SR or sustained-release and XL or extended-release versions of 
Wellbutrin® both release bupropion at a slower rate. 
     This antidepressant seems to be well-tolerated and is relatively safe, even in overdose 
situations (Carson, Butcher, & Mineka, 2002). Common side effects with this antidepressant are 
agitation, insomnia, dizziness, headache, rapid heartbeat, and weight loss (GlaxoSmithKline, 
2006).   
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Other Antidepressants 
     Two chemically related antidepressants Desyrel® (trazodone HCl) and Serzone® (nefazodone 
HCl), which are unrelated to other classes of antidepressants, were approved by the U.S. FDA to 
treat depression, in 1982 and 1994 respectively (United States Food and Drug Administration, 
2007).  Desyrel® is believed to inhibit the reuptake of serotonin, while Serzone® inhibits the 
reuptake of serotonin and norepinephrine (MedicineNet.com, 1997; MedicineNet.com, 2003).   
     Desyrel® can be helpful in treating patients that are depressed but also have symptoms of 
anxiety, as it has a sedative effect (MedicineNet.com, 2003).  Serzone® has been associated with 
side effects such as low blood pressure, sleepiness, dry mouth, nausea, dizziness, vision 
problems, and confusion (United States Food and Drug Administration, 2005c).  More critically, 
Serzone® has been associated with liver failure.  Serzone® has been removed from many markets 
including the European, Australian, New Zealand, and Canadian markets (United States Food 
and Drug Administration, 2005c; WebMD, 2004).  As of June 14, 2004, Bristol-Myers Squibb 
stopped selling Serzone®, however generic versions of the antidepressant are still available 
(United States Food and Drug Administration, 2005c; WebMD, 2004).  The U.S. FDA now 
requires that nefazodone’s label carry a black box warning of life-threatening liver damage 
(United States Food and Drug Administration, 2007; WebMD, 2004).    
Outcome Measures Utilized in Randomized Clinical Trails 
     The randomized clinical trials (RCTs) for antidepressants and psychotherapy have utilized 
several different outcome measures to quantify patients’ response to treatment.  Table 2.3 
provides an overview of the measures utilized in the antidepressant and psychotherapeutic RCTs, 
which will be described in the following section.   
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Table 2.3:  Instruments Utilized to Measure Patient Outcomes in Randomized Clinical 
Trials 
Scale Reference Number of Items 
on the Scale 
Age for which 
Scale is 
Appropriate 
Purpose of Scale 
Beck Depression 
Inventory (BDI) 
(Beck & Steer, 
1987) 
21 Adolescents and 
Adults (13-80 yrs.) 
Self-inventory 
scale designed to 
measure 
depressive 
symptoms 
Child Behavior 
Checklist (CBCL) 
(Achenbach & 
Rescorla, 2001) 
118 plus 2 open-
ended questions 
Children (6-18 
yrs.) 
Parent-report scale 
designed to 
measure the child’s 
behavior and social 
competency 
Children’s 
Depression 
Inventory (CDI) 
(Kovacs, 1992) 27 Children and 
Adolescents (7-17 
yrs.)  
Self-reported 
inventory to assess 
depression 
Children’s 
Depression Rating 
Scale (CDRS-R) 
(Poznanski & 
Mokros, 1996) 
17 Children (6-12 
yrs.) and 
Adolescents 
Semi-structured 
interview to 
diagnose 
depression or 
monitor treatment 
response 
Children’s Global 
Assessment Scale 
(CGAS) 
(American 
Psychiatric 
Association, 2000) 
Numeric Scale  
1-100 
Children and 
Adolescents (< 18 
yrs.) 
Utilized by 
clinicians to rate 
the general 
functioning of a 
child 
Clinical Global 
Impressions (CGI) 
(Guy, 1979) 3 Appropriate for all 
Ages 
Utilized by 
clinicians to assess 
a patient’s 
response to 
treatment 
Hamilton 
Depression Rating 
Scale (HAM-D) 
(Hamilton, 1960) 21 Adults (> 18 yrs.) Semi-structured 
interview to 
designed to rate 
the severity of 
depressive 
symptoms 
Raskin Depression 
Scale 
(Rush, 2000) 3 Adults (> 18yrs.) Utilized by 
clinicians to assess 
the severity of 
depression 
Social Adjustment 
Scale Self Report 
(SAS-SR) 
(Weissman & 
Bothwell, 1976) 
54 17 yrs. and older Self-report 
inventory designed 
to assess 
individuals ability 
to adapt and be 
satisfied with their 
social situation  
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Efficacy of Antidepressants in Children and Adolescents with Major Depressive Disorder  
 
     Few studies regarding the efficacy of MAOIs in treating any psychiatric disorder in the child 
and adolescent population can be found in the literature (Emslie et al., 1999).  Ryan et al. (1988) 
conducted a published chart review of 23 adolescent patients who had been diagnosed with 
depression and treated with MAOIs.  While this study demonstrated some improvement in 
depressive symptoms among patients, the authors concluded that the potential risks associated 
with these antidepressants outweighed the therapeutic benefit (Ryan et al., 1988).     
     Despite the fact that TCAs have demonstrated efficacy in adults, this has not proved to be the 
case in the child and adolescent population (Hazell et al., 1995; Geller, Reising, Leonard, Riddle, 
& Walsh, 1999).  Unlike the MAOI class of antidepressant, where there have been few scientific 
studies conducted in the child and adolescent population, many RCTs have been conducted for 
TCAs.  Unfortunately, the results of these trials have not proved TCAs to be efficacious in the 
treatment of major depressive disorder in children and adolescents.  Included in the literature is a 
meta-analysis conducted by (Hazell et al., 1995).  This study includes 12 RCTs of TCAs, such as 
amitriptyline, desipramine, impramine, and nortriptyline (Hazell et al., 1995).  The conclusion of 
this study was that TCAs are no more effective than placebo in treating child and adolescent 
depression (Hazell et al., 1995).  Geller et al. (1999) conducted a systematic review of tricyclic 
antidepressant use in children and adolescents.  This review also concluded that the TCAs did 
not demonstrate efficacy in the treatment of child and adolescent depression (Geller et al., 1999).        
     Although the literature contains no published RCTs of the tetracyclic antidepressants, there 
are results of two unpublished, multi-center, double-blind, placebo controlled trials of Remeron® 
in outpatient children and adolescents with major depressive disorder (Dubitsky, 2004).  The two 
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trials (hereafter, referred to as Trial #1 and Trial #2) had identical protocols (Medicines and 
Healthcare Products Regulatory Agency, 2004).    Trial #1 randomized 126 children and 
adolescents, while Trial #2 randomized 133 children and adolescents seven to17 years of age to a 
dose of 15 milligram (mg) to 45 mg of Remeron® or placebo for eight weeks (Dubitsky, 2004; 
Medicines and Healthcare Products Regulatory Agency, 2004).  Patients randomized to the 
Remeron® arm began treatment with a 15 mg dose of the antidepressant (Dubitsky, 2004).  The 
investigators had the option of increasing the dose in 15 mg increments to a maximum of 45 mg 
(Dubitsky, 2004).  The primary efficacy measure was the change in the score on the Children’s 
Depression Rating Scale-Revised from baseline to the eight-week study endpoint (Medicines and 
Healthcare Products Regulatory Agency, 2004; Emslie, Ryan, & Wagner, 2005).  There was no 
statistically significant difference between treatment groups in either of these trials (Emslie et al, 
2005; Medicines and Healthcare Products Regulatory Agency, 2004).       
     The SSRIs have been shown to have greater efficacy than other antidepressants in the 
treatment of child and adolescent depression, and have subsequently been studied more in this 
population than other classes of antidepressants (Emslie et al., 2005).  However, efficacy has not 
been consistently demonstrated across RCTs in which children and adolescents diagnosed with 
major depressive disorder have been treated with SSRIs (Emslie et al., 2005).    
     Simeon, Denicola, Ferguson, & Copping (1990) conducted a placebo-controlled double-blind 
trial of fluoxetine.  The study population consisted of 40 outpatients and inpatients between the 
ages of 13 and 18 years who had been diagnosed with major depressive disorder (Simeon et al., 
1990)  The 40 adolescents were randomized to a seven-week treatment period (Simeon et al., 
1990).  The fluoxetine treatment was 20 mg per day, increased to 40 mg daily after four to seven 
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days, and then increased to 60 mg during the second week of treatment (Simeon et al., 1990).  
Outcome measures for this study included the following:  Hamilton Rating Scale for Depression, 
Clinical Global Impression, and Raskin Depression Scale (Simeon et al., 1990).  The researchers 
found that fluoxetine was not a statistically superior treatment to placebo based on any of these 
outcome measures (Simeon et al., 1990).       
     Emslie et al. (1997) conducted an eight-week double-blind randomized, placebo-controlled 
trial to evaluate the efficacy, safety, and tolerability of fluoxetine (20 mg per day) compared to 
placebo in a child and adolescent population.  The study population consisted of outpatients 
between the ages of seven and 17 years who met the DSM-III-R criteria for major depressive 
disorder (Emslie et al., 1997).  After a one week, single-blind placebo run-in period, 96 children 
were randomized to either an eight-week treatment of fluoxetine or placebo (Emslie et al., 1997).  
Primary outcome measures were the Clinical Global Impressions and the Children’s Depression 
Rating Scale-Revised  (Emslie et al., 1997).  At the completion of the treatment period, the 
fluoxetine arm was found to be statistically significant to the placebo arm, on both of the primary 
outcome measures (p = .02 Clinical Global Impressions; p<.001 Children’s Depression Rating 
Scale-Revised) (Emslie et al., 1997).  In the fluoxetine arm, 27 of the 48 patients compared to 16 
of the 48 patients in the placebo arm responded to treatment (χ2 =5.097, df = 1, p = .02) (Emslie 
et al., 1997).    
     Keller et al. (2001) conducted an eight-week trial, which randomized 275 patients 12 to 18 
years of age who had been diagnosed with major depressive disorder, to three treatment arms.  
The three treatments included paroxetine (20 mg – 40 mg per day), imipramine (gradual titration 
to 200 mg -300 mg per day), and placebo (Keller et al., 2001).  The primary outcome measure 
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was the Hamilton Rating Scale for Depression and the authors defined a response to treatment as 
a Hamilton Rating Scale for Depression score of less than or equal to  eight, or a greater than or 
equal to 50% reduction in baseline Hamilton Rating Scale for Depression score at end of 
treatment (Keller et al., 2001).  The percentage of patients who achieved a Hamilton Rating 
Scale for Depression score of less than or equal to eight were as follows: paroxetine 63.3%, 
imipramine 50.0%, and placebo 46.0% (Keller et al., 2001).  There were significantly more 
“responders” in the paroxetine treatment groups than in the placebo group (p = 0.02) (Keller et 
al., 2001).  The percentage of patients who achieved a Hamilton Rating Scale for Depression of 
less than or equal to eight or a greater than or equal to 50% reduction in baseline Hamilton 
Rating Scale for Depression score were as follows: paroxetine 66.7%, imipramine 58.5%, and 
placebo 55.2% (Keller et al., 2001).  On this second measure of response neither the paroxetine 
group nor the imipramine group was statistically significant when compared to the placebo group 
(Keller et al., 2001).   
     Emslie et al. (2002) conducted a second RCT in children and adolescents, eight to 18 years of 
age, who had been diagnosed with major depressive disorder.  This trial included a three-week 
screening period, then a single-blind, placebo run-in period (Emslie et al., 2002).  Those patients 
(n = 219) who did not respond to placebo were randomized to either treatment with Prozac® or 
placebo (Emslie et al., 2002).  The primary outcome measure was a treatment response as 
measured by the Children’s Depression Rating Scale-Revised.  A treatment response was defined 
as a greater than or equal to 30% decrease in Children’s Depression Rating Scale-Revised score 
from week zero to study endpoint (Emslie et al., 2002).  A treatment remission was defined as an 
endpoint Children’s Depression Rating Scale-Revised score of less than 28 (Emslie et al., 2002).  
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The mean change in Children’s Depression Rating Scale-Revised score was statistically 
significant (p < 0.001) for fluoxetine as compared to placebo (Emslie et al., 2002).  The response 
rate for patients treated with fluoxetine (65.1%) compared to those treated with placebo (53.5%) 
was not statistically significant (Emslie et al., 2002).  The remission rate for patients treated with 
fluoxetine (41.3%) compared to those treated with placebo (19.8%) was statistically significant 
(p < 0.01) (Emslie et al., 2002).          
     Mandoki, Tapia, Tapia, Sumner, & Parker (1997) conducted a six-week, double-blind, 
placebo-controlled trial with 40 patients between the ages of eight and 17 years who had major 
depressive disorder (Mandoki et al., 1997).  Among patients receiving Effexor® the dose varied 
from 37.5 mg per day for children and 75 mg per day for adolescents (Mandoki et al., 1997).  
Response was measured by the Hamilton Depression Rating Scale, and the Children’s 
Depression Rating Scale, Children’s Depression Inventory, and the Children’s Behavioral 
Checklist (Mandoki et al., 1997).  All rating scales indicated an improvement in depressive 
symptoms, but there were no statistically significant differences found between treatment groups 
(Mandoki et al., 1997).  Therefore, this study did not demonstrate efficacy of Effexor® in 
children and adolescents with major depressive disorder (Mandoki et al., 1997).  The authors 
stated that the insignificant findings could be a result of the fact that all of the patients received 
cognitive-behavioral therapy along with the antidepressant or placebo, which might have 
obscured any treatment effect (Mandoki et al., 1997).  Also, the insignificant result may have 
been a result of the small doses of Effexor® (Mandoki et al., 1997).  However, later trials of this 
antidepressant have not shown efficacy in the treatment of children and adolescents with major 
depressive disorder.         
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     Two unpublished eight-week, double-blind, placebo-controlled trials evaluated the efficacy of 
Effexor ER® in children and adolescents with major depressive disorder (Medicines and 
Healthcare Products Regulatory Agency, 2004).  Patients began on a dose of 37.5 mg per day 
and then were titrated up to a maximum of 225 mg per day (Medicines and Healthcare Products 
Regulatory Agency, 2004).  Primary efficacy measurement for both trials was the change in 
Children’s Depression Rating Scale-Revised score (Medicines and Healthcare Products 
Regulatory Agency, 2004).  There was no statistically significant difference between treatment 
groups, therefore Effexor ER® did not demonstrate efficacy in the treatment of children and 
adolescents with major depressive disorder (Medicines and Healthcare Products Regulatory 
Agency, 2004). 
     Emslie, Findling, Yeung, Kunz, & Li (2007) conducted an eight-week, double-blind, placebo-
controlled trial evaluated the efficacy of Effexor ER®.  Patients seven to seventeen years of age 
were randomized to a flexible dose of Effexor ER® or placebo (Emslie et al., 2007).  The primary 
outcome was change from baseline on the Children’s Depression Rating Scale (Emslie et al., 
2007).  There was no statistical significant improvement between the treatment and placebo 
groups (Emslie et al., 2007).  A post-hoc analysis showed greater improvement for adolescents 
(p=0.022) based on the Children’s Depression Rating Scale, but no significant improvement for 
children (Emslie et al., 2007).  Therefore, this analysis indicates efficacy for Effexor ER®  in the 
adolescent population (Emslie et al., 2007).           
     The NDRIs’ efficacy have not been tested for children and adolescents with major depressive 
disorder.  Although these antidepressants have been studied for the treatment of children and 
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adolescents with other disorders, no RCTs of Wellbutrin®, Wellbutrin SR®, or Wellbutrin XL® 
exist in the literature involving children and adolescents with major depressive disorder.   
     Only one unpublished trial was located for the “Other Antidepressants”, including Desyrel® 
and Serzone®.  Rynn, Riddle, Yeung, & Kunz, (2007) conducted a trial to determine the efficacy 
of Serzone® in the treatment of major depressive disorder in children and adolescents before liver 
damage warnings were made public (Rynn et al., 2007).  However, this study did not 
demonstrate the antidepressant’s efficacy in this population (Rynn et al., 2007).  The lack of 
RCTs for this group of antidepressants may be a result of the liver damage that has been 
associated with their use and Bristol Myers Squibb pulled Serzone® from the U.S. market, 
however the generic version nefazodone HCL is still available (U.S. FDA, 2008).                
Psychotherapy Treatment for Major Depressive Disorder  
     According to the 1998 American Academy of Child and Adolescent Psychiatry Practice 
Parameters, psychotherapy is an appropriate treatment for depressive disorders in both children 
and adolescents (American Academy of Child and Adolescent Psychiatry, 1998).  There are 
many different types of psychotherapy and some of these are utilized to treat children and 
adolescents with major depressive disorder.  These types are defined in Table 2.4.   
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Table 2.4:  Definitions of Psychotherapy 
Cognitive Behavioral Therapy (CBT) teaches the patient to identify and counteract cognitive 
distortions.  CBT is based on the premise that people with depression have cognitive distortions of 
themselves, the world, and the future; that these cognitive distortions contribute to their depression 
(American Academy of Child and Adolescent Psychiatry, 1998).   
 
Interpersonal Therapy (IPT) focuses on the clarification and resolution of problem areas such as 
prolonged grief, interpersonal roles, role disputes, role transitions, and personal difficulties 
(Agency for Health Care Policy and Research, 1993; American Academy of Child and Adolescent 
Psychiatry, 1998).      
 
Supportive Counseling establishes and maintains rapport with the patient and provides support to 
the patient and helps the patient identify and express feelings.  The health care provider can 
achieve these goals through the use of reflective listening, empathy, and discussions of personal 
problems (Brent, 1997).       
 
Play Therapy utilizes the therapeutic powers of play to help patients prevent or resolve 
psychosocial difficulties and achieve optimal growth and development (O’Connor, 2000). 
    
Family Therapy is a treatment approach that makes the assumption that the within-family 
behavior of a particular family member is largely influenced by the behaviors and communication 
patterns of other family members (Carson, 2002).  
 
 
     Unfortunately, efficacy of psychotherapy for the treatment of major depressive disorder in 
children and adolescents is difficult to assess due to the limited number of RCTs in the scientific 
literature.  Of those RCTs conducted the sample sizes have been small (Ryan, 2005).  Small 
samples sizes and high placebo rates make the results of these existing studies difficult to 
interpret (Ryan, 2005).  Studies found in the literature are described in the next section.     
     Although there are no empirically validated psychotherapy treatments for children with major 
depressive disorder (Bridge, Salary, Birmaher, Asare, & Brent, 2005) there is some support for 
two different psychotherapeutic approaches in the treatment of major depressive disorder in 
adolescents (Dopheide, 2006; Bridge et al., 2005; Ryan, 2005; Compton et al., 2004).  These two 
approaches are cognitive behavioral therapy (CBT) and interpersonal therapy (IPT).  Brent et al. 
(1997) conducted a trial in which 107 adolescents who had been diagnosed with major 
 
 
 36 
depressive disorder were randomized to receive 12 to 16 sessions of CBT, family therapy, or 
supportive therapy.  Those patients treated with CBT showed a more rapid treatment response (p 
= 0.03) and a higher remission rate than family therapy (p = 0.03) or supportive therapy (p = 
0.04) than patients in other treatment arms (Brent et al., 1997).  Remission was defined as 
absence of major depressive disorder as defined by the DSM-III-R and three consecutive scores 
of nine or less on the Beck Depression Inventory (Brent et al., 1997).   
     Mufson, Weissman, Moreau, & Garfinkel (1999) conducted a randomized controlled clinical 
trial in which 48 adolescents aged 12 to 18 years were randomized to 12-weeks of IPT or clinical 
monitoring.  The clinical monitoring consisted of therapists reviewing patients’ depressive 
symptoms, school attendance, supportive listening, and assessing the patients’ suicidality 
(Mufson et al., 1999).  The adolescents who received interpersonal therapy had a higher rate of 
recovery than the control group (p = 0.04).  The recovery criterion was a score of six or less on 
the Hamilton Rating Scale for Depression at the end of the 12-weeks of treatment (Mufson et al., 
1999). 
     In 2004 Mufson et al. conducted another RCT in which 63 adolescents aged 12 to 18 years 
who had been diagnosed with major depressive disorder were randomized to 16 weeks of IPT or 
treatment as usual (Mufson et al., 2004).  At the end of the 16 weeks, the adolescents who had 
received IPT had significantly fewer depressive symptoms as measured by the Hamilton 
Depression Rating Scale (p = 0.04), significantly better functioning on the Children’s Global 
Assessment Scale (p = 0.04), significantly better overall social functioning on the Social 
Adjustment Scale-Self-Report (p = 0.01), significantly greater clinical improvement (p = 0.03) 
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and greater decrease in clinical severity (p = 0.03) as measured by the Clinical Global 
Impressions Scale (Mufson et al., 2004).              
Combination Therapy for Major Depressive Disorder 
     Another strategy is the combination of pharmacotherapy and psychotherapy.  However, 
effectiveness for this treatment combination has been established only for adolescents who have 
been diagnosed with major depressive disorder (March & The Treatment for Adolescents with 
Depression Study (TADS) Team, 2004).  A description of the only RCT, sponsored by the 
National Institute of Mental Health, which supports this type of therapy, follows.     
     The TADS team conducted an RCT which randomized 439 adolescents 12 to 17 years of age, 
who were diagnosed with major depressive disorder (March & TADS Team, 2004).  The 
adolescents received one of four treatments for 12-weeks.  These treatments included fluoxetine 
(10 mg per day for week one, then increased to 20-40 mg per day), CBT, a combination of 
fluoxetine and CBT, or placebo (March & TADS Team, 2004).  The primary outcome measures 
consisted of the Children’s Depression Rating Scale-Revised and the Clinical Global 
Impressions improvement score (March & TADS Team, 2004).  This study found that the 
combination treatment of fluoxetine and CBT was superior and statistically significant to placebo 
as measured by the Children’s Depression Rating Scale-Revised (p = 0.001) (March & TADS 
Team, 2004).  Additionally, treatment with fluoxetine and CBT was superior to either fluoxetine 
(p = 0.02) or CBT (p = 0.01) alone, as measured by the Children’s Depression Rating Scale-
Revised (March & TADS Team, 2004).    
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Physician Prescribing Decisions    
     As the reviewed studies in the above sections indicate, some types of antidepressant therapy 
and psychotherapy have been shown to have efficacy in the treatment of major depressive 
disorder in children and/or adolescents.  However, opinions vary as to which of these treatments 
should be offered as a first-line of treatment or whether they should be offered as a combination 
treatment (American Academy of Child and Adolescent Psychiatry, 1998).  Ideally the choice of 
antidepressant medication should rely on Evidence-Based Medicine (EBM) (Depont et al., 
2003).  Evidence- Based Medicine has been defined as the “use of current best evidence in 
making decisions about the care of individual patients” (Sackett, Rosenberg, Gray, Haynes, & 
Richardson, 1996).  
     Fluoxetine is the only antidepressant approved by the U.S. FDA for the treatment of major 
depressive disorder in children and adolescents (United States Food and Drug Administration, 
2007).  However, 40% of patients will not respond to this antidepressant and off-label use of 
other antidepressants for the treatment of major depressive disorder in children and adolescents 
is common (Brent, 2005; March & TADS Team, 2004).  Therefore, EBM is not the only factor 
to influence physicians’ decision to prescribe antidepressants to children and adolescents.  
According to the American Academy of Child and Adolescent Psychiatry, the choice of initial 
therapy depends in part on “clinical”, “psychosocial factors”, and the “therapist’s expertise” 
(American Academy of Child and Adolescent Psychiatry, 1998).  Since the choice of 
antidepressant treatment for children and adolescents is not based solely on empirical research, it 
is important to explore other factors that influence physicians’ decision-making.   
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Prescribing Decisions for Adult Populations      
     Characteristics of physicians’ decisions is that they tend to be made quickly, require an 
enormous amount of information, and differ in style depending on the physician and the clinical 
problem (Eisenberg, 1979).  Researchers have proposed models that depict factors which 
influence physicians’ prescribing decisions.  However, the majority of these studies focused on 
prescribing any type of medication to adults rather than focusing on antidepressant prescribing 
decisions to children and adolescents.  One study did focus on antidepressant prescribing to 
adults and will be discussed first.  Sleath & Shih (2003) demonstrated that Eisenberg’s model of 
sociological influences on physicians’ prescribing could be applied to antidepressant prescribing 
to depressed adults.  In 1979 Eisenberg’s theory of decision-making by clinicians stated that in 
addition to the scientific criteria (EBM and clinical information) upon which physicians’ 
decisions are based, there are four types of sociological factors which influence physicians’ 
decision-making (Eisenberg, 1979).  These sociological factors are as follows: characteristics of 
the patient, characteristics of the physician, the physician’s interaction with his profession and 
the health care system, and the physician’s relationship with the patient (Eisenberg, 1979).  
Sleath & Shih (2003) determined that patients’ age, patients’ depression severity (any type of 
depression was examined, not only major depressive disorder), patients’ insurance, geographic 
location, and physicians’ specialty influenced physicians’ prescribing of antidepressants to 
adults. 
     Benson (1983) modeled the relative influence of patient characteristics, physician 
characteristics, and treatment setting characteristics on antipsychotic drug prescribing by North 
Carolina psychiatrists.  Patients’ level of functional impairment, patients’ diagnosis, physicians’ 
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board certification, psychiatrists’ professional activism, psychiatrists’ comfort with their 
knowledge of psychopharmacology, and the treatment setting were factors Benson (1983) 
determined to influence the antipsychotic prescribing decision.        
     Cates (2001) suggested that when considering an antidepressant for the treatment of major 
depressive disorder, drug-related factors should be considered.  These factors include efficacy, 
adverse effects, drug interactions, dosing, and cost (Cates, 2001).  Other researchers have 
suggested that marketing and promotional efforts influence physicians’ prescribing decisions 
(Caplow & Raymond, 1954; Chew et al., 2000; Freeman, Barnes, Summers, & Szeinbach, 1993).  
Chew et al. (2000) demonstrated that the availability of drug samples influenced physicians’ 
decisions to prescribe antidepressants. 
     Freeman et al. (1993) determined that side effects, efficacy, and patient characteristics were 
most influential to physicians’ prescribing decisions for the treatment of panic disorder.  
Additionally, Freeman et al. (1993) demonstrated that product attributes and promotional 
influences were also influential, but to a lesser extent. 
     A more recent study by Nutescu et al. (2005) demonstrated the importance of some drug-
related factors to physicians’ prescribing decisions.  Nutescu et al. (2005) suggested that the 
decision to prescribe one drug instead of another within a specific therapeutic class (low-
molecular-weight-heparins) is influenced by a variety of factors.  Nutescu et al. (2005) 
determined that drug efficacy, drug formulary status, restrictions on prescribing, physicians’ 
personal experience, safety, cost, prescribing guidelines, and U.S. FDA approval were important 
factors in the physicians’ decision-making process.  Nutescu et al. (2005) determined that 
marketing and promotional factors such as face-to-face detailing by pharmaceutical 
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representatives, samples of drugs, free drugs to indigent patients, and advertising efforts were 
somewhat influential to physicians’ decision-making process.  However, these factors were 
much less influential than other drug-related factors which physicians considered when making a 
decision to prescribe one drug instead of another within the same therapeutic class (Nutescu et 
al., 2005).   
Prescribing Decisions for Children and Adolescents 
     Chen & Chang (2002) determined that specific patient factors are related to increased 
utilization of prescription medications.  It was determined that race, insurance status, and family 
income levels had significant impact on child and adolescent prescription drug utilization (Chen 
& Chang, 2002).  Children who were white, had private insurance, and were from high-income 
families were more likely to use prescription medications (Chen & Chang, 2002).  This study 
focused on all prescription medications whereas, other studies have focused specifically on the 
prescribing patterns associated with psychotropic medications in children and adolescents.  The 
sections that follow will review the scientific literature pertaining to factors associated with 
physicians prescribing medication to children and adolescents.  The first section will consist of a 
review of the scientific literature pertaining to factors associated with physicians prescribing of 
psychotropic medication to children and adolescents.  The second section will consist of a review 
of the literature pertaining to factors associated specifically with physicians prescribing of 
antidepressants to children and adolescents.     
Psychotropic Prescribing to Children and Adolescents  
     Hong & Shepherd (1996) examined prescription drug benefit data for children and 
adolescents during the 1992-1993 time-period.  The researchers found that children and 
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adolescents were more likely to take psychotropic medication if their parents took them (Hong & 
Shepherd, 1996).  Males were more likely to take psychotropic medications at younger ages, 
while females were more likely to take psychotropic medications at older ages (Hong & 
Shepherd, 1996).  For the antidepressant drug class, children and adolescents from single parent 
homes were less likely than children from two parent homes to utilize antidepressants (Hong & 
Shepherd, 1996).  Additionally, parental use of antidepressants was associated with child and 
adolescent utilization of antidepressants (Hong & Shepherd, 1996). 
     Kaplan & Busner (1997) compared the psychotropic medication prescribing practices of 
inpatient child psychiatrists at a state hospital, a private hospital, and a county-university hospital 
in New York during 1991.  The percentage of patients at the state, private and county-university 
hospital who received psychotropic medications were 79%, 76%, and 68%, respectively (Kaplan 
& Busner, 1997).  Of  those patients who received medication, more children and adolescents at 
the private hospital (80%) compared with those patients at the state (26%), or county-university 
(26%) hospital received antidepressants (p < 0.001) (Kaplan & Busner, 1997).  Additionally, 
significantly more county-university patients (74%) received antipsychotic medications than 
those patients in the private (35%) hospital (Kaplan & Busner, 1997). 
     Safer (1997) examined the records of outpatient children and adolescents (their outpatient 
information was supplemented with inpatient records, if available) who were seen by child 
psychiatrists at four community mental health care centers in Maryland.  Safer (1997) found that 
from 1988 to 1994 there was an increase in psychotropic medication treatment for children and 
adolescents.  There was also an increase in SSRI utilization (Safer, 1997).  Additionally, it was 
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found that most children and adolescents who were prescribed psychotropic medications 
discontinued this treatment within three months (Safer, 1997).         
     Jensen et al. (1999) conducted a study which utilized prescribing data from the 1995 National 
Ambulatory Medical Care Survey (NAMCS) and the 1995 National Disease and Therapeutic 
Index (NDTI) to determine national trends for prescribing psychotropic medications to children 
18 years and younger.  Jensen et al. (1999) determined that stimulants are the most commonly 
prescribed psychotropic medication for this population (Jensen et al., 1999).  Stimulant 
prescriptions were followed in frequency by SSRIs, anticonvulsant mood stabilizers, TCAs, 
central adrenergic agonists, antipsychotics, benzodiazepines, and lithium (Jensen et al., 1999).       
     Zito et al. (2000) utilized two Medicaid databases and one health maintenance organization 
(HMO) database to determine the prevalence and utilization trends of psychotropic medication 
use in children aged two through four.  Zito et al. (2000) determined that psychotropic 
medication utilization trends increased for children aged two through four during the years 1991 
to1995 (Zito et al., 2000).  All three databases indicated that stimulants were the most widely 
utilized psychotropic medication for children aged two through four (Zito et al., 2000).  
Stimulant use frequency was followed by antidepressants, clonidine, and neuroleptics in both of 
the Medicaid populations (Zito et al., 2000).  The HMO database indicated that clonidine was the 
second most frequently utilized psychotropic medication followed by antidepressants and 
neuroleptics (Zito et al., 2000).  It should be noted that the TCA class of antidepressants 
represented the majority of the antidepressant use in this population during the years 1991-1995 
(Zito et al., 2000).       
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     Goodwin, Gould, Blanco, & Olfson (2001) utilized the National Ambulatory Medical Care 
Survey from 1992 - 1996 to determine prescribing patterns, patient characteristics, and clinical 
management of physicians who prescribed psychotropic medications to children and adolescents.  
It was found that a majority (84.8%) of psychotropic medications were prescribed by 
pediatricians and general practitioners (Goodwin et al., 2001).  It was also determined that 
stimulants (53.9%) were the most often prescribed psychotropic medication prescribed 
(Goodwin et al., 2001).  Antidepressants (30%) were the second most commonly prescribed 
psychotropic medication (Goodwin et al., 2001).  This study demonstrated that there are 
significant differences by gender, age, payment source, and race among those children and 
adolescents receiving prescriptions for psychotropic medications (Goodwin et al., 2001).          
     Rushton & Whitmire (2001) conducted a study utilizing the North Carolina Medicaid 
database to describe prescription trends for SSRIs and stimulants in children.  Stimulants and 
SSRI utilization increased during the 1992 to 1998 timeframe (Rushton & Whitmire, 2001).  For 
the year 1998, SSRI utilization was also higher for white males (2.8%) than it was for black 
females (0.6%) (Rushton & Whitmire, 2001).   
     Elfron et al. (2003) conducted a survey of pediatricians and child and adolescent psychiatrists 
in Australia to determine the prescribing patterns for psychotropic medications.  Stimulants and 
clonidine were the most frequently prescribed medications (Elfron et al., 2003).  Child 
psychiatrists were more likely than pediatricians to indicate prescribing SSRIs (93% versus 75%) 
(Elfron et al., 2003).        
     Olfson, Gameroff, Marcus, & Waslick (2003) utilized the Medical Expenditure Panel Survey 
(MEPS) from 1996 through 1999 to describe treatment patterns of children and adolescents 
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(aged six to 18 years) with depression.  More than half (56.9%) of the children and adolescents 
were prescribed an antidepressant medication and most of these patients were treated with an 
SSRI (Olfson et al., 2003).  Children and adolescents who were treated with an antidepressant 
were more likely (as compared to those patients not treated with an antidepressant) to have 
parents who graduated from high school, have health insurance, and live in large communities 
(Olfson et al., 2003).    
     Zito et al. (2003) utilized information from two Medicaid (a Midwestern state Medicaid 
database (MWM) and a mid-Atlantic state Medicaid database (MAM)) and one health 
maintenance organization (HMO) databases over a ten year period (1987 – 1996) to examine the 
changes in the prevalence and utilization trends of psychotropic medication use in children and 
adolescents less than 20 years of age.  During the ten year period, there was a three-fold increase 
in total psychotropic medication prevalence in the MWM and HMO population, and a two-fold 
increase in total psychotropic medication prevalence in the MAM (Zito et al., 2003).  By 1996, 
stimulants followed by antidepressants were the most commonly prescribed psychotropic 
medications for children and adolescents in all three populations (Zito et al., 2003).  Additionally 
in 1996, ten to 14 year old children and adolescents were utilizing more psychotropic 
medications in both Medicaid populations, while 15 to 19 year olds were utilizing more 
medications in the HMO population (Zito et al., 2003).  In 1996, antidepressant utilization was 
highest in the 15 to 19 year old group for the HMO population, and highest in the ten to 14 year 
old group in both Medicaid populations (Zito et al., 2003).  In 1996, the antidepressant utilization 
rate for males was two times that of the female rate (Zito et al., 2003).  Over the ten year period, 
males increased their utilization of antidepressants more than females in the MAM population, 
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and males and females had similar antidepressant utilization rates in the MWM population (Zito 
et al., 2003).  In the HMO population, during the same ten-year period, more males than females 
utilized antidepressants in the zero to four, five to nine, and ten to 14 year olds (Zito et al., 2003).  
However, in the 15 to 19 year old group more females than males utilized antidepressants during 
this ten year period (Zito et al., 2003).  There were race disparities among whites and African 
American patients in the MAM population, as shown by a greater utilization of antidepressant 
among white patients (Zito et al., 2003).                     
     Haapasalo-Pesu, Erkolahti, Saarijarvi, & Aalberg (2004) assessed adolescent psychiatrists’ 
prescribing practices in hospital settings in Finland.  The researchers sent a questionnaire to 
adolescent psychiatrists in 1991 and again in 1999 (Haapaslo-Pesu et al., 2004).  It was 
determined by these surveys that 30% of inpatients in 1991 and 68% in 1999 received a 
psychotropic medication (Haapaslo-Pesu et al., 2004).  The researchers conclude that this 
increase may be related to availability of newer antidepressants (Haapaslo-Pesu et al., 2004).   
     Lekhwani, Nair, Nikhinson, & Ambrosini (2004) conducted a chart review of inner city 
children, age nine or younger, receiving public assistance, and who were admitted as inpatients 
during the 1998 to 2001 time period.  The study objective was to determine prescribing patterns 
of psychotropic medications to these patients (Lekhwani et al., 2004).  It was determined that 
51.8% of the children were taking a psychotropic medication when they were admitted to the 
hospital, and 78.7% of the patients were taking a psychotropic medication at the time of 
discharge (Lekhwani et al., 2004).  Additionally, stimulants were the most widely utilized 
psychotropic medication (Lekhwani et al., 2004).      
 
 
 47 
     Najjar et al. (2004) examined inpatient prescribing patterns of psychotropic medications for 
children and adolescents utilizing hospital pharmacy dispensing data from 1991 through 1998.  
Researchers found that there was a 73.0% increase in use of psychotropic medications during the 
1991 to 1998 time frame (Najjar et al., 2004).  Additionally, there was a significant increase in 
the use of antidepressants from 35.6% to 77.3% during the same time frame (Najjar et al., 2004).        
     Hugtenburg, Heerdink, & Tso (2005) conducted a survey of child psychiatrists in the 
Netherlands to gain more information about the prescribing patterns of psychoactive 
medications.  This survey gathered information regarding the preferred medication treatment for 
various disorders (Hugtenburg et al., 2005).  For depressive disorders (including major 
depressive disorders, dsythymia, and bipolar disorder), child psychiatrists reported a preference 
for paroxetine (Hugtenburg et al., 2005). 
     Harpaz-Rotem & Rosenheck (2006), in the year 2000, compared prescribing practices of 
psychiatrists and primary care physicians (PCP) for children and adolescents with any mental 
illness.  Utilizing MarketScan®, a national claims database from private insurance plans, Harpaz-
Rotem and Rosenheck determined that PCPs were more likely to see younger children and 
psychiatrists were more likely to see adolescents (Harpaz-Rotem & Rosenheck, 2006).  
However, no differences were found in psychotropic prescribing practices including the 
proportion of patients receiving psychotropic medication, types of psychotropic medications 
prescribed, or the dosages of psychotropic medications prescribed (Harpaz-Rotem & Rosenheck, 
2006).   
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Antidepressant Prescribing to Children and Adolescents  
     Other studies have focused specifically on the prescribing of antidepressant medications to 
children and adolescent patients.  Bramble (1995) conducted a mail survey of child psychiatrists 
in Britain to gain information about prescribing patterns of antidepressants.  Of those 
psychiatrists who responded 85% had prescribed antidepressants to their patients (Bramble, 
1995).  The most frequently prescribed antidepressants were amitriptyline and imipramine, and 
SSRIs were prescribed only “very rarely” at the time of this survey (Bramble, 1995).   
     Rushton, Clark, & Freed (2000) conducted a survey of North Carolina pediatricians and 
primary care physicians to determine the prescribing patterns of SSRIs in the child and 
adolescent population.  This study determined that 72% of the surveyed physicians had 
prescribed an SSRI to a child or adolescent patient (Rushton et al., 2000).  Physicians indicated 
that depression was the most frequent reason for prescribing an SSRI to these patients (Rushton 
et al., 2000).  Furthermore, primary care physicians were more likely to prescribe SSRIs to 
adolescents than young children, with only 6% of the physicians surveyed indicating that they 
had prescribed an SSRI to a child less than six years of age (Rushton et al., 2000).  Additionally, 
primary care physicians were also more likely than pediatricians to prescribe SSRIs to an 
adolescent (41% versus 26%) (Rushton et al., 2000).  Primary care physicians were more likely 
than pediatricians (91% versus 58%) to prescribe SSRIs to all youth (including both children and 
adolescent patients) (Rushton et al., 2000).  Primary care physicians also indicated a greater 
belief in the effectiveness (40% versus 32%) and safety (63% versus 48%) of the SSRI 
medication, and indicated they were more comfortable with the management of depression in the 
child and adolescent population (22% versus 11%) as compared to pediatricians (Rushton et al., 
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2000).  This study also indicated that physicians were more likely to prescribe an SSRI to 
children and adolescents if they were primary care physicians, could not refer patients to another 
health care provider, felt comfortable managing depressed patients, and believed in the safety 
and efficacy of SSRIs (Rushton et al., 2000).              
     Bhatia et al. (2008) conducted a survey of prescribing clinicians (child psychiatrists, general 
psychiatrists, pediatricians, family practice physicians, nurse practitioners, and physician 
assistants) within the state of Nebraska, to evaluate the impact of the U.S. FDA black box 
warning on physician prescribing.  Almost all (96.8%) of the clinicians were aware of the black 
box warning (Bhatia et al., 2008).  Of the responding clinicians 76.9% prescribed antidepressants 
to children and/or adolescents before the 2004 warning.  Of the clinicians, who prescribed before 
the warning, 15.5% reported a decrease in prescribing antidepressants to children after the 
warning, while 36.6% reported a decrease in prescribing to adolescents (Bhatia et al., 2008).  
Some clinicians reported making modifications to their monitoring, with 31.9% of the clinicians 
reporting increasing contacts with the patients (Bhatia et al., 2008).  Slightly more than a third 
(36.0%) of the clinicians reported increasing referrals to mental health professionals (Bhatia et 
al., 2008).          
     Zito et al. (2002) examined changes in antidepressant utilization and factors associated with 
antidepressant utilization in the child and adolescent population by examining two Medicaid and 
one HMO database.  Between the years 1988 and 1994 antidepressant use increased among this 
population (Zito et al., 2002).  Additionally, the study indicated a modest significant difference 
in utilization associated with male gender (58.0% versus 49.5%; p<.001) (Zito et al., 2002).      
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     Murray, deVries, & Wong (2004) examined prescribing patterns of antidepressants to 
children and adolescents in the United Kingdom during the 1992 to 2001 time frame.  Murray et 
al. (2004) utilized the United Kingdom Practice Research Database to determine that 55.7% of 
all antidepressant prescriptions were for TCAs, 41.3% for SSRIs, and 2.9% for other 
antidepressants.  Overall, antidepressant prevalence increased 1.7 times from 1992 to 2001 
(Murray et al., 2004).  During the same time frame, prevalence of TCAs decreased from 3.6 to 
2.5 per 1000, and SSRI prevalence increased from 0.5 to 4.6 per 1000 (Murray et al., 2004).   
     Murray, Thompson, Santosh, & Wong (2005) compared the prevalence and incidences of 
children and adolescents who were prescribed antidepressant treatment in the United Kingdom 
during the 2000 to 2004 time frame.  The researchers utilized information from Mediplus 
database, which contains records from primary care visits (Murray et al., 2005).  Antidepressant 
prevalence increased from 5.4 to 6.6 patients per 1000 people during the 2000 to 2002 time 
frame (Murray et al., 2005).  Additionally, prevalence decreased from 6.6 to 5.7 patients per 
1000 people during the 2002 to 2004 time frame (Murray et al., 2005).          
     Fegert, Kolch, Zito, Glaeske, & Janhsen (2006) examined prescription patterns of 
antidepressants (including St. John’s Wort, an herb with antidepressant properties) for patients 
less than 20 years of age in Germany.  The researchers utilized prescription data from a HMO for 
the years 2000 to 2003 (Fegert et al., 2006).  It was determined that prevalence of antidepressants 
increased from 3.43 per 1000 in 2000, to 3.74 per 1000 in 2003 (Fegert et al., 2006).  Fegert et 
al. (2006) defined prevalence as the dispensing of one or more prescriptions for an antidepressant 
per calendar year per 1000 continuously enrolled children and adolescents.  St. John’s Wort and 
TCAs accounted for approximately 80% of the antidepressant use (Fegert et al., 2006).  Females 
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were two times as likely as males to use an antidepressant, and females aged 15 to19 years of age 
accounted for most of the antidepressant use in Germany during the 2000 to 2003 time frame 
(Fegert et al., 2006).        
     Vitiello, Zuvekas, & Norquist (2006) analyzed the Medical Expenditure Panel Survey 
database for the 1997 to 2002 time frame to determine the utilization of antidepressants among 
children and adolescents (patients less than 19 years of age).  During this time period, the 
percentage of children and adolescents receiving an antidepressant increased significantly from 
1.3% to 1.8% (p < 0.01) (Vitiello et al., 2006).  Utilization was highest in the 13 to 18 year olds 
and lowest among children less than six year of age (Vitiello et al., 2006).  In 1996, utilization 
was highest among male children and adolescents when compared to females (Vitiello et al., 
2006).  However, by 2002 utilization of antidepressants was similar between males and females 
(Vitiello et al., 2006).  In 2002, there was significantly more utilization among whites than 
blacks or Hispanics (Vitiello et al., 2006).  Between 1997 and 2002, utilization of antidepressants 
increased among blacks and Hispanics (Vitiello et al., 2006).  There were significant increases in 
utilization for children and adolescents from poor families and among those children and 
adolescents who had public insurance (Vitiello et al., 2006).  Additionally, there was a 
significant increase in the utilization of SSRIs and other “newer antidepressants” but no increase 
for TCAs during the 1997 to 2002 time-frame (Vitiello et al., 2006).    
     Kurian et al. (2007) utilized Tennessee’s Medicaid database to evaluate the impact of the 
2004 warnings on prescriptions of antidepressants to pediatric patients.  Data from 2002 to 2005 
was analyzed and it was found there was a 33% decrease in antidepressant users after the 
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warnings (Kurian et al., 2007).  Non-fluoxetine SSRIs and SNRIs showed the greatest decrease 
(54%) in use, while new users of fluoxetine, actually increased 60% (Kurian et al., 2007).   
     Nemeroff et al. (2007) utilized retail pharmacy database, Verispan, to investigate prescribing 
trends in the United States.  This study found that the number of children and adolescents 
prescribed an antidepressant after the 2004 warnings decreased significantly (p=0.02) (Nemeroff 
et al, 2007).  The other impacts of the warnings seem to be a shift away from “generalist” care to 
“specialist” care for patients seeking antidepressants (Nemeroff et al., 2007).  Also, the study 
showed a slight shift or increase in prescriptions of Wellbutrin® to children and adolescents 
(Nemeroff et al., 2007).        
Summary of Factors Influencing Physician Prescribing Decisions 
     Based on the studies above, factors related to antidepressant prescribing in children and 
adolescents include patients’ gender (Fegert et al., 2006; Vitiello et al., 2006) patients’ race 
(Goodwin et al., 2001; Olfson et al., 2003; Vitiello et al., 2006), type of insurance (Goodwin et 
al., 2001; Olfson et al., 2003), patients’ age (Fegert et al., 2006; Goodwin et al., 2001; Vitiello et 
al., 2006; Zito et al., 2002), geographic location (Olfson et al., 2003) and physicians’ specialty 
(Rushton et al., 2000).  Additional factors were found to influence physicians’ decisions 
regarding antidepressant prescriptions to children and adolescents.  These factors were family 
income (Olfson et al., 2003), parents education level (Olfson et al., 2003), parental use of 
antidepressant medication (Hong & Shepherd, 1996), single parent household (Hong & 
Shepherd, 1996), physicians’ comfort level in managing depression (Rushton et al., 2000), and 
physicians’ belief in the safety and efficacy of antidepressants for youth (Rushton et al., 2000).   
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     The reviewed randomized clinical trials illustrate that there is no sound epidemiological basis 
for choosing antidepressant treatment in children and adolescents with major depressive disorder 
(Brent, 2005).  Even those antidepressants demonstrating efficacy in the treatment of major 
depressive disorder in children and adolescents have been subject to the 2004 U.S. FDA black 
box warning.  However, scientific evidence is not the only factor to impact physicians’ 
prescribing decisions.  The last part of this chapter reviewed research regarding factors which 
impact physicians’ prescribing decisions.  The purpose of the current study is to examine 
physician antidepressant choices for children and adolescents with major depressive disorder and 
to examine the factors which impact these choices.  The methods to accomplish these goals will 
be the focus of the next chapter.  
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CHAPTER THREE:  METHODOLOGY 
     The purpose of this study was to examine physician antidepressant choices for children and 
adolescents with major depressive disorder and to examine the factors which impact these 
choices.  The study consisted of two phases.  Thus, this chapter outlines the conceptual 
framework for each phase of the study, the study population, sample size, and data collection.  
This will be followed by a description of the development and validation of each survey 
instrument.  The chapter concludes with a description of the data analysis for each objective.    
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Conceptual Framework 
     The optimal treatment for children and adolescents who have major depressive disorder is not 
a clear decision for physicians.  There is no empirical basis for choosing antidepressant treatment 
in children and adolescents with major depressive disorder (Brent, 2005).  In the absence of 
empirical research to guide the selection of antidepressant treatment, additional research needs to 
be conducted to examine what physicians consider to be the most appropriate antidepressant 
treatment and  recommended course of treatment.  These goals were accomplished in Phase I and 
Phase II of this study.   
     It has been suggested that ideally the choice of antidepressant treatment could be based on 
evidence-based medicine (Depont et al., 2003).  However, this would exclude other factors 
which may influence physicians’ antidepressant prescribing decisions to newly diagnosed 
children and adolescents with major depressive disorder.  The current literature has highlighted 
some patient and physician-related factors that influence physicians’ prescribing decisions, 
including decisions to prescribe antidepressants (Benson, 1983; Sleath & Shih, 2003).  
Additionally, research suggests that drug-related factors, including marketing-related factors, 
also influence prescribing decisions of physicians, but may be less influential, at least in some 
situations, than patient and physician-related factors (Freeman et al., 1993; Nutescu et al., 2005).   
     Furthermore, prescribing decisions have been conceptualized as a two-stage process (Benson, 
1983; Sleath & Shih, 2003).  First, the physician makes a decision about whether or not to 
prescribe an antidepressant (Benson, 1983; Sleath & Shih, 2003).  Second, the decision of which 
specific antidepressant to prescribe must be made (Benson, 1983; Sleath & Shih, 2003).   
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     Phase II of the current study examined variables/factors associated with the first stage, 
“whether or not to prescribe an antidepressant” to children and adolescents with major 
depressive disorder.  This study is a more comprehensive examination of variables associated 
with the decisions to prescribe an antidepressant, than any found in the scientific literature to 
date and allowed for the relative influence of these factors to be determined.    The conceptual 
framework for each study phase is depicted below.    
Phase I:  Identification of Physicians   
     Phase I of this study consisted of a short survey to a sample of pediatricians to determine 
which physicians treat children and adolescents with newly diagnosed major depressive disorder.  
Figure 3.1a shows a visual representation of the conceptual framework for Phase I.      
         Figure 3.1:  Conceptual Framework for Phase I 
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Phase II:  Determination of Physician Prescribing Behavior 
     Phase II of the study surveyed pediatricians and child psychiatrists.  This portion of the study 
determined treatment behavior and specific antidepressant prescribing behavior for children and 
adolescents with newly diagnosed major depressive disorder.  A visual representation of the 
conceptual framework for Phase II can be seen in Figure 3.1b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 58 
Figure 3.2:  Conceptual Framework of Phase II 
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Phase II:  Variables Influencing Physicians’ Decisions to Prescribe Antidepressants 
 
     Additionally, Phase II of this study determined the variables, and the importance of the variables 
which influence pediatricians’ and child psychiatrists’ antidepressant prescribing behavior.  A listing 
of the 28 variables examined in this portion of the study and subjected to exploratory factor analysis 
are listed in Table 3.1. 
    
Table 3.1:  28 Variables Utilized in Exploratory Factor Analysis 
 
 
 
 
 Variables 
 
Advertisements to physicians via journals 
Availability of patient education materials 
Clinical experience with prescribing antidepressants 
Co-existing conditions of patients (eg. OCD) 
Comfort in managing MDD in youth 
Direct-to-consumer advertising 
Drug efficacy 
Drug safety 
Face-to-face detailing by medical sciences liaison and/or pharmaceutical 
representatives 
Familiarity with an antidepressant being prescribed 
FDA approval 
Formulary inclusion 
Frequency in dosing 
Generic form of drug available 
Manufacturer provides free drugs to indigent patients 
Medication cost 
Monitoring requirements 
Parents’ education level 
Parental use of antidepressants 
Patient’s ability to perform daily activities  
Patient’s age 
Patient’s family income 
Patient’s gender 
Patient’s insurance  
Potential adverse events 
Sample drugs available 
Severity of MDD symptoms 
Suicidal Thinking 
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Study Population 
     In any study the reference, target, or study population “is the group we wish to study” and the 
random sample “is selected from the study population” (Rosner, 2000).  The random sample is a 
“sample in which each group member has the same probability of being selected” (Rosner, 2000).  
The population in the current study consisted of all pediatricians and child psychiatrists in the United 
States (U.S.).  Child psychiatrists, undoubtedly treat children and adolescents with major depressive 
disorder, as they are trained to do so (American Academy of Child and Adolescent Psychiatrists, 
2006).  Since there is currently a shortage of child psychiatrists in the U.S., it has been documented 
in the literature that some children and adolescents with major depressive disorder receive treatment 
from other types of physicians such as pediatricians (American Academy of Child and Adolescent 
Psychiatry, 2006).  However, all pediatricians are not willing to treat children and adolescents with 
major depressive disorder (American Academy of Child and Adolescent Psychiatry, 2006).  To 
obtain adequate responses for Phase II, it was important to first identify which physicians treat these 
patients.       
     The SK&A Informational Services, Inc. maintains databases of over two million medical records, 
including records of 615,000 physicians.  Another database is the American Medical Association’s 
Member list.  This database served as the sampling frame for the current study.  This database was 
chosen because it is a more exhaustive list of physicians (compared to others that were identified) in 
the U.S.  The specialty count includes 59,237 pediatricians and 7,496 child and adolescent 
psychiatrists for a total of 66,733 physicians. 
     The sample for Phase I consisted of a random sample of pediatricians in the U. S. selected from 
the total population of these specialty areas.  The information collected from Phase I of this survey 
provides an estimate of the number of pediatricians who are currently treating major depressive 
disorder in newly diagnosed children and/or adolescents in the U.S.  The sample for Phase II 
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consisted of those pediatricians who indicated they treat children and/or adolescents with major 
depressive disorder, and who were willing to participate in a follow-up survey designed to gain 
information about prescribing habits to newly diagnosed children and adolescents with major 
depressive disorder.  The sample for Phase II also included a random sample of child psychiatrists 
from the SK&A database.    
 
Sample Size Estimation 
 
     The sample size was calculated using the following formula: 
 
n = Z2 * (p * 1-p)    
               C2 
 
n = the sample size 
Z = the Z value for the confidence interval, or the number of standard errors away from the mean 
p = the true proportion of the population  
C = the confidence interval 
 
     Several samples were utilized for this study.  First, it was necessary to calculate the sample size 
for Phase I of the study.  This sample size was estimated utilizing a 95% confidence level and a 
confidence interval equal to 5%, so that C = 0.05 and Z = 1.96.  This means that the researcher is 
95% confident that an estimate of the true proportion of the variable of interest will be no more than 
+ 5% (Salant & Dillman, 1994).  No prior knowledge of the true proportion of the population is 
known.  Since this was the case, a conservative estimate was assumed and p = 0.5 (Salant & 
Dillman, 1994).  Substituting these values (Z = 1.96, p = 0.5, and C = 0.05) in the formula above, a 
sample size of 384 was calculated.           
     Research suggests that response rates for physicians are low compared to the response rates of the 
general public and this may impair the generalizability of the results of the survey (Kellerman & 
Herold, 2001).  A study which reviewed the medical literature during a one year time frame 
indicated that the physician response rate was 54% (Martin, 1974).  Another study, which examined 
survey methodology of physician surveys from 1967 through 1999 found response rates to range 
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from 38% to 84% (Kellerman & Herold, 2001).  The current study assumed a much more 
conservative response rate of 20%.  Therefore, 2,000 ((1, 920 = 384 * 5) plus an additional 80 for 
incorrect addresses) randomly selected pediatricians were sent a survey, for a total of 2,000 surveyed 
in Phase I of this study.  
     The sample for Phase II consisted of those pediatricians who indicated they treat children and/or 
adolescents with major depressive disorder, and who indicated they were willing to participate in 
Phase II of this study.  In addition, a random sample of 2,500 (384*5 = 1,920 plus an additional 580 
for incorrect addresses and non-responses) child psychiatrists were surveyed.        
     When conducting factor analysis it is usually suggested that a sample size of between 10 and 20 
subjects for each variable being measured be utilized (Thompson, 2004).  An absolute minimum of 
five subjects per measured variable has also been suggested (Gorsuch, 1983).  The current study had 
28 variables.  Therefore, a minimum sample size of 28*5 = 140 was needed for conducting the factor 
analysis in this study.           
Data Collection 
     This study utilized primary data for both phases.  Primary data may be collected by telephone, 
face-to-face, internet, or mail surveys.  Mail surveys have some advantages over some other data 
collection methods.  These advantages include the facts that mail surveys typically require less time, 
money, and research staff than other primary data collection methods (Salant & Dillman, 1994).  The 
major reason mail surveys were utilized for this study was to reach physicians nationally.  Research 
indicates that phone surveys yield only slightly higher, but not statistically significant, response rates 
as compared to response rates of mail surveys of physicians (Kellerman & Herold, 2001).  
Furthermore, personal interviews of physicians yield significantly higher response rates than mail 
surveys of physicians (Kellerman & Herold, 2001).  However, to conduct personal interviews on a 
national basis, for this study, was not feasible.  Therefore, mail surveys were utilized. 
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     Research suggests a survey mailing procedure that consists of four separate mailings (Salant & 
Dillman, 1994).  This begins with an initial letter sent to all sample participants.  The purpose of this 
letter is to alert the participants who have been selected for the survey and to make them aware that 
they will be receiving a questionnaire (Salant & Dillman, 1994).  The next mailing, which should 
take place approximately a week after the initial letter, consists of a cover letter providing the details 
of the survey, the questionnaire, and a return postage-paid envelope (Salant & Dillman, 1994).  
Approximately four to eight days after the questionnaire is sent, a postcard thanking those who have 
responded and asking for a response from those participants who have not responded should be 
mailed (Salant & Dillman, 1994).  The fourth mailing occurs approximately three weeks after the 
questionnaire was sent (Salant & Dillman, 1994).  This mailing entails mailing to those people who 
have not returned the first questionnaire and consists of a new cover letter which again asks for their 
participation and includes a replacement questionnaire and return postage-paid envelope (Salant & 
Dillman, 1994).  According to Salant & Dillman (1994) this procedure should yield a 50-60% 
response rate from the general public.  Due to limited resources, the current study varied Salant & 
Dillman’s (1994) recommendations slightly.  Data for each phase was collected via two survey 
mailings.  The first mailing for each phase consisted of a cover letter, survey, and return postage-
paid envelope to each physician.  The second mailing consisted of a cover letter, survey, and return 
postage-paid envelop to each physician who did not respond to the first mailing.    
     Approval for the research protocol, cover letters, survey for Phase I, and survey for Phase II, was 
obtained from the Institutional Review Board of West Virginia University.     
Instrument Development 
     Surveys for this study were developed by obtaining information from reviews of the scientific 
literature and from informal discussions with psychiatrists who treat children and adolescents.  
Instrument development for each phase of the study will be discussed in detail. 
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Phase I 
     The survey for Phase I (See Appendix A) was designed to determine which physicians treat 
newly diagnosed children and adolescents with major depressive disorder.  Additionally, the 
information gathered from this survey combined with demographic information discerned from the 
physician database allowed the researcher to detect whether there are geographical differences in 
pediatricians’ willingness to treat children or adolescents with major depressive disorder.  The 
survey also asked physicians if they would be willing to participate in a more in-depth questionnaire 
in the next phase of this study. 
Phase II 
     The survey utilized in Phase II consisted of eight sections.  The questions were designed to obtain 
information about prescribing habits to newly diagnosed children and adolescents with major 
depressive disorder.  A copy of the survey can be found in Appendix B and each section will be 
discussed in detail.  The first section of the survey gathered information regarding whether or not 
physicians treated and/or referred children and adolescents for the treatment of major depressive 
disorder, as it was possible that physicians treated only one of these groups of patients.  The second 
section of the survey gathered information about physicians’ preferred first-line of treatment for 
newly diagnosed children and adolescents with major depressive disorder.  This section also 
determined a physicians’ antidepressant prescribing habits regarding these patients, including 
dosage, titration, and length of treatment.  Section three of the survey obtained information regarding 
the physicians’ preferred second-line of treatment (in the event of a treatment failure with the first-
line of treatment).  The fourth section asked physicians to indicate their preferred third-line of 
treatment assuming the second-line of treatment is a failure.  The fifth section gathered some basic 
information about physicians’ counseling and psychotherapy practices.  Section six collected 
information regarding pharmacotherapy monitoring of children and adolescents receiving 
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antidepressants.  Section seven consisted of a listing of variables which may influence the 
physicians’ decision to prescribe an antidepressant medication to a child or adolescent who has been 
newly diagnosed with major depressive disorder.  The physicians were asked to indicate how much 
influence each factor has when making the decision to prescribe an antidepressant medication to 
children and adolescents.  A four point, Likert scale (where 1 = not influential and 4 = extremely 
influential) was utilized to determine the degree of influence each variable has on the physicians’ 
decision to prescribe antidepressant medication.  The last section of the instrument collected 
physician demographic information, including age, gender, specialty, practice location, practice 
volume, and training. 
Instrument Validation 
     In general, the validity of a measurement has to do with the correctness or accuracy of the 
measurement.  More specifically, the validity of an instrument or measurement reflects the extent to 
which scores on the instrument are reflective of the true differences of the measured characteristic 
among individuals (Churchill, 1991).  One type of validity is content validity.  Content validity is the 
ability of the measurement or instrument to capture all of the content, or all domains of the 
characteristic the researchers wants to measure (Churchill, 1991).  Face validity refers to what an 
instrument appears to measure (Churchill, 1991).     
     Content and face validity were assessed for both surveys utilized in this study.  During the 
development of the surveys, the input of experts in psychiatry and faculty members with expertise in 
health outcomes research at West Virginia University was sought.  The psychiatry experts and 
researchers assessed the readability, clarity of the questions, and the relevance of the questions in 
this survey.   
     Non-response bias was assessed by comparing the responses of early responders to those of late 
responders.  This method of assessing non-response bias involves viewing non-response bias as a 
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continuum, with early respondents at one end and late responders at the other.  It is also assumed that 
late responders are more like non-responders and may be used as proxy for non-respondents.  
Therefore, a comparison of the responses from the early responders to the late responders (i.e., Non-
responders) can be made as a method for assessing non-response bias (Armstrong & Overton, 1977).    
     A pilot study was conducted for Phase II of the study.  The pilot study consisted of a random 
sample equal to 10% (or 250 subjects) of the sample size for Phase II.  This study allowed the 
researchers to determine the clarity of the survey questions.  Based on the feedback from the pilot 
study, final adjustments to the content of the survey instrument were made, prior to the first mailing.  
A copy of the survey utilized in the pilot study can be found in Appendix C.            
Data Analysis  
     Objectives for each of the two phases are stated and followed by the data analysis to be utilized in 
this study.  All statistical analyses were conducted utilizing either Statistical Package for the Social 
Sciences, SPSS® Version 16.0 or Statistical Analysis Software, SAS® Version 9.1.   
Phase I :   
 
     The overall goal of Phase I was to identify pediatricians who treat children and/or adolescents 
with major depressive disorder.  There were four specific objectives for this phase.     
 
Objective 1:  To determine the proportion of pediatricians who treat children and adolescents with 
major depressive disorder. 
 
The Phase I survey asked pediatricians to indicate all age groups they treat for major depressive 
disorder.  The choices were “children (5-12 years old)”, “adolescents (13-18 years old)”, or “do not 
treat”.  Descriptive statistics were calculated for the responses.  More specifically the frequencies 
and proportions of pediatricians who treat children and/or adolescents with major depressive 
disorder were calculated based on physicians’ responses.    
Objective 2:  To determine the proportion of pediatricians who refer children and adolescents with 
major depressive disorder.  
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The Phase I survey asked pediatricians to indicate all age groups they refer for the treatment of 
major depressive disorder.  The choices were “refer children (5-12 years old)”, “refer adolescents 
(13-18 years old)”, or “do not refer”.  Descriptive statistics were calculated for the responses.  More 
specifically the frequencies and proportions of pediatricians who refer children and/or adolescents 
with major depressive disorder were calculated based on physicians’ responses.    
Objective 3:   To determine the health care provider to whom pediatricians refer a child or 
adolescent with major depressive disorder. 
 
Pediatricians were asked to indicate in an open ended format what type of health care provider they 
would refer children and then adolescents, in the event they refer these patients.  The frequencies of 
the type of health care provider, to which pediatricians refer children and/or adolescents, were 
calculated.      
Objective 4:  To determine geographic differences in pediatricians’ willingness to treat versus 
referral of children and/or adolescents with major depressive disorder.    
 
Null Hypothesis 4.0:  There is no difference in the geographic locations of pediatricians who treat 
versus refer children and/or adolescents for major depressive disorder.   
 
Some physicians indicated they treated and referred, so that treating and referring patients was not a 
mutually exclusive decision.  Frequencies and proportions of pediatricians who treat children and/or 
adolescents with major depressive disorder were calculated directly from the phase I survey 
questions, as indicated above.  The geographic location (state) was ascertained from the mailing 
address for each pediatrician.  The geographic regions were specified according to the U.S. Census 
Bureau’s definitions.  The U.S. Census Bureau divides the United States into five geographic regions 
as follows:  Northeast, South, Midwest, West, and Pacific.  The states included in each of the 
geographic regions are listed below in Table 3.2.   
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Table 3.2:  States Included in Each Geographic Region  
Northeast South Midwest West Pacific 
Connecticut 
Maine 
Massachusetts 
New Hampshire 
New Jersey 
Pennsylvania 
Rhode Island 
Vermont 
 
Alabama 
Arkansas 
Delaware 
District of Columbia 
Florida 
Georgia 
Kentucky 
Louisiana 
Maryland 
Mississippi 
North Carolina 
Oklahoma 
South Carolina 
Tennessee 
Texas 
Virginia 
West Virginia 
Illinois 
Indiana 
Iowa 
Kansas  
Michigan 
Minnesota 
Missouri 
Nebraska 
North Dakota 
Ohio 
South Dakota 
Wisconsin 
 
Arizona 
California 
Colorado 
Idaho 
Montana 
Nevada 
New Mexico 
Oregon 
Utah 
Washington 
Wyoming 
 
Alaska 
Hawaii 
 
 
Since both variables (treat, categorized as “yes” or “no” and geographic region, categorized as 
“northeast”, “south”, “midwest”, “west”, and “pacific”) are categorical in nature the results of the χ2 
statistic tested whether the proportion of pediatricians who treat children and adolescents by 
geographic location are equal.          
Phase II: 
     The overall goal of Phase II was to determine what physicians consider to be the most appropriate 
treatment for children and/or adolescents with major depressive disorder, their recommended course 
of treatment (i.e., length of treatment, pharmacotherapy monitoring), and the factors which impact 
their decisions to treat major depressive disorder in children and adolescents with an antidepressant.  
There were 20 specific objectives for this phase.     
Objectives and Analysis for Children 
     Objectives 5 through 13 focused on the treatment, prescribing patterns, and factors which impact 
the treatment of children (five through 12 years of age) with major depressive disorder.   
 
Objective 5:  To determine the demographic characteristics of physicians who treat newly diagnosed 
children with major depressive disorder. 
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This objective was determined from the pediatricians’ and child psychiatrists’ responses to the 
survey questions in section eight of the Phase II survey.  Descriptive statistics or frequency 
distributions were estimated for these categorical variables (physicians’ gender, age, year of 
graduation, practice site, geographic location, population of practice area, specialty, board 
certifications, patient volume, and length of time treating children and adolescents).  
Objective 6:  To determine physicians’ first line of treatment for newly diagnosed children with 
major depressive disorder by: a) type of treatment, b) drug category, and c) specific antidepressant 
prescribed. 
 
Descriptive statistics were calculated for the pediatricians’ and child psychiatrists’ responses to the 
questions in section two of the Phase II survey.  Frequency distributions were estimated for the 
categorical variables type of treatment, drug category, and specific antidepressant prescribed.      
Objective 7:  To determine physicians’ second and third lines of treatment for newly diagnosed 
children with major depressive disorder by:  a) drug category, and b) specific antidepressant 
prescribed.  
 
These categorical variables are the responses to the survey questions in section three and section 
four, of the Phase II survey.  For both pediatricians and child psychiatrists, analysis consisted of 
descriptive statistics, of the drug category and specific antidepressant variables.     
Objective 8: To determine the difference in first, second, and third lines of antidepressant treatment 
prescribed by physicians (pediatricians versus child psychiatrists) to newly diagnosed children with 
major depressive disorder by a) the pharmacotherapy category and b) specific antidepressant 
prescribed. 
 
Null Hypothesis 8.a:  There is no difference in the pharmacotherapy category prescribed by 
physicians (pediatricians versus child psychiatrists) for first, second, and third lines of antidepressant 
treatment for newly diagnosed children with major depressive disorder. 
 
Sections two, three, and four of the Phase II survey gathered information from the physicians 
regarding their first, second, and third lines of antidepressant treatment.  The physicians were asked 
to give their specific antidepressant choices.  The variable, class of antidepressant, was created by 
the researcher based on the specific answers from the physicians.  Since both variables 
(pharmacotherapy category and physician type) are categorical the χ2 statistic was utilized.  The χ2 
 
 
 70 
statistic tested whether the proportion of Monoamine Oxidase Inhibitors (MAOIs), Tricyclic 
Antidepressants (TCAs), Tetracyclic Antidepressants, Selective Serotonin Reuptake Inhibitors 
(SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Norepinephrine and Dopamine 
Reuptake Inhibitors (NDRIs), and Other Antidepressants for the first, second, and third lines of 
treatment were equal for pediatricians versus child psychiatrists. 
Null Hypothesis 8.b:  There is no difference in the specific antidepressant prescribed by physicians 
(pediatricians versus child psychiatrists) for first, second, and third lines of treatment for newly 
diagnosed children with major depressive disorder.  
 
Both variables are categorical (specific type of antidepressant and physician type) and the χ2 statistic 
was utilized to test for an association between specific antidepressant (Celexa®, Cymbalta®, 
Effexor®, etc.) and first, second, and third lines of treatment prescribed by pediatricians versus child 
psychiatrists.  
Objective 9:  To predict which physician characteristics affect the treatment prescribed for children 
with major depressive disorder. 
 
The χ2 statistic is useful when the researcher wants to find the association between two categorical 
variables.  However, when there are more than one predictor variable regression is usually a more 
useful statistical tool (Rosner, 2000; Vittinghoff, Glidden, Shiboski, & McCulloch, 2005).  Logistic 
regression is commonly utilized to investigate the association between binary outcomes and multiple 
predictors (Rosner, 2000; Vittinghoff et al., 2005).  This objective was met by using logistic 
regression.  Logistic regression was utilized to investigate the association between categorical 
outcome variables (type of treatment, type of antidepressant treatment) and physician characteristics 
(e.g. age, gender, year of graduation, specialty, board certifications, practice site, geographic 
location, patient volume, and length of time treating children and adolescents).     
Objective 10:  To determine the average length of antidepressant treatment for newly diagnosed 
children with major depressive disorder. 
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Section two of the Phase II survey asked the physicians “how long they continue to prescribe the 
antidepressant(s)” to the child, if the antidepressant is a successful treatment.  The frequencies, as 
these are categorical variables, related to how long physicians continue prescribing an antidepressant 
assuming it is a successful treatment were calculated. 
These categorical variables were transformed into continuous variables so that comparisons could be 
made to the newly published American Academy of Child and Adolescent Psychiatry’s 
recommended six months minimum length of treatment with antidepressant medication (AACAP, 
2007).       
Objective 11:  To determine the types of pharmacotherapy monitoring in newly diagnosed children 
with major depressive disorder. 
 
Section six of the Phase II survey asked the physicians to indicate their primary mode of 
pharmacotherapy monitoring, who conducts the monitoring, and the specific types of monitoring 
conducted.  Based on these responses the frequencies of the categorical variables (mode of 
monitoring, who conducts the monitoring, type of monitoring, and frequency of monitoring) were 
calculated. 
Objective 12:  To determine differences in antidepressant monitoring for newly diagnosed children 
with major depressive disorder and the U.S. FDA recommendations for monitoring children treated 
with antidepressants. 
 
Null Hypothesis 12.0:  There is no difference in pharmacotherapy monitoring for newly diagnosed 
children with major depressive disorder and the U.S. FDA recommendations for monitoring children 
treated with antidepressants.   
 
Section six of the Phase II survey contained questions designed to determine how often physicians 
monitor for the first, second, and third month of treatment.  These categorical variables were 
transformed into continuous variables so comparisons could be made to the U.S. FDA 
recommendations.  The average number of times the physicians monitor per month for month one, 
two, and three of treatment were then compared to the U.S. FDA recommendations for months one, 
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two, and three of treatment.  A t-test was utilized to test for any significant differences between how 
often physicians report they monitor and the U.S. FDA recommendations. 
  
Objective 13:  To determine whether there are differences, by physician type, in the average number 
of times per month physicians monitor children with major depressive disorder. 
 
Null Hypothesis 13.0:  There is no difference, by physician type, in the average number of times per 
month physicians monitor children with major depressive disorder.  
 
The information gathered in section six of the Phase II survey was utilized to determine whether 
there are differences in the average number of times per month physicians monitor children treated 
with antidepressants by physician type.  A comparison of the average number of times per month 
child psychiatrists and pediatricians monitor was tested utilizing the t-test.  
Objectives and Analysis for Adolescents 
     Next, Objectives 14 through 22 focused on the treatment, prescribing patterns, and factors which 
impact the treatment of adolescents (13 through 18 years of age) with major depressive disorder. 
 
Objective 14:  To determine the demographic characteristics of physicians who treat newly 
diagnosed adolescents with major depressive disorder. 
 
This objective was determined from the pediatricians’ and child psychiatrists’ responses to the 
survey questions in section eight of the Phase II survey.  Descriptive statistics or frequency 
distributions were estimated for these categorical variables  
(physicians’ gender, age, year of graduation, practice site, geographic location, population of 
practice area, specialty, board certifications, patient volume, and length of time treating children and 
adolescents). 
 Objective 15:  To determine physicians’ first line of treatment for newly diagnosed adolescents with 
major depressive disorder by: a) type of treatment, b) drug category, and c) specific antidepressant 
prescribed. 
 
Descriptive statistics were calculated for the pediatricians’ and child psychiatrists’ responses to the 
questions in section two of the Phase II survey.  Frequency distributions were estimated for the 
categorical variables type of treatment, drug category, and specific antidepressant prescribed.      
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Objective 16:  To determine physicians’ second and third lines of treatment for newly diagnosed 
adolescents with major depressive disorder by:  a) drug category, and b)specific antidepressant 
prescribed.  
 
These categorical variables are the responses to the survey questions in section three and section 
four, of the Phase II survey.  For both pediatricians and child psychiatrists, analysis consisted of 
descriptive statistics of the drug category and specific antidepressant variables.     
Objective 17:  To determine the difference in first, second, and third lines of antidepressant 
treatment prescribed by physicians (pediatricians versus child psychiatrists) to newly diagnosed 
adolescents with major depressive disorder by a) the pharmacotherapy category and b) specific 
antidepressant prescribed. 
 
Null Hypothesis 17.a:  There is no difference in the pharmacotherapy category prescribed by 
physicians (pediatricians versus child psychiatrists) for first, second, and third lines of antidepressant 
treatment for newly diagnosed adolescents with major depressive disorder. 
 
Sections two, three, and four of the Phase II survey gathered information from the physicians 
regarding their first, second, and third lines of antidepressant treatment.  The physicians were asked 
to give their specific antidepressant choices.  The variable, class of antidepressant, was created by 
the researcher based on the specific answers from the physicians.  Since both variables 
(pharmacotherapy category and physician type prescribed) are categorical the χ2 statistic was 
utilized.  The χ2 statistic tested whether the proportion of Monoamine Oxidase Inhibitors (MAOIs), 
Tricyclic Antidepressants (TCAs), Tetracyclic Antidepressants, Selective Serotonin Reuptake 
Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Norepinephrine and 
Dopamine Reuptake Inhibitors (NDRIs), and Other Antidepressants for the first, second, and third 
lines of treatment are equal for pediatricians versus child psychiatrists.   
Null Hypothesis 17.b:  There is no difference in the specific antidepressant prescribed by physicians 
(pediatricians versus child psychiatrists) for first, second, and third lines of treatment for newly 
diagnosed adolescents with major depressive disorder.  
  
Both variables are categorical (specific type of antidepressant and physician type) and the χ2 statistic 
was utilized to test for an association between specific antidepressant (Celexa®, Cymbalta®, 
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Effexor®, etc.) and first, second, and third lines of treatment prescribed by pediatricians versus child 
psychiatrists.  
Objective 18:  To predict which physician characteristics affect the treatment prescribed for 
adolescents with major depressive disorder. 
 
The χ2 statistic is useful when the researcher want to find the association between two categorical 
variables.  However, when there are multiple predictors regression is a more useful statistical tool 
(Rosner, 2000; Vittinghoff et al., 2005).  Specifically, logistic regression is commonly utilized to 
investigate the association between binary outcomes and multiple predictors (Rosner, 2000; 
Vittinghoff et al., 2005).  This objective was met by using logistic regression.  Logistic regression 
was utilized to investigate the association between categorical outcome variables (type of treatment, 
type of antidepressant treatment) and physician characteristics (e.g. age, gender, year of graduation, 
specialty, board certifications, practice site, geographic location, patient volume, and length of time 
treating children and adolescents).     
Objective 19:  To determine the average length of antidepressant treatment for newly diagnosed 
adolescents with major depressive disorder. 
 
Section two of the Phase II survey asked the physicians “how long they continue to prescribe the 
antidepressant(s)” to the child, if the antidepressant is a successful treatment.   The frequencies, as 
these are categorical variables, related to how long physicians continue prescribing an 
antidepressant, assuming it is a successful treatment, were calculated.  These categorical variables 
were transformed into continuous variables so that comparisons may be made to the newly published 
American Academy of Child and Adolescents Psychiatry’s recommended six month minimum 
length of treatment with antidepressant medication (AACAP, 2007). 
Objective 20:  To determine the types of pharmacotherapy monitoring in newly diagnosed 
adolescents with major depressive disorder. 
 
Section six of the Phase II survey asked the physicians to indicate their primary mode of 
pharmacotherapy monitoring, who conducts the monitoring, and the specific types of monitoring 
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conducted.  Based on these responses the frequencies of the categorical variables (mode of 
monitoring, who conducts the monitoring, type of monitoring, and frequency of monitoring) were 
calculated. 
Objective 21:  To determine differences in antidepressant monitoring for newly diagnosed 
adolescents with major depressive disorder and the U.S. FDA recommendations for monitoring 
adolescents treated with antidepressants. 
 
Null Hypothesis 21.0:  There is no difference in pharmacotherapy monitoring for newly diagnosed 
adolescents with major depressive disorder and the U.S. FDA recommendations for monitoring 
children treated with antidepressants.   
 
Section six of the Phase II survey contained questions designed to determine how often the 
physicians monitor for the first, second, and third month of treatment.  These categorical variables 
were transformed into continuous variables so comparisons could be made to the U.S. FDA 
recommendations.  The average number of times the physicians monitor per month for month one, 
two, and three of treatment were compared to the U.S. FDA recommendations for months one, two, 
and three of treatment.  A t-test was utilized to test for any significant differences between how often 
physicians report they monitor and the U.S. FDA recommendations. 
Objective 22:  To determine whether there are differences, by physician type, in the average number 
of times per month physicians monitor adolescents with major depressive disorder. 
 
Null Hypothesis 22.0:  There is no difference, by physician type, in the average number of times per 
month physicians monitor adolescents with major depressive disorder.  
 
The information gathered in section six of the Phase II survey was also utilized to determine whether 
there are differences in the average number of times per month physicians monitor children treated 
with antidepressants by physician type.  A comparison of the average number of times per month 
child psychiatrists and pediatricians monitor was tested utilizing the t-test.  
Objectives for Factor Analysis  
Objective 23:   To determine the relative importance which physicians place on each factor prior to 
prescribing antidepressants to newly diagnosed children and adolescents with major depressive 
disorder. 
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Objective 24:  To determine the factors associated with physicians’ antidepressant prescribing 
behavior for children and adolescents newly diagnosed with major depressive disorder.   
 
Objectives 23 and 24 utilized the information collected in section seven of the Phase II survey. This 
portion of the survey asked physicians to rate the extent to which 28 variables influences their 
decision of whether or not to prescribe an antidepressant medication to a child or adolescent.  The 
physicians rated the influence of the 28 variables on a scale from 1-4, where 1= not influential, 2= 
somewhat influential, 3= influential, and 4= extremely influential.  Descriptive statistics including 
measures of central tendency (mean) and dispersion (standard deviation) were calculated for the 
physicians’ ratings of each of the variables.  An exploratory factor analysis was utilized to identify 
the hypothetical constructs that influence these 28 variables.  The results of the analyses for both 
phases of this study will be the focus of Chapter Four. 
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CHAPTER FOUR: RESULTS  
 
 
     This chapter contains the results for this study.  The results of the Phase I survey of pediatricians 
is presented first.  As part of Phase II, a pilot study was conducted to evaluate the survey instrument.  
These results are presented next in this chapter, followed by the results of the final survey to 
pediatricians and child psychiatrists.        
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Results for Phase I 
 
     A national random sample of 2,000 pediatricians was obtained from SK&A Informational 
Services, Inc’s, American Medical Association member list.  A cover letter, phase I survey, and 
return postage-paid envelope was sent to 2,000 pediatricians.  A second mailing was conducted 
approximately five weeks later to those pediatricians who did not respond to the first mailing.  
According to Salant & Dillman (1994) mailings of questionnaires should occur more closely 
together than the five weeks allowed in this study.  In this case, however, the second mailing would 
have coincided with the Christmas holiday season.  The decision was made to delay the second 
mailing of the survey until after the holiday season in order to potentially increase the response rate 
of the pediatricians.        
     Of the 2,000 pediatricians surveyed, a total of 424 responded and a total of 200 surveys were 
retuned as bad addresses.  Of the 424 pediatricians who responded 11 indicated they had retired or 
were not in practice and another five surveys were not completed.  Therefore, a total of 408 useable 
surveys were received.  This resulted in a usable response rate of 22.9% for phase I of the study.     
Table 4.1:  Response Rate for Phase I 
__________________________________________N__________Percentage (%)_______________ 
 
Original sample size                                                2,000 
Undeliverable surveys                                                200 
Effective Sample Size                                            1,800                      100.0 
Number of Surveys Returned                                     424                        23.6                          
Unusable Surveys                                                         16 
Usable Surveys                                                           408 
Usable Response Rate                                                                            22.9 
 
     The first three objectives intended to determine the proportion of pediatricians in the United 
States who children and adolescents with major depressive disorder.  In the case a pediatrician did 
not treat major depressive disorder in this population the researcher sought to determine which type 
of health care provider children and/or adolescents would likely be referred.  The purpose for 
determining this information was two-fold.  This information is not in the current scientific literature 
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and the researcher could identify pediatricians who would be willing to participate in Phase II of this 
study.  Each objective will be noted followed by the findings from the study.          
Objective 1:  To determine the proportion of pediatricians who treat children and adolescents with 
major depressive disorder. 
  
     The frequency and proportion of pediatricians who treat children and/or adolescents with major 
depressive disorder was calculated.  The majority of pediatricians (60.0%) indicated they do not treat 
either children or adolescents with major depressive disorder.  Additionally, 28.2% of the 
pediatricians surveyed indicated they treat both children and adolescents for major depressive 
disorder.   No pediatricians indicated they treat children only, while 11.8% indicated they treat 
adolescents only.  The results for Objective 1 are listed in Table 4.2.       
 
Table 4.2:  Pediatricians Treating Children and/or Adolescents with Major Depressive 
Disorder   
 Frequency 
(N) 
Percentage 
(%) 
Treat Children Only  0 0.0 
Treat Adolescents Only 48 11.8 
Treat Both Children and Adolescents  115 28.2 
Do Not Treat  245 60.0 
 
Objective 2:  To determine the proportion of pediatricians who refer children and adolescents with 
major depressive disorder.  
 
     A minority of pediatricians (6.7%) indicated they do not refer either children or adolescents to 
another type of health care provider for the treatment of major depressive disorder.  Approximately 
the same percentage of pediatricians indicated they refer children only (4.2%) or adolescents only 
(4.5%) to another type of health care provider for the treatment of major depressive disorder.  The 
majority of the pediatricians (84.6%) indicated they referred both children and adolescents for the 
treatment of major depressive disorder.  These results are listed in Table 4.3.      
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Table 4.3:  Pediatricians Referring Children and/or Adolescents with Major Depressive 
Disorder   
 Frequency 
(N) 
Percentage 
(%) 
Refer Children Only  17 4.2 
Refer Adolescents Only 18 4.5 
Refer Both Children and Adolescents  341 84.6 
Do Not Refer  27 6.7 
 
 
Objective 3:   To determine the health care provider to whom pediatricians refer a child or 
adolescent with major depressive disorder. 
 
     The results for pediatricians seeing children with major depressive disorder will be discussed first 
followed by the results for adolescents.  Pediatricians listed up to three different health care 
providers to which they would refer children for treatment.  This resulted in 358 total responses.  
Pediatricians cited they most often refer children to some type of psychiatrist (67.6%), with 29.3% of 
the responses indicating a child and adolescent psychiatrist and 38.3% indicating a psychiatrist.  The 
second most popular health care provider to refer children was a psychologist.  A small percentage 
of responses indicated they refer specifically to a child psychologist (1.4%), while some responses 
(13.7%) indicated referral to a psychologist.  A small percentage 5.9% of responses indicated 
referral to a counselor, therapist, or Master’s in Social Work (MSW).  These results are listed in 
Table 4.4.     
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Table 4.4:  Health Care Provider to whom Pediatricians Refer Children and Adolescents with 
Major Depressive Disorder 
 
 
Health Care Provider 
Total 
Frequency-
children  
(N) 
Percentage-
children 
(%) 
Total 
Frequency-
adolescents  
(N) 
Percentage-
adolescents 
(%) 
Psychiatrist 137 38.3 154 42.3 
Child & Adolescent 
Psychiatrist 
105 29.3 91 25.0 
Psychologist 49 13.7 51 14.0 
Counselor, Therapist,  
or MSW 21 5.9 25 6.9 
Crisis Center, Mental 
Health Clinic, Hospital 
20 5.5 23 6.3 
Other Physician 10 2.8 6 1.6 
Unspecified Mental 
Health Care Provider 
6 1.7 5 1.4 
Any Available Mental 
Health Care Provider  
5 1.4 5 1.4 
Child Psychologist 5 1.4 4 1.1 
Total  358 100.0 364 100.0 
 
 
     The responses for adolescents mirrored that of children.  Pediatricians listed up to three different 
health care providers to which they would refer adolescents for treatment.  This resulted in 364 total 
responses.  Pediatricians cited they most often refer adolescents to some type of psychiatrist 
(67.3%), with 25.0% of the responses indicating a child and adolescent psychiatrist and 42.3% 
indicating a psychiatrist.  The second most popular health care provider to refer adolescents was a 
psychologist.  A small percentage of responses indicated they refer specifically to a child 
psychologist (1.1%), while some responses (14.0%) indicated referral to a psychologist.  A small 
percentage 6.9% of responses indicated referral to a counselor, therapist, or Master’s in Social Work 
(MSW).  These results are listed in Table 4.4.     
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     The next study objective sought to determine whether there were geographic differences in 
pediatricians’ willingness to treat versus refer children and/or adolescents with major depressive 
disorder.  This objective and null hypothesis read as follows:   
Objective 4:  To determine geographic differences in pediatricians’ willingness to treat versus 
referral of children and/or adolescents with major depressive disorder.    
 
Null Hypothesis 4.0:  There is no difference in the geographic locations of pediatricians who treat 
versus refer children and/or adolescents for major depressive disorder.   
.          
     Based on the responses, the results showed, that treating and referring patients was not a mutually 
exclusive choice for pediatricians.  Some physicians indicated they treated and referred.  Some 
pediatricians even indicated they would try one line of treatment and if that treatment did not 
produce a response they would refer.  Since treating and referring were not mutually exclusive 
events it was decided to analyze the data by geographic region according to whether or not 
pediatricians treated children.  Next, the data was analyzed by geographic region according to 
whether or not pediatricians treated adolescents.  Since none of the pediatricians indicated they 
“treated children only”, pediatricians were said to treat children if they indicated they “treat both 
children and adolescents”.  Likewise, pediatricians where said not to treat children if they indicated 
they “treated adolescents only” or “did not treat”.  Similarly, pediatricians were classified as treating 
adolescents if they indicated they “treated adolescents only” or “treated both children and 
adolescents”.  Pediatricians were said not to treat adolescents if they indicated they “did not treat”.  
Geographic regions were specified according to the U.S. Census Bureau’s definitions.  The U.S. 
Census Bureau divides the United States into five geographic regions as follows:  Northeast, South, 
Midwest, West, and Pacific.  The states included in each geographic region are listed in Table 4.5.   
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Table 4.5:  States Included in Each Geographic Region  
Northeast South Midwest West Pacific 
Connecticut 
Maine 
Massachusetts 
New Hampshire 
New Jersey 
Pennsylvania 
Rhode Island 
Vermont 
 
Alabama 
Arkansas 
Delaware 
District of Columbia 
Florida 
Georgia 
Kentucky 
Louisiana 
Maryland 
Mississippi 
North Carolina 
Oklahoma 
South Carolina 
Tennessee 
Texas 
Virginia 
West Virginia 
Illinois 
Indiana 
Iowa 
Kansas  
Michigan 
Minnesota 
Missouri 
Nebraska 
North Dakota 
Ohio 
South Dakota 
Wisconsin 
 
Arizona 
California 
Colorado 
Idaho 
Montana 
Nevada 
New Mexico 
Oregon 
Utah 
Washington 
Wyoming 
 
Alaska 
Hawaii 
 
 
     There were only four pediatricians classified as practicing in the Pacific geographic location.  
Instead of dropping these physicians from the analysis it was decided to collapse or combine the 
Pacific and West categories.  This was conducted for the analysis of children and adolescents 
(below).  The results, for pediatricians treating children, are shown in Table 4.6 below and reflect the 
combining of the Pacific and West categories.     
Table 4.6: Treatment of Children Across Geographic Regions   
Treatment 
of Children 
Northeast South Midwest Pacific and 
West 
Total 
Yes 21 35 37 22 115 
No 86 85 68 54 293 
Total 107 120 105 76 408 
Proportion 0.1963 0.2917 0.3524 0.2895 -- 
 
     The χ2 statistic was utilized to determine whether or not there were differences in whether or not 
pediatricians treated children across the four geographic regions.  The χ2 statistic was equal to 6.532, 
df =3, and p= 0.088.  This means that the proportion of pediatricians who treat children does not 
significantly vary according to geographic region and we fail to reject the Null Hypothesis 4.0.  
Since the p-value is close to 0.05, this result warranted a closer look because it is marginally 
significant.  Examining the results and the proportions of physicians who treat in each region 
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revealed the following trend.  Pediatricians in the Midwest are somewhat more likely to treat 
children, while pediatricians in the Northeast are somewhat less likely to treat children for major 
depressive disorder.  Again this is not a significant difference, but a trend.           
     Next, the χ2 statistic was utilized to determine whether or not there were differences in whether or 
not pediatricians treated adolescents across the four geographic regions.  The results are shown in 
Table 4.7 below.     
Table 4.7: Treatment of Adolescents Across Geographic Regions   
Treatment 
of 
Adolescents 
Northeast South Midwest Pacific and 
West 
Total 
Yes 37 44 47 35 163 
No 70 76 58 41 245 
Total 107 120 105 76 408 
 
     The χ2 statistic was equal to 4.019, df = 3, and p=0.259.  This result means the proportion of 
pediatricians who treat adolescents does not significantly vary by geographic region and again we 
fail to reject the Null Hypothesis 4.0.   
     One purpose of Phase I of this study was to identify study participants for Phase II of this study.  
This was important since all pediatricians do not treat children and/or adolescents for major 
depressive disorder and Phase II of the study was designed to determine the treatment and 
prescribing practices of pediatricians and child psychiatrists.  If a pediatrician indicated they treated 
either children or adolescents, they were asked if they would be willing to participate in the Phase II 
survey.  The results indicate that 110 pediatricians were both eligible and willing to participate in 
Phase II.  These results are listed below in Table 4.8 and depicted in Figure 4.1.   These 110 
pediatricians were included in Phase II of this study.    
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Table 4.8:  Treating Pediatricians Willing to Participate in Phase II 
 Frequency  
(N) 
Percentage 
(%) 
Yes 106 26.4 
Yes, depending on length of survey 4 1.0 
No 46 11.5 
Not Applicable  245 61.1 
 
 
 
Figure 4.1:  Breakdown of Pediatricians in Phase I    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participants for 
Phase I: 
Pediatricians 
N = 2,000 
Refer 
Children only= 17 
Adolescents only=18 
Both=341 
Treat 
Adolescents = 48 
Both= 115 
Willing to 
Participate in 
Phase II 
Participants = 110 
Not Willing to 
Participate in 
Phase II = 46 
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Results for the Pilot Study 
 
     A national random sample of 2,500 child psychiatrists was obtained from SK&A Informational 
Services, Inc’s, American Medical Association member list.  A cover letter, Phase II survey, and 
return postage-paid envelope were sent to 10% or 250 of these 2,500 pediatricians.  Due to resource 
constraints only one mailing was performed for the pilot study.  Of the 250 child psychiatrists 
surveyed 22 returned a usable survey and six surveys were returned due to bad addresses.  This 
information is listed below in Table 4.9.          
Table 4. 9:  Response Rate for Pilot Study 
__________________________________________N______________Percentage (%)___________ 
 
Original sample size                                                   250 
Undeliverable surveys                                                    6 
Effective Sample Size                                               244                            100.00% 
Number of Surveys Returned                                       22                                 9.02% 
Unusable Surveys                                                           0 
Usable Responses                                                         22                                 
Usable Response Rate                                                                                    9.02% 
 
     The demographics for the 22 child psychiatrists, who returned surveys for the pilot study are 
listed in Table 4.10.  The majority of the physicians were males (68.18%) and between 41 and 60 
years of age (54.55%).  The year of graduation from medical school varied:  36.36% indicated they 
graduated in 1996- 2003, 22.73% indicated they graduated in 1976 -1985, 18.18% indicated they 
graduated in 1966 – 1975, another 18.18% indicated they graduated in 1986 – 1995, and only 4.55% 
graduated in 1965 or earlier.  The majority (63.63%) of the physicians indicated their primary 
practice site was private-based, as opposed to hospital-based.  The geographic region of the 
physicians’ primary practice site varied.  No physicians practice in the Pacific region, while the 
number practicing in the other regions ranged from 9.09% to 31.82%.  The population of the primary 
practice area varied as 47.62% practice in areas with 250,000 – 999,999 people, 33.33% have 
primary practice sites in areas with 50,000 – 249,999 people, 19.05% practice in areas with a 
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population of 1 million or more people, and none of the physicians practice in areas with 50,000 
people or less.  The majority (81.82%) of the physicians indicated specialties of both adult and child 
psychiatry.  The preponderance of the physicians are board certified as either both adult psychiatrists 
and child psychiatrists (47.62%) or as adult psychiatrists (38.09%).  The majority of physicians 
(78.95%) indicated they treat 10 or less children per week.  Additionally, the bulk (55.00%) of the 
physicians indicated they treat 10 or less adolescents per week.  The majority (54.55%) of the 
physicians indicated they treated children and/or adolescents for greater than 10 years.   
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Table 4.10:  Demographics of Child Psychiatrists from Pilot Study 
Variable N (%) 
Type of Physician: 
Child Psychiatrists 
 
22 (100.00%) 
Gender: 
Male  
Female 
 
15 (68.18%) 
7 (31.82%) 
Age: 
40 years or younger 
41 years – 60 years 
61 years or older 
 
6 (27.27%) 
12 (54.55%) 
4 (18.18%) 
Year Graduated from Medical School: 
1965 or Before  
1966 – 1975 
1976 - 1985 
1986 - 1995 
1996 – 2003 
 
1 (4.55%) 
4 (18.18%) 
5 (22.73%) 
4 (18.18%) 
8 (36.36%) 
Primary Practice Site: 
Private Based Practice 
Hospital Based Practice 
Other (ex.hospital and private) 
 
14 (63.63%) 
3 (13.64%) 
5 (22.73%) 
Geographic Location of Practice: 
Northeast 
South 
Midwest 
West 
Pacific 
 
2 (9.09%) 
7 (31.82%) 
6 (27.27%) 
7 (31.82%) 
0 (0.00%) 
Population of Practice Area: 
Less than 50,000 
50,000 – 249,999 
250,000 – 999,999 
1 million or more 
 
0 (0.00%) 
7 (33.33%) 
10 (47.62%) 
4 (19.05%) 
Physician Specialty: 
Adult Psychiatrist 
Child Psychiatrist 
Adult and Child Psychiatrist 
 
1 (4.54%) 
3 (13.64%) 
18 (81.82%) 
Board Certification: 
Adult Psychiatrist 
Adult and Child Psychiatrist 
Not Board Certified 
 
8 (38.09%) 
10 (47.62%) 
3 (14.29%) 
Child Patient Volume Per Week: 
10 or less 
11 – 40 
 
15 (78.95%) 
4 (21.05%) 
Adolescent Patient Volume Per Week: 
10 or less 
11 – 40 
 
11 (55.00 %) 
9 (45.00%) 
Number of Years Treating Children and/or 
Adolescents: 
Greater than 1 year to 5 years 
Greater than 5 years to 10 years 
Greater than 10 years 
 
 
2 (9.09%) 
8 (36.36%) 
12 (54.55%) 
 
     The purpose of the pilot study was to assess the survey instrument within the population prior to 
mailing to the study population.  All of the child psychiatrists who returned surveys for the pilot 
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study indicated they treat both children and adolescents for major depressive disorder.  The majority 
(59.09%) of the child psychiatrists indicated they treat children with counseling/psychotherapy as a 
first-line of treatment.  Additionally, the majority (68.18%) of the child psychiatrists indicated they 
treat adolescents with both antidepressants and counseling as a first-line of treatment.  Physicians 
were then asked to indicate, which antidepressant they would prescribe as their first-line of 
treatment, in the event they utilized both antidepressants and counseling as the first-line of treatment.  
The results of the pilot study showed that many of the physicians, who indicated they treat children 
and adolescents with counseling only, as a first-line of treatment, also indicated an antidepressant for 
this line of treatment.  More specifically, 12 of the physicians who indicated they treat children with 
counseling only as the first-line of treatment also indicated they utilize an antidepressant.  Another 
six of the physicians who indicated they treat adolescents with counseling only as the first-line of 
treatment also indicated they utilize an antidepressant.  Therefore, 54.55% of the physicians 
answered the first-line of treatment for children incorrectly.  Another, 27.27% of the physicians 
answered the first-line of treatment for adolescents incorrectly.  Based on these findings, it was 
concluded the questions regarding treatment for children and adolescents were not clear and were 
misunderstood and lacked clarity.  Thus the questions regarding first, second, and third-line of 
treatment were revised before the final survey was mailed to the larger sample of child psychiatrists.   
     The following changes were made to the survey instrument.  First, the questions regarding 
treatment were re-worded and headings denoting first, second, and third-lines of treatment were 
added to the survey.  Second, the directions, associated with these treatment questions were altered 
by telling physicians if they indicated use of antidepressants for their first-line of treatment, then 
they should answer the question regarding antidepressant treatment.  More specifically, the 
directions read as follows:  “If your first-line of treatment (in Question #4) included antidepressants 
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(either alone or in combination with counseling/psychotherapy), for EITHER children or adolescents 
please answer Questions #5 - #8, otherwise skip to Section 3, Question #9”.  
     Based on the results from the final survey, the changes in the questions on the survey seemed to 
help clarify the issue in the pilot study, somewhat.  Only nine pediatricians (15.00%) indicated they 
utilized counseling only as a first-line of treatment for children and/or adolescents and listed an 
antidepressant also on the first-line of treatment.  Only sixty-four child psychiatrists (20.25%) 
indicated their preferred first line of treatment was counseling only for children and/or adolescents 
and listed an antidepressant also on the first-line of treatment.  The majority of the physicians went 
on to list this same antidepressant as their answer for the second line of treatment.  Since this was the 
case, it was assumed, that counseling only was truly their first-line of treatment and the 
antidepressant listed was actually part of their choice for the second-line of treatment.   
 
 
Results for Phase II 
 
     Two groups of physicians were surveyed for Phase II of this study.  The pediatricians (n=110) 
who indicated in phase I they treated children and/or adolescents diagnosed with major depressive 
disorder, and whom agreed to participate in phase II were included.  Additionally, a random sample 
of child psychiatrists (n=2,250) were surveyed in phase II.  Pediatricians and child psychiatrists were 
mailed a cover letter, eight-page survey, and return postage paid-envelope.  Those who did not 
respond to the first mailing were mailed a second copy of the cover letter, survey, and postage-paid 
envelope approximately two and a half weeks later.  Response rates are based on those surveys 
received two months after the initial mailing, for both groups of physicians.  Details of the number 
of respondents are discussed next.      
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Child Psychiatrists:   
     Of the 2,250 mailed surveys, 316 surveys were returned, and 268 were undeliverable, due to bad 
addresses.  Of the 316 returned surveys, 14 surveys were unusable as these physicians indicated they 
were either retired or no longer in practice.  Another three surveys were unusable because the 
physicians failed to complete the survey.  The usable number of surveys from the child psychiatrists 
equaled 299.      
Table 4.11:  Response Rate for Child Psychiatrists - Phase II 
__________________________________________N__________Percentage (%)_______________ 
 
Original sample size                                                2,250 
Undeliverable surveys                                                268 
Effective Sample Size                                            1,982                        100.0% 
Number of Surveys Returned                                     316                          15.9% 
Unusable Surveys                                                         17 
Usable Responses                                                        299 
Usable Response Rate                                                                              15.1% 
 
Pediatricians: 
 
     One hundred ten pediatricians indicated they treated children and/or adolescents and were willing 
to participate in the phase II survey.  Of these 110 pediatricians surveyed, 60 returned surveys were 
returned.  Of the 60 returned surveys three were not useable, so these mailings resulted in 57 useable 
surveys from pediatricians. 
     
Table 4.12:  Response Rate for Pediatricians - Phase II 
__________________________________________N__________Percentage (%)_______________ 
 
Original sample size                                                    110 
Undeliverable surveys                                                     0 
Effective Sample Size                                                110                            100.0 
Number of Surveys Returned                                        60 
Unusable Surveys                                                            3 
Usable Responses                                                          57 
Usable Response Rate                                                                                  51.8% 
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Results for Non-Response Analysis 
     
     Bias refers to any differences between an estimate from a survey and the actual value in the 
population.  Non-response is a type of bias and refers to the difference between respondents and 
non-respondents of a survey.  More specifically, non-response bias refers to the idea that people who 
do not respond to surveys may answer questions differently than those people who do respond to 
surveys.  One method to assess non-response bias involves comparing “early responders” to “late 
responders”.   This method assumes late responders are similar to non-responders and thus late 
responders serve as a proxy for non-responders.  Utilizing this method revealed no statistical 
differences among the demographic characteristics of early responders and non-responders, in this 
study.  Table 4.13 shows the statistical results of the comparisons of the demographic variables.      
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Table 4.13:  Comparison of Demographics of Early Responders and Non-Responders  
Variable Early 
Responders  
(N) 
Non-
Responders 
(N) 
Test 
Statistic 
Significance 
(p) 
Gender: 
Male 
Female 
 
80 
42 
 
66 
51 
 
χ2=2.110 
 
0.146 
Primary Practice Site: 
Hospital-Based  
Private Practice 
 
20 
76 
 
25 
65 
 
χ2=1.221 
 
0.269 
Population of Practice Area: 
Less than 50,000 
50,000-249,999 
250,000-999,999 
1 million or more   
 
18 
42 
24 
34 
 
18 
32 
35 
33 
 
 
χ2=3.417 
 
 
0.332 
Geographic Location of Practice: 
Northeast 
South 
Midwest 
West 
Pacific  
 
37 
29 
31 
19 
1 
 
24 
44 
23 
23 
1 
 
 
χ2=7.402 
 
 
0.116 
Physician Specialty: 
Child & Adolescent Psychiatry 
Pediatrics 
Adult/Child & Adolescent Psychiatry 
 
10 
17 
87 
 
15 
18 
82 
 
 
χ2=1.172 
 
 
0.557 
Board Certification: 
Adult Psychiatry 
Child & Adolescent Psychiatry 
Pediatrics 
Not Board Certified 
Adult/Child & Adolescent Psychiatry 
 
17 
0 
20 
10 
65 
 
22 
1 
20 
5 
66 
 
 
χ2=3.298 
 
 
0.509 
Number of Years Treating Children 
and/ or Adolescents: 
1-5 years 
5-10 years 
Greater than 10 years 
 
 
7 
17 
96 
 
 
8 
21 
87 
 
 
χ2=0.863 
 
 
0.650 
 
     Comparisons were also made to see if early responders and non-responders differed in the way 
they answered treatment questions for children and adolescents.  These comparisons are listed in 
Table 4.14.  No statistical differences were found between early responders and non-responders on 
the age groups they treat, first-line of treatment for children, first-line of treatment for adolescents, 
antidepressant treatment for children, antidepressant treatment for adolescents, and patient volume.     
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Table 4.14:  Comparisons of Treatment Variables of Early Responders and Non-Responders  
Variable Early 
Responders 
(N) 
Non-
Responders 
(N) 
Test 
Statistic 
Significance 
(p) 
Age Group Physician Treats: 
Adolescents 
Both Children and Adolescents 
 
3 
113 
 
8 
112 
 
χ2=2.210 
 
0.137 
First-line of Treatment (Children): 
Antidepressants or Antidepressants and 
Counseling 
Counseling Only 
 
 
3 
105 
 
 
2 
110 
 
Fisher’s 
Exact 
Test 
 
 
0.679 
First-line of Treatment (Adolescents): 
Antidepressants or Antidepressants and 
Counseling 
Counseling Only 
 
 
1 
107 
 
 
1 
111 
 
Fisher’s 
Exact 
Test 
 
 
1.000 
First-line of Antidepressant Treatment 
for Children: 
Non-Prozac
®
 
Prozac
® 
 
 
32 
35 
 
 
36 
39 
 
 
χ2=0.001 
 
 
0.977 
First-line of Antidepressant Treatment 
for Adolescents: 
Non-Prozac
®
 
Prozac
® 
 
 
47 
46 
 
 
53 
49 
 
 
χ2=0.039 
 
 
0.843 
Child Patient Volume Per Week: 
40 patients or less 
Greater than 40 patients 
 
112 
6 
 
111 
5 
 
χ2=0.078 
 
0.780 
Adolescent Patient Volume Per Week: 
40 patients or less 
Greater than 40 patients 
 
109 
9 
 
111 
5 
 
χ2=1.144 
 
0.285 
 
     Based on the non-response analysis, it was found that there was no significant statistical 
difference between early responders and non-responders.   
 
Phase II:  Results for Children with Major Depressive Disorder- Objectives 5-13 
 
     Objectives 5 through 13 focus on the treatment and prescribing patterns of children (five through 
12 years of age) with major depressive disorder.  Each objective will be stated followed by the 
results pertaining to the objective.     
 
Objective 5:  To determine the demographic characteristics of physicians who treat newly diagnosed 
children with major depressive disorder. 
 
     The demographics of physicians who treat children with major depressive disorder are listed in 
Table 4.15 below.  Of those physicians from phase II who indicated they treat children with major 
depressive disorder, 42 (12.50%) were pediatricians and 294 (87.50%) were child psychiatrists.  The 
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majority of physicians who treat children with major depressive disorder are males (61.75%), and 
are between 41 and 60 years of age (66.57%).  The year of graduation from medical school varied:  
33.66% indicated they graduated in 1986 -1995, 27.83% indicated they graduated in 1976 – 1985, 
20.06% indicated they graduated in 1966 – 1975, 11.97% indicated they graduated in 1996 – 2003, 
and only 6.47% graduated in 1965 or earlier.  The majority (56.93%) of the physicians indicated 
their primary practice site was private-based, as opposed to hospital-based.  The geographic region 
of the physicians’ primary practice site varied as only 0.63% practice in the Pacific.  The number 
practicing in the other four regions ranged between 19.75% and 29.15%.  The population of the 
primary practice area varied as 34.26% have primary practice sites in areas with 50,000 – 249,999 
people, 25.93% practice in areas with a population of 1 million or more people, 24.38% practice in 
areas with 250,000 – 999,999 people, and 15.43% practice in areas with 50,000 people or less.  The 
majority (73.57%) of the physicians indicated specialties of both adult and child psychiatry, and the 
majority (57.14%) are board certified as both adult psychiatrists and child psychiatrists.  The practice 
volume also varied somewhat, however the majority of physicians indicated they treat both, 10 or 
less children (70.68%) and 10 or less adolescents (56.17%) per week.  The majority (74.77%) of the 
physicians reported treating children for greater than 10 years.       
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Table 4.15:  Demographics of Physicians Who Treat Children for Major Depressive Disorder 
Variable N (%) 
Type of Physician: 
Pediatricians 
Child Psychiatrists 
 
42 (12.50%) 
294 (87.50%) 
Gender: 
Male  
Female 
 
205 (61.75%) 
127 (38.25%) 
Age: 
40 years or younger 
41 years – 60 years 
61 years or older 
 
43 (12.95%) 
221 (66.57%) 
68 (20.48%) 
Year Graduated from Medical School: 
1965 or Before 
1966 – 1975 
1976 - 1985 
1986 - 1995 
1996 – 2003 
 
20 (6.47%) 
62 (20.06%) 
86 (27.83%) 
104 (33.66%) 
37 (11.97%) 
Primary Practice Site: 
Private Based Practice 
Hospital Based Practice 
Other (ex. hospital and private)  
 
189 (56.93%) 
66 (19.88%) 
77 (23.19%) 
Geographic Location of Practice: 
Northeast 
South 
Midwest 
West 
Pacific 
 
73 (22.88%) 
93 (29.15%) 
88 (27.59%) 
63 (19.75%) 
2 (0.63%) 
Population of Practice Area: 
Less than 50,000 
50,000 – 249,999 
250,000 – 999,999 
1 million or more 
 
50 (15.43%) 
111 (34.26%) 
79 (24.38%) 
84 (25.93%) 
Physician Specialty: 
Child Psychiatrist 
Pediatrics 
Adult and Child Psychiatrist 
Other (ex. adult and child psychiatry and general practice) 
 
36 (10.81%) 
37 (11.11%) 
245 (73.57%) 
15 (4.50%) 
Board Certification: 
Adult Psychiatrist 
Child Psychiatrist 
General Practitioner 
Pediatrician 
Adult and Child Psychiatrist 
Other (ex. adult and child psychiatry and pediatrics) 
Not Board Certified 
 
58 (17.63%) 
1 (0.30%) 
1 (0.30%) 
41 (12.46%) 
188 (57.14%) 
18 (5.47%) 
22 (6.69%) 
Child Patient Volume Per Week: 
10 or less 
11 – 40 
41 – 80 
81 or greater 
 
229 (70.68%) 
79 (24.38%) 
13 (4.01%) 
3 (0.93%) 
Adolescent Patient Volume Per Week: 
10 or less 
11 – 40 
41 – 80 
81 or greater 
 
182 (56.17%) 
121 (37.35%) 
16 (4.94%) 
5 (1.54%) 
Number of Years Treating Children and/or Adolescents: 
Greater than 1 year to 5 years 
Greater than 5 years to 10 years 
Greater than 10 years 
 
24 (7.29%) 
59 (17.93%) 
246 (74.77%) 
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Objective 6:  To determine physicians’ first-line of treatment for newly diagnosed children with 
major depressive disorder by: a) type of treatment, b) drug category, and c) specific antidepressant 
prescribed. 
 
     A majority of physicians, both pediatricians (63.46%) and child psychiatrists (52.19%) indicated 
their preferred first-line of treatment for children with major depressive disorder is a combination 
treatment of antidepressants and counseling.  Counseling only was the next most frequently 
preferred choice as a first-line of treatment for both pediatricians (28.85%) and child psychiatrists 
(40.07%).  Few pediatricians (7.69%) and child psychiatrists (1.01%) indicated they use 
antidepressants only as a first-line of treatment for children.  The results for the first-line of 
treatment for children with major depressive disorder are listed in Table 4.16.      
Table 4.16 :  First-Line of Treatment for Children with Major Depressive Disorder 
Type of Treatment All Physicians 
N (%) 
Pediatricians 
N (%) 
Child 
Psychiatrists  
N (%) 
Antidepressants Only 7 (2.00%) 4 (7.69%) 3 (1.01%) 
Counseling/Psychotherapy Only 134 (38.40%) 15 (28.85%) 119 (40.07%) 
Both Antidepressants and Counseling 188 (53.87%) 33 (63.46%) 155 (52.19%) 
Other Treatment 20 (5.73%) 0 (0.00%) 20 (6.73%) 
 
 
     In the event a physician utilized antidepressants as a first-line of treatment, all of the pediatricians 
(100.00%) indicated their first-line of treatment would include an Selective Serotonin Reuptake 
Inhibitors (SSRI) type antidepressant.  The majority of the child psychiatrists (96.00%) also 
indicated they utilize an SSRI type antidepressant.  The results for the first-line of treatment by drug 
class are listed in Table 4.17.  
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Table 4.17:  Therapeutic Category of Antidepressants Used as First-Line of Treatment for 
Children  
Drug Class All Physicians  
N (%) 
Pediatricians 
N (%) 
Child 
Psychiatrists 
 N (%) 
Tricyclic Antidepressants (TCAs) 2 (0.95%) 0 (0.00%) 2 (1.14%) 
Tetracyclic Antidepressants 1 (0.47%) 0 (0.00%) 1 (0.57%) 
Selective Serotonin Reuptake 
Inhibitors (SSRIs) 
204 (96.68%) 36 (100.00%) 168 (96.00%) 
Norepinephrine and Dopamine 
Reuptake Inhibitors (NDRIs) 
4 (1.90%) 0 (0.00)% 4 (2.29%) 
 
     The specific type of antidepressant varied somewhat for both pediatricians and child psychiatrists.  
Still greater than half of the pediatricians (56.76%) and child psychiatrists (51.98%) indicated they 
utilized Prozac® as their first-line of antidepressant treatment for children with major depressive 
disorder.  For first-line treatment, both pediatricians (24.33%) and child psychiatrists (27.12%) 
indicated Zoloft® to be the second most commonly utilized antidepressant.  Results for the first-line 
of antidepressant treatment for children are listed in Table 4.18.       
Table 4.18:  Specific Antidepressant Used as First-Line Treatment for Children  
Antidepressant All Physicians  
N (%) 
Pediatricians  
N (%) 
Child 
Psychiatrists  
N (%) 
Prozac® 113 (52.80%) 21 (56.76%) 92 (51.98%) 
Zoloft® 57 (26.64%) 9 (24.33%) 48 (27.12%) 
Celexa® 21 (9.81%) 5 (13.51%) 16 (9.04%) 
Lexapro® 11 (5.14%) 0 (0.00%) 11 (6.21%) 
Wellbutrin® 4 (1.87%) 0 (0.00%) 4 (2.26%) 
Tofranil® 2 (0.93%) 0 (0.00%) 2 (1.13%) 
Paxil® 1 (0.47%) 1 (2.70%) 0 (0.00%) 
Remeron® 1 (0.47%) 0 (0.00%) 1 (0.57%) 
Listed multiple antidepressants 4 (1.87%) 1 (2.70%) 3 (1.69%) 
 
Objective 7:  To determine physicians’ second and third-lines of treatment for newly diagnosed 
children with major depressive disorder by:  a) drug category, and b) specific  antidepressant 
prescribed.  
 
     In the event the first-line of treatment was not successful, pediatricians indicated they would 
switch to a different antidepressant (48.00%), while another 26.00% indicated they would add 
antidepressant treatment.  The majority (53.85%) of child psychiatrists, reported switching to a 
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different antidepressant, in the event the first-line of treatment was not successful.  Many child 
psychiatrists (39.86%) indicated they would add antidepressant treatment to the first-line of 
treatment.  The results for the second-line of treatment for children are listed in Table 4.19.   
Table 4.19:  Second-Line of Treatment for Children with Major Depressive Disorder  
Type of Treatment All 
Physicians 
N (%) 
Pediatricians  
N (%) 
Child 
Psychiatrists 
N (%) 
Augment with Antidepressants  127 (37.80%) 13 (26.00%) 114 (39.86%) 
Switch to a Different Antidepressant 178 (52.98%) 24 (48.00%) 154 (53.85%) 
Augment with 
Counseling\Psychotherapy 
11 (3.27%) 4 (8.00%) 7 (2.45%) 
Switch or Augment with 
Antidepressant 
4 (1.19%) 1 (2.00%) 3 (1.04%) 
Other Treatment 16 (4.76%) 8 (16.00%) 8 (2.80%) 
 
 
     As was the case for the first-line of treatment, the majority of pediatricians (97.22%) and child 
psychiatrists (85.43%) indicated they utilize SSRIs as the second-line of treatment for children with 
major depressive disorder.  The majority of pediatricians (Prozac® 36.85%, Zoloft® 28.95%) and 
child psychiatrists (Prozac® 30.08%, Zoloft® 27.82%) reported either Prozac® or Zoloft® as their 
principal choices of antidepressants for second-line of treatment.  The antidepressant class and 
specific antidepressant reported as second-line of treatment are listed in Table 4.20 and Table 4.21.    
Table 4.20:  Therapeutic Category of Antidepressant Used as Second-Line of Treatment for 
Children  
Drug Class All 
Physicians  
N (%) 
Pediatricians 
N (%) 
Child 
Psychiatrists 
N (%) 
Tricyclic Antidepressant (TCAs) 6 (2.07%) 1 (2.78%) 5 (1.97%) 
Tetracyclic Antidepressants 2 (0.69%) 0 (0.00%) 2 (0.79%) 
Selective Serotonin Reuptake Inhibitors 
(SSRIs) 
252 (86.90%) 35 (97.22%) 217 (85.43%) 
Selective-Norepinephrine Reuptake 
Inhibtors (SNRIs) 
8 (2.76%) 0 (0.00%) 8 (3.15%) 
Norepinephrine and Dopamine Reuptake 
Inhibitors (NDRIs) 
21 (7.24%) 0 (0.00%) 21 (8.27%) 
Other Antidepressants 1 (0.34%) 0 (0.00%) 1 (0.39%) 
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Table 4.21:  Specific Antidepressant Used as Second-Line Treatment for Children  
Antidepressant All 
Physicians 
N (%) 
Pediatricians 
N (%) 
Child 
Psychiatrists 
N (%) 
Prozac® 94 (30.92%) 14 (36.85%) 80 (30.08%) 
Zoloft® 85 (27.96%) 11 (28.95%) 74 (27.82%) 
Celexa® 29 (9.54%) 3 (7.89%) 26 (9.77%) 
Lexapro® 21 (6.91%) 3 (7.89%) 18 (6.77%) 
Wellbutrin® 21 (6.91%) 0 (0.00%) 21 (7.90%) 
Cymbalta® 4 (1.31%) 0 (0.00%) 4 (1.50%) 
Effexor® 4 (1.31%) 0 (0.00%) 4 (1.50%) 
Tofranil® 3 (0.99%) 0 (0.00%) 3 (1.13%) 
Remeron 2 (0.66%) 0 (0.00%) 2 (0.75%) 
Pamelor® 2 (0.66%) 0 (0.00%) 2 (0.75%) 
Desyrel® 1 (0.33%) 0 (0.00%) 1 (0.38%) 
Elavil® 1 (0.33%) 1 (2.63%) 0 (0.00%) 
Paxil® 1 (0.33%) 1 (2.63%) 0 (0.00%) 
Listed multiple 
antidepressants 
36 (11.84%) 5 (13.16%) 31 (11.65%) 
 
     In the event the second-line of treatment was not successful the majority (51.28%) of 
pediatricians indicated they would try some “other” type of treatment for children with major 
depressive disorder.  In comparison, the majority of child psychiatrists (66.43%) reported they would 
persist with antidepressant treatment by switching these children to another antidepressant treatment.  
Table 4.22 shows the results for the third-line of treatment for children.  
Table 4.22:  Third-Line of Treatment for Children with Major Depressive Disorder 
Type of Treatment All 
Physicians 
N (%) 
Pediatricians 
N (%) 
Child 
Psychiatrists 
N (%) 
Augment with Antidepressants  21 (6.58%) 1 (2.56%) 20 (7.15%) 
Switch to a Different Antidepressant 191 (59.88%) 5 (12.82%) 186 (66.43%) 
Augment with Counseling\Psychotherapy 24 (7.52%) 11 (28.21%) 13 (4.64%) 
Switch or Augment with Antidepressant 4 (1.25%) 2 (5.13%) 2 (0.71%) 
Switch or Other Treatment 3 (0.94%) 0 (0.00%) 3 (1.07%) 
Other Treatment 76 (23.83%) 20 (51.28%) 56 (20.00%) 
 
     The majority of the pediatricians (95.00%), who indicated they would try some “other” type of 
treatment for children, indicated they would refer these patients to psychiatry.  The majority of the 
child psychiatrists (71.44%) indicated they would try some other type of medication.  The four 
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medications reported to be utilized most often were antipsychotics, mood stabilizers, 
anticonvulsants, or lithium.  These “other treatment” choices are listed in Tables 4.23 and 4.24.      
 
Table 4.23:  Pediatricians’  “Other 3rd Line of Treatment” for Children     
Type of Treatment Pediatricians N (%) 
Refer to Psychiatry 19 (95.00%) 
Antipsychotic 1 (5.00%) 
 
 
Table 4.24:  Child Psychiatrists’  “Other 3rd Line Treatment” for Children    
Type of Treatment Child Psychiatrists N (%) 
Antipsychotic 10 (17.86%) 
Mood Stabilizer 10 (17.86%) 
Anticonvulsants 5 (8.93%) 
Lithium 5 (8.93%) 
Combination of Antidepressants  3 (5.35%) 
Antipsychotic or Anticonvulsant 2 (3.56%) 
Thyroid 1 (1.79%) 
Lithium or Thyroid 1 (1.79%) 
Mood Stabilizer or Antipsychotic 1 (1.79%) 
Lithium or Antipsychotic 1 (1.79%) 
Thyroid or Antipsychotic 1 (1.79%) 
Other: Re-evaluate environment, 
hospitalization, other counseling, etc 
16 (28.56%) 
 
     The third-line of treatment for children with major depressive disorder still included the use of an 
SSRI antidepressant for the majority (52.94%) of the child psychiatrists.  One-third, of the child 
psychiatrists (33.16%) indicated they would utilize Norepinephrine and Dopamine Reuptake 
Inhibitors (NDRIs) as their third-line of treatment in comparison a majority (55.56%) of 
pediatricians indicated they would utilize an NDRI type antidepressant as their third-line of 
treatment.  In contrast, pediatricians (44.44%) indicated they utilize SSRIs in their third-line of 
treatment.  Findings for the therapeutic category associated with the third-line of treatment of 
children with major depressive disorder are listed in Table 4.25.    
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Table 4.25:  Therapeutic Category of Antidepressant Used as Third-Line of Treatment for 
Children 
Drug Class All 
Physicians 
N (%) 
Pediatricians 
N (%) 
Child 
Psychiatrists 
N (%) 
Tricyclic Antidepressants (TCAs) 1 (0.51%) 0 (0.00%) 1 (0.53%) 
Tetracyclic Antidepressants 2 (1.02%) 0 (0.00%) 2 (1.07%) 
Selective Serotonin Reuptake Inhibitors 
(SSRIs) 
103 
(52.55%) 
4 (44.44%) 99 (52.94%) 
Selective-Norepinephrine Reuptake 
Inhibitors (SNRIs) 
22 (11.23%) 0 (0.00%) 22 (11.77%) 
Norepinephrine and Dopamine Reuptake 
Inhibitors (NDRIs) 
67 (34.18%) 5 (55.56%) 62 (33.16%) 
Other Antidepressants 1 (0.51%) 0 (0.00%) 1 (0.53%) 
    
     Results for the specific antidepressant associated with the third-line of treatment for children are 
listed in Table 4.26.  The majority of pediatricians indicated the use of either Wellbutrin® (55.56%) 
or Zoloft® (33.33%) as their third-line of treatment for children with major depressive disorder.  
Child psychiatrists’ choice of antidepressant for use as their third-line of treatment for children was 
more varied than pediatricians’.  Child psychiatrists indicated Wellbutrin® as their most frequently 
(30.24%) utilized antidepressant for the third-line of treatment.  As indicated above SSRIs were the 
most frequently utilized class of antidepressants, however the specific type of SSRI medication 
varied from Zoloft® 16.10%, Prozac® 11.22%, Celexa® 8.29%, Lexapro® 5.36%, and Paxil® 1.95%.   
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Table 4.26:  Specific Antidepressant Used as Third-Line Treatment for Children  
Antidepressant All Physicians 
N (%) 
Pediatricians 
N (%) 
Child 
Psychiatrists 
N (%) 
Prozac® 24 (11.22%) 1 (11.11%) 23 (11.22%) 
Zoloft® 36 (16.82%) 3 (33.33%) 33 (16.10%) 
Celexa® 17 (7.94%) 0 (0.00%) 17 (8.29%) 
Lexapro® 11 (5.14%) 0 (0.00%) 11 (5.36%) 
Wellbutrin® 67 (31.31%) 5 (55.56%) 62 (30.24%) 
Cymbalta® 5 (2.33%) 0 (0.00%) 5 (2.44%) 
Effexor® 15 (7.01%) 0 (0.00%) 15 (7.32%) 
Tofranil® 1 (0.47%) 0 (0.00%) 1 (0.49%) 
Remeron® 2 (0.93%) 0 (0.00%) 2 (0.98%) 
Desyrel® 1 (0.47%) 0 (0.00%) 1 (0.49%) 
Paxil® 4 (1.87%) 0 (0.00%) 4 (1.95%) 
Listed multiple antidepressants  31 (14.49%) 0 (0.00%) 31 (15.12%) 
 
Objective 8: To determine the difference in first, second, and third-lines of antidepressant treatment 
prescribed by physicians to newly diagnosed children with major depressive disorder by a) the 
pharmacotherapy category and b) specific antidepressant prescribed. 
 
Null Hypothesis 8.a:  There is no difference in the pharmacotherapy category prescribed by 
physicians (pediatricians versus child psychiatrists) for first, second, and third lines of 
antidepressant treatment for newly diagnosed children with major depressive disorder. 
 
Null Hypothesis 8.b:  There is no difference in the specific antidepressant prescribed by physicians 
(pediatricians versus child psychiatrists) for first, second, and third lines of treatment for newly 
diagnosed children with major depressive disorder.  
 
     In order to determine whether there is an association between the first, second, and third lines of 
antidepressant treatment and physician type several steps were needed in the statistical analysis. Chi 
Square (χ2) tests were utilized to examined the association between two variables:  physician type 
(pediatrician versus child psychiatrist) and pharmacotherapy category or antidepressant (TCAs, 
Tetracyclics, SSRIs, SNRIs, NDRIs, and Other Antidepressants).  Separate χ2 tests examined the 
association between the first-line of pharmacotherapy class and physician type, second-line of 
pharmacotherapy class and physician type, and third-line of pharmacotherapy class and physician 
type.  Each of these three χ2 tests indicated no significance between the variables.  Furthermore, over 
20% of the cell counts for each of the tests were less than five.  When this is the case the χ2 test is 
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probably not a valid statistical test.  To manage small cell sizes cells can be collapsed or combined.  
For this study, groups of antidepressant categories were collapsed or combined.  Since the majority 
of the scientific research has focused on utilizing SSRIs in treating children antidepressant 
categories, were combined into SSRIs and Non-SSRIs.  Therefore, the next set of analyses 
determined whether there was a relationship between physician type (pediatrician versus child 
psychiatrist) and SSRIs versus Non-SSRIs, for first, second, and third-lines of treatment.  Even after 
collapsing the antidepressant drugs into these two groups, χ2 tests still resulted in small expected 
values.  In this case, the Fisher’s exact test may be used to examine the associations between 
physician type and antidepressant categories.  The Fisher’s exact test may be utilized when a 
researcher wants to make a comparison between two binomial variables and is especially useful for 
small sample sizes because the assumption of normal approximation to the binomial distribution is 
relaxed.   
     The association between physician type and antidepressant category prescribed for children is not 
statistically significant at the p< 0.05 level.  These results are listed in Table 4.27.  Therefore, we fail 
to reject the Null Hypothesis 8.a:  There is no difference in the pharmacotherapy category 
prescribed by physicians (pediatricians versus child psychiatrists) for first, second, and third lines of 
antidepressant treatment for newly diagnosed children with major depressive disorder. 
Table 4.27:   Association Between Physician Type and Antidepressant Category 
Association Two-sided Probability 
Children’s First-line of Antidepressant: 
    Physician Type * Antidepressant Type  
 
 
0.6058 
Children’s Second-line of Antidepressant: 
    Physician Type * Antidepressant Type  
 
 
0.0616 
Children’s Third-line of Antidepressant: 
    Physician Type * Antidepressant Type  
 
 
0.7382 
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     For Objective 8, several steps were used to determined the association between the first, second, 
and third lines of specific antidepressant treatment and physician type.  First, three χ2 tests, one for 
each line of treatment (first, second, and third-line) were conducted to examine the association 
between two variables:  physician type (pediatrician versus child psychiatrist) and specific 
antidepressant prescribed.  Results showed the specific type of antidepressant medication used by the 
physicians varied across all three lines of treatment (first-line of treatment there were 11 different 
antidepressants, for the second-line of treatment there were 29 different antidepressants, and for the 
third-line there were 34 different antidepressants).  Thus, it was necessary to collapse the 
antidepressant categories into two groups.  Since Prozac® is the only FDA approved antidepressant, 
the researcher collapsed the specific antidepressants into, either a Prozac® or non- Prozac®  group.  
After the antidepressants were recoded into these groups, χ2 tests were utilized to determine the 
association between physician type (pediatrician versus child psychiatrist) and specific 
antidepressant (Prozac® versus non- Prozac®) for each line of treatment (first, second, and third).  
Results of these analyses are below in Table 4.28.    
Table 4.28:  Association Between Physician Type and Prozac
®
 versus Non-Prozac
®
 Groups 
 Pediatrician 
(N) 
Child 
Psychiatrist 
(N) 
Test Statistic p-value 
1
st
-Line of Antidepressant  
Treatment: 
Non-Prozac® 
Prozac® 
 
 
16 
21 
 
 
84 
92 
 
 
χ2=0.2468 
 
 
0.6193 
2nd-Line of Antidepressant 
Treatment: 
Non-Prozac® 
Prozac®  
 
 
24 
14 
 
 
186 
80 
 
 
χ2=0.7128 
 
 
0.3985 
3
rd
-Line of Antidepressant 
Treatment: 
Non-Prozac® 
Prozac® 
 
 
8 
1 
 
 
182 
23 
 
Fisher’s 
Exact Test 
 
 
1.0000 
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     Based on the χ2 tests and the Fisher’s exact test it was concluded there is no statistically 
significant association between physician type and the specific antidepressant (Prozac® versus Non-
Prozac®) prescribed to children.  On the basis of these tests the Null Hypothesis 8.b:  There is no 
difference in the specific antidepressant prescribed by physicians (pediatricians versus child 
psychiatrists) for first, second, and third lines of treatment for newly diagnosed children with major 
depressive disorder, is not rejected.  
Objective 9:  To predict which physician characteristics affect the treatment prescribed for children 
with major depressive disorder. 
 
     Regression is a useful statistical tool to assess the possible association between an outcome 
variable and one or more predictor variables.  In this study, the association between the outcome 
variable type of treatment prescribed for children and physician characteristics will be assessed.  For 
this analysis, the first line of treatment is the outcome or dependent variable.   This line of treatment 
may be categorized as treatment type (antidepressant treatment versus counseling).  The outcome 
variable is categorical in nature and necessitates a form of regression called logistic regression.  
Logistic regression provides a method to model the dependency of a binary outcome variable on one 
or more predictor or independent variables and was utilized to examine the association between first-
line of treatment for major depressive disorder in children and physician characteristics.  In this 
study, the predictor or independent variables are physician characteristics such as:  specialty of 
physician, gender, age, physicians’ primary practice site, geographic location of practice, population 
of community of physicians’ primary practice site, board certification, patient volume per week, and 
the length of time the physician has treated the child and adolescent population.  The logistic 
regression equation predicts the probability an individual will be in one of the two levels of the 
binary outcome.  The logistic regression equation is as follows:   
 
                          logit(p) =  α +   β1x1 +……….. +   βk xk  
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     If x1,…….., xk are the independent variables of interest and y is a binomial outcome  
 
variable with a probability of success = pi (Rosner, 2000).                     
 
     Variable selection involves coming up with the best subset of independent variables for the 
regression model.  There are several variable selection methods which may be utilized including 
forward, backward, and stepwise (Cody & Smith, 1997).  Forward selection enters the most 
significant, independent variable followed by the next most significant independent variable until a 
specific criterion has been met.  This criterion is usually based on statistical significance in the 
model (Cody & Smith, 1997).  Backward selection involves starting with all of the independent 
variables in the model and then removing the least significant variable, then the next least significant 
variable, and so on until the computer program finds the best subset of independent variables.  
Stepwise selection begins like forward selection, however in stepwise selection variables may leave 
the model as well as enter.  After an independent variable is added to the regression model, the 
model is tested for significance.  If the addition of the variable still results in a significant model the 
variable is retained, if not it is removed from the regression model.  Stepwise selection provides an 
effective method to screen a relatively large number of independent variables.  This method is 
especially useful if the outcome being studied is somewhat new and associations between the 
outcome and independent variables are not understood (Hosmer & Lemeshow, 2000).  The objective 
in this study is to examine the relationship between physician treatment choices and physician 
characteristics for a relatively large number of independent variables.  Additionally, the relationships 
between the outcome and independent variables have not been studied in the context of the treatment 
of childhood or adolescent depression.  Therefore, stepwise logistic regression will provide a means 
to screen the various physician characteristics (independent variables) and examine whether or not 
these associations exit.   
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     When utilizing stepwise logistic regression, the researcher selects the entry criterion or level of 
statistical significance for which independent variables enter the model.  Research has shown that 
the choice of p = 0.05 is too stringent and often excludes important variables from the model 
(Hosmer & Lemeshow, 2000).  Hosmer & Lemeshow (2000) recommend choosing a p-value in 
range of 0.15 – 0.20.  A conservative approach was taken and the entry criterion was set at 0.15.         
     Stepwise methods were utilized to estimate the probability a physician would prescribe an 
antidepressant versus prescribing counseling for children with major depressive disorder.  The 
explanatory variables utilized in this model were physician characteristics (physicians’ specialty, 
gender, age, primary practice site, geographic location of physician, population of community of 
physicians’ primary practice site, physicians’ board certification, patient volume per week, and the 
length of time the physician has treated the child and adolescent population).  Based on our pre-
specified criterion (p=0.15) four variables, type of physician, age of physician, geographic location 
of primary practice site, and number of adolescents seen per week, were retained in the model.    
     Although, the four variables contribute significantly in statistical terms to the model there are 
other considerations.  Clinical considerations, biological considerations, and common sense are also 
needed when deciding which variables to retain in a model (Hosmer & Lemeshow, 2000).  It seems 
unlikely that the number of adolescents a physician sees per week is associated with the type of 
treatment the physician prescribes for a child.  Therefore, this variable will be excluded from the 
final model.  It can be concluded from the logistic regression model that specialty of the physician, 
age of physician, and southern, midwest, and pacific/west geographic locations of the primary 
practice site are significantly associated with physicians prescribing antidepressants to children with 
major depressive disorder.  Variables were retained in the final model if the p-value was less than or 
equal to 0.05 and the final regression model is as follows: 
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 logit(p) =  0.3991 +(-0.9124 * Specialty of Physician) + (0.6197 * Age of Physician) +  (0.9649 * Southern 
Geographic Region) + (0.9911 * Midwest Geographic Region) + (0.8840 * Pacific/West Geographic Region)  
 
     Odds ratios were used to examine the magnitude of these associations and are listed in Table 
4.29.  After controlling for all other variables in the model, the odds in favor of a child psychiatrist 
prescribing an antidepressant is only 0.402 times greater than   pediatricians.  The odds ratio of 1.85 
indicates that the odds in favor of a physician prescribing an antidepressant medication is 1.85 times 
greater for physicians who are more than 60 years of age, as compared to those who are less than 60 
years of age.  Finally, the odds in favor of physicians prescribing antidepressant medication for 
physicians whose practice location is in the South, Midwest, or Pacific/West are 2.625, 2.694, and 
2.421, respectively, times greater  as compared to physicians located in the Northeast. 
     Next, the goodness of fit of the model was assessed.  Assessing the goodness-of-fit of the model, 
involves deciding whether the predicted values are an accurate representation of the observed values 
(Hosmer & Lemeshow, 2000).  In other words, the goodness-of-fit is a measure of how well the 
model describes the dependent variable.  The Hosmer-Lemeshow test is a goodness-of-fit test which 
allows for any number of independent variables (Bewick, Cheek, & Ball, 2005).  For this model, the 
Hosmer-Lemeshow test is non-significant (p=0.8634).  This indicates that the overall fit of the model 
is good. 
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Table 4.29:  Logistic Regression Analysis of Physicians’ Antidepressant Prescribing to 
Children with Major Depressive Disorder   
Variable Estimate 
β 
SE β Wald’s 
χ2 
df p-value Point 
Estimate 
95% CI 
Intercept 0.3991 0.4537 0.7738 1 0.3790 NA NA 
Child Psychiatrist  -0.9124 0.4069 5.0280 1 0.0249* 0.402 0.181 – 0.891 
Age of Physician 
Greater than 60 years 
0.6197 0.3230 3.6805 1 0.0551* 1.858 0.987 – 3.500 
Southern Geographic 
Region 
0.9649 0.3353 8.2788 1 0.0040* 2.625 1.360 – 5.064 
Midwest Geographic 
Region 
0.9911 0.3496 8.0375 1 0.0046* 2.694 1.358 – 5.346 
Pacific/West 
Geographic Region  
0.8840 0.3697 5.7182 1 0.0168* 2.421 1.173 - 4.996 
SE=Standard Error, df=degrees of freedom, CI=Confidence Interval, *Significance at p < 0.05 
 
    Multicollinearity occurs when there are strong linear dependencies among the independent 
variables (Allison, 1999).  Basically, the independent variables should not be highly correlated with 
each other, as it is difficult to obtain good estimates of their association with the dependent variable.  
Multicollinearity can be assessed by utilizing the diagnostics tolerance and variance inflation factor.  
The tolerance can be computed by regressing each of the independent variables on all of the other 
independent variables, calculating the R2 (the proportion of the variance of y that can be explained by 
x) and subtracting from one (Rosner, 2000).  The variance inflation factor (VIF) is the reciprocal of 
the tolerance and tells how inflated the variance of the coefficient is compared to what it would be if 
the variable were not correlated with other variables in the model (Allison, 1999). Tolerance ranges 
between zero and one and VIF is one or greater, while tolerances below 0.40 may be an indication of 
multicollinearity (Allison, 1999).  Others have suggested that VIF values of less than 4.00 should be 
considered acceptable (Allison, 1999).  In conclusion, there is no strict rule for assessing 
multicollinearity.  In this model the tolerances ranged from 0.61166 to 0.98574 and VIF values 
ranged from 1.01447 to 1.63488, and therefore multicollinearity is not an issue in this model.                 
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Objective 10:  To determine the average length of antidepressant treatment for newly diagnosed 
children with major depressive disorder. 
 
     Physicians were asked to indicate how long on average would they continue to prescribe an 
antidepressant to a child, if the treatment was successful in terms of decreasing depressive 
symptoms.  The majority of the physicians, both pediatricians (51.35%) and child psychiatrists 
(65.17%) indicated they would prescribe the antidepressant medication to the child for ten months or 
longer.  These frequencies are listed in Table 4.30.   
Table 4.30:  Frequencies of Average Length of Antidepressant Treatment for Children    
Length of 
Antidepressant 
Treatment 
All Physicians 
N(%) 
Pediatricians  
N(%) 
Child Psychiatrists 
N(%) 
1-3 months 3  (1.40) 1 (2.70) 2 (1.12) 
4-6 months 34 (15.81) 10 (27.03) 24 (13.48) 
7-9 months 43 (20.00) 7 (18.92) 36 (20.23) 
10-12 months 84 (30.07) 8 (21.62) 76 (42.70) 
Greater than 12 
months 
51 (23.72) 11 (29.73) 40 (22.47) 
 
     The American Academy of Child and Adolescent Psychiatry has recently recommended children 
be treated for a minimum of six months (American Academy of Child and Adolescent Psychiatry, 
2007).  The categorical variable, length of treatment, was then transformed into a continuous 
variable so comparisons could be made to the six month minimum.  The categorical variable was 
recoded by taking the average number of months the physician treats the children with an 
antidepressant.  The variable was re-coded as follows:  1-3 months was transformed into 2 months, 
4-6 months was transformed into 5 months, 7-9 months was transformed into 8 months, 10-12 
months was transformed into 11 months, and greater than 12 months was transformed into 12 
months.  The average length of time pediatricians and child psychiatrists prescribed antidepressant 
treatment for children was then compared to the six month minimum length of time.  It was found 
that both pediatricians and child psychiatrists treated children significantly longer than the six month 
minimum.  These results are listed in Table 4.31.      
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Table 4.31:  Length of Antidepressant Treatment Compared to AACAP Recommendations 
Physician 
Type 
Length of 
Antidepressant 
Treatment 
(Mean + SD)  
Minimum Length 
of AACAP 
Recommendations 
(months) 
Test Statistic Significance p 
Pediatrician 8.865 + 3.102 6 t=5.618 0.000* 
Child 
Psychiatrist 
9.708 + 2.485 6 t=19.909 0.000* 
*Significant at p<0.05, SD=Standard Deviation 
      
Objective 11:  To determine the types of pharmacotherapy monitoring in newly diagnosed children 
with major depressive disorder. 
 
     Physicians were asked to indicate how they monitor antidepressants prescribed to children with 
major depressive disorder.  More specifically physicians were asked the mode of monitoring (e.g., 
how is the monitoring done), who conducts the monitoring, the type of monitoring they conduct, and 
the frequency with which they monitor children.  Physicians’ responses to the mode of monitoring, 
who conducts the monitoring, and the type of monitoring conducted are listed in Table 4.32, Table 
4.33, and Table 4.34, respectively.  The majority of pediatricians (89.58%) and child psychiatrists 
(96.04%) indicated they conduct monitoring by an individual office visit with the child.  Both 
pediatricians (95.83%) and child psychiatrists (96.04%) reported, almost exclusively, they would 
conduct the monitoring themselves.  The majority of pediatricians and child psychiatrists monitor for 
adverse events, suicidality, and clinical symptoms.  Some pediatricians (29.79%) and child 
psychiatrists (72.95%) also require the patient to get some type of labwork.  Some pediatricians 
(4.26%) and child psychiatrists (24.91%) indicated they conduct some other type of monitoring for 
children.  Other types of monitoring physicians listed included monitoring ongoing psychotherapy 
progress, monitoring school, social, family, or interpersonal functioning, and monitoring depressive 
symptoms through the use of scales (ex. Beck’s Depression Inventory).                  
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Table 4.32:  Mode of Antidepressant Monitoring for Children 
Mode of 
Monitoring 
All Physicians 
N (%) 
Pediatricians 
N (%) 
Child Psychiatrists 
N(%) 
Individual Office 
Visit 
310 (95.09) 43 (89.58) 267 (96.04) 
Telephone 7 (2.15) 3 (6.25) 4 (1.44) 
Other 9(2.76) 2 (4.17) 7 (2.52) 
 
Table 4.33:  Healthcare Provider Conducting Antidepressant Monitoring for Children 
Healthcare Provider All Physicians 
N (%) 
Pediatricians 
N (%) 
Child Psychiatrists 
N (%) 
Physician 313 (95.09) 46 (95.83) 267 (96.04) 
Nurse/Nurse Practitioner 4 (1.23) 0 ( 0.00) 4 (1.44) 
Counselor/Psychotherapist 4 (1.23) 2 (4.17) 2 (0.72) 
Other 5 (1.53) 0 (0.00) 5 (1.80) 
 
Table 4.34:  Type of Antidepressant Monitoring for Children 
Type of 
Monitoring 
All Physicians 
(N=328) 
Pediatricians 
(N=47) 
Child Psychiatrists 
(N=281) 
Adverse Events 326 (99.39) 47 (100.00) 279 (98.93) 
Suicidality 323 (98.48) 45 (95.74) 278 (98.93) 
Conduct Labwork 219 (66.77) 14 (29.79) 205 (72.95) 
Clinical Symptoms 324 (98.78) 47 (100.00) 277 (98.58) 
Other 72 (21.95) 2 (4.26) 70 (24.91) 
      
     Physicians were asked to indicate how frequently they monitor children treated with 
antidepressants during the first three months of treatment.  During the first month of treatment the 
majority of pediatricians (54.35%) indicated they monitor children every two weeks, with another 
39.13% of pediatricians monitoring once a week.  The majority of child psychiatrists reported 
monitoring children either once a week (41.43%) or every two weeks (30.71%) during the first 
month of antidepressant treatment.  Results for the frequency of antidepressant monitoring during 
the first month of treatment are shown in Table 4.35.  
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Table 4.35:  Frequency of Antidepressant Monitoring: Month One 
 All Physicians 
(N) 
Pediatricians 
(N) 
Child Psychiatrists 
(N) 
Frequency of Monitoring:    
Two Times per Week  3 (0.92%) 0 (0.00%) 3 (1.07%) 
Once a Week 134 (41.11%) 18 (39.13%) 116 (41.43%) 
Every Two Weeks 111 (34.05%) 25 (54.35%) 86 (30.71%) 
Every Three Weeks 12 (3.68%) 0 (0.00%) 12 (4.29%) 
Once a Month 36 (11.04%) 2 (4.35%) 34 (12.14%) 
Greater than Once a Month 0 (0.00%) 0 (0.00%) 0 (0.00%) 
Other 30 (9.20%) 1 (2.17%) 29 (10.36%) 
 
     Physicians were asked to indicate how frequently they monitor children treated with 
antidepressants during the second month of treatment.  During this time period the majority of 
pediatricians (65.23%) reported monitoring children once a month compared to 42.65% of the child 
psychiatrists.  Another 21.74% of the pediatricians indicated they monitor children every two weeks, 
while 34.06% of the child psychiatrists monitor children every two weeks.  Table 4.36 shows the 
results for the frequency of monitoring during the second month of treatment.   
 
Table 4.36:  Frequency of Antidepressant Monitoring: Month Two 
 All Physicians 
(N) 
Pediatricians 
(N) 
Child Psychiatrists 
(N) 
Frequency of Monitoring:    
Two Times per Week  3 (0.92%) 1 (2.17%) 2 (0.72%) 
Once a Week 14 (4.31%) 0 (0.00%) 14 (5.02%) 
Every Two Weeks 105 (32.31%) 10 (21.74%) 95 (34.05%) 
Every Three Weeks 27 (8.31%) 1 (2.17%) 26 (9.32%) 
Once a Month 149 (45.84%) 30 (65.23%) 119 (42.65%) 
Greater than Once a Month 13 (4.00%) 3 (6.52%) 10 (3.58%) 
Other 14 (4.31%) 1 (2.17%) 13 (4.66%) 
 
     During month three, the majority of pediatricians (52.18%) reported monitoring children on 
antidepressants at some time interval greater than one month, while another 39.13% indicated they 
monitor children once a month.  The majority of child psychiatrists (62.72%) monitor children 
taking an antidepressant once a month with another 20.43% indicating they monitor children at some 
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interval greater than once a month.  Results for the frequency of monitoring children during the third 
month of antidepressant treatment are listed in Table 4.37.   
Table 4.37:  Frequency of Antidepressant Monitoring: Month Three 
 All Physicians 
(N) 
Pediatricians 
(N) 
Child Psychiatrists 
(N) 
Frequency of Monitoring:    
Two Times per Week  2 (0.62%) 0 (0.00%) 2 (0.72%) 
Once a Week 7 (2.15%) 0 (0.00%) 7 (2.51%) 
Every Two Weeks 12 (3.69%) 1 (2.17%) 11 (3.94%) 
Every Three Weeks 15 (4.62%) 2 (4.35%) 13 (4.66%) 
Once a Month 193 (59.38%) 18 (39.13%) 175 (62.72%) 
Greater than Once a Month 81 (24.92%) 24 (52.18%) 57 (20.43%) 
Other 15 (4.62%) 1 (2.17%) 14 (5.02%) 
 
Objective 12:  To determine differences in antidepressant monitoring for newly diagnosed children 
with major depressive disorder and the United States Food and Drug Administration (U.S. FDA) 
recommendations for monitoring children treated with antidepressants. 
 
Null Hypothesis 12.0:  There is no difference in pharmacotherapy monitoring for newly diagnosed 
children with major depressive disorder and the U.S. FDA recommendations for monitoring children 
treated with antidepressants.   
 
     The frequencies associated with physician monitoring of children treated with antidepressant 
medication was provided in Objective #11.  This information was gained from the Phase II survey as 
physicians were asked to indicate how often they monitored children on antidepressant therapy 
during the first, second, and third-months of treatment.  Physicians could answer this question as 
follows: “two times per week”, “once a week”, “every two weeks’, “every three weeks”, “once a 
month”, greater than once a month”, or “other”.  These variables are categorical in nature.  So that 
comparisons could be made to the U.S. FDA recommendations, these categorical variables needed to 
be transformed into continuous variables.  Therefore, to compute an average number of times per 
month, the physicians’ answers were transformed into a number corresponding to the number of 
times per month physicians monitored children.  This was done as follows:  “two times per week” 
was transformed into eight times per month, “once a week” was transformed into four times a 
month, “every two weeks” was transformed into two times per month, “every three weeks” was 
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transformed into 1.4 times per month, “once a month” was transformed into 1 time per month, and 
“greater than once a month” was transformed into .5 times per month.  In this case the “other” 
category was eliminated from the analysis.  Frequencies of the transformed variables are provided 
below in Tables 4.38, 4.39, and 4.40. 
Table 4.38:  Recoded Frequency of Antidepressant Monitoring: Month One 
Frequency of Monitoring 
(Number of Times per 
Month) : 
All Physicians 
(N) 
Pediatricians 
(N) 
Child Psychiatrists 
(N) 
0.5 0 0 0 
1 36 2 34 
1.4 12 0 12 
2 111 25 86 
4 134 18 116 
8 3 0 3 
 
Table 4.39:  Recoded Frequency of Antidepressant Monitoring: Month Two 
Frequency of Monitoring 
(Number of Times per 
Month): 
All Physicians 
(N) 
Pediatricians 
(N) 
Child Psychiatrists 
(N) 
0.5 13 3 10 
1 149 30 119 
1.4 27 1 26 
2 105 10 95 
4 14 0 14 
8 3 1 2 
 
Table 4.40:  Recoded Frequency of Antidepressant Monitoring: Month Three 
Frequency of Monitoring 
(Number of Times per 
Month): 
All Physicians 
(N) 
Pediatricians 
(N) 
Child Psychiatrists 
(N) 
0.5 81 24 57 
1 193 18 175 
1.4 15 2 13 
2 12 1 11 
4 7 0 7 
8 2 0 2 
 
     The U.S. FDA made recommendations that a child receiving antidepressant treatment should be 
seen by a physician once per week for the first four weeks of treatment (U.S. FD, 2005).  During the 
second month of treatment the patient should be seen biweekly and at week 12 during the third 
month (U.S. FDA, 2005).  Comparisons were made between the U.S.FDA recommendations and the 
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number of times per month the physicians reported monitoring children, during the first three 
months of antidepressant treatment.  Pediatricians (t=-7.967, p=0.000) and child psychiatrists (t=-
14.004, p=0.000) monitor significantly less than the U.S. FDA recommended four times, during the 
first month of treatment.  During the second month of treatment again, both pediatricians (t=-3.905, 
p=0.000) and child psychiatrists (t=-7.156, p=0.000) monitor significantly less than the U.S. FDA 
recommended two times per month.  The findings show that pediatricians (t=-4.507, p=0.000) still 
monitor significantly less than the U.S. FDA recommendations, during the third month of treatment.  
However, child psychiatrists’ (t=1.660, p=0.098) monitoring does not differ significantly from the 
U.S. FDA recommendations of one time during month three.  These comparisons are listed in Table 
4.41.              
Table 4.41: Comparisons of Physician Monitoring to U. S. FDA Recommendations 
 Mean +  SD Test Statistic Significance (p) 
Month One: 
All Physicians 
Pediatricians 
Child Psychiatrists 
 
2.820 + 1.282 
2.756 + 1.048 
2.832 + 1.322 
 
t=-15.827 
t=-7.967 
t=-14.004 
 
0.000* 
0.000* 
0.000* 
Month Two: 
All Physicians 
Pediatricians 
Child Psychiatrists 
 
1.554 + 0.967 
1.272 + 1.111 
1.588 + 0.939 
 
t=-8.130 
t=-3.905 
t=-7.156 
 
0.000* 
0.000* 
0.000* 
Month Three: 
All Physicians 
Pediatricians 
Child Psychiatrists 
 
1.040 + 0.795 
0.773 + 0.337 
1.086 + 0.840 
 
t=0.893 
t=-4.507 
t=1.660 
 
0.372 
  0.000* 
0.098 
*Significant at p<0.05, SD=Standard Deviation , U.S. FDA= United States Food and Drug Administration  
 
Objective 13:  To determine whether there are differences, by physician type, in the average number 
of times per month physicians monitor children with major depressive disorder. 
 
Null Hypothesis 13.0:  There is no difference, by physician type, in the average number of times per 
month physicians monitor children with major depressive disorder.  
 
     The hypothesis that there is no difference by physician type (pediatricians versus child 
psychiatrists) in the average number of times per month physicians monitor children was tested.  The 
survey for Phase II asked physicians to indicate how often they monitored children on antidepressant 
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therapy during the first, second, and third-months of treatment.  Physicians could answer this 
question as follows: “two times per week”, “once a week”, “every two weeks’, “every three weeks”, 
“once a month”, greater than once a month”, or “other”.  To compute an average number of times 
per month that physicians monitor children on antidepressant therapy, the categorical variables 
above, were converted to the number of times per month physicians monitored children.  This was 
accomplished by transforming the variables as follows:  “two times per week” was transformed into 
eight times per month, “once a week” was transformed into four times a month, “every two weeks” 
was transformed into two times per month, “every three weeks” was transformed into 1.4 times per 
month, “once a month” was transformed into 1 time per month, and “greater than once a month” was 
transformed into .5 times per month.  After recoding, the average number of times per month that 
physicians monitor children, were computed for each group of physicians.  The results are provided 
above in Tables 4.38. 4.39, and 4.40.   
     Next, comparisons for months one, two, and three, of the average number of times per month 
pediatricians monitor children could be made with the average number of times child psychiatrists 
monitor children.  The Levene’s test for equality of variances was first conducted on each of the 
comparisons.  If the Levene’s test for equality was significant then equal variances could not be 
assumed.  If the Levene’s test for equality was not significant then equal variances were assumed.  
Next, the appropriate two sample t-test, either for the assumption of equal variances or unequal 
variances was conducted.  The results are listed below in Table 4.42.   
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Table 4.42:  Comparison of Pediatricians and Child Psychiatrists Monitoring of Children   
 Mean + SD Test Statistic p-value 
Month One: 
Pediatricians 
Child Psychiatrists 
 
2.76 +  1.05 
2.83 + 1.32 
 
 
t = -0.431 
 
 
0.668 
Month Two: 
Pediatricians 
Child Psychiatrists 
 
1.35 + 1.11 
1.59 + 0.94 
 
t = -1.508 
 
0.133 
Month Three: 
Pediatricians 
Child Psychiatrists 
 
0.77 + 0.34 
1.09 + 0.84 
 
t = -2.457 
 
0.015* 
* Significant at p< 0.05 
 
     The average number of times physicians (pediatricians versus child psychiatrists) monitored 
children did not significantly differ during the first (p=0.668) and second months (p=0.133) of 
antidepressant treatment.  However, during the third month of treatment there was a significant 
difference in the average number of times, pediatricians versus child psychiatrists, monitored 
children on antidepressant therapy.  Child psychiatrists monitored significantly (p=0.015) more than 
pediatricians during the third month of treatment.  Therefore, Null Hypothesis 13.0:  There is no 
difference, by physician type, in the average number of times per month physicians monitor children 
with major depressive disorder, will fail to be rejected for months one and two, and will be rejected 
for month three of treatment.      
 
Phase II:  Results for Adolescents with Major Depressive Disorder- Objectives 14-22 
 
 
     Objectives 14 through 22 are identical to Objectives 1 through 13 for children with major 
depressive disorder except the population studied were adolescents (13 through 18 years of age) with 
major depressive disorder. 
 
Objective 14:  To determine the demographic characteristics of physicians who treat newly 
diagnosed adolescents with major depressive disorder. 
 
     Of those physicians from phase II who indicated they treat adolescents with major depressive 
disorder 57 (16.06%) were pediatricians and 298 (83.94%) were child psychiatrists.  The majority of 
physicians who treat adolescents with major depressive disorder are males (61.25%).  Additionally, 
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the majority (66.10%) of the respondents who treat adolescents indicated they are between 41 and 60 
years of age.  The year of graduation from medical school varied:  33.03% indicated they graduated 
in 1986 -1995, 27.83% indicated they graduated in 1976 – 1985, 20.18% indicated they graduated in 
1966 – 1975, 11.93% indicated they graduated in 1996 – 2003, and only 7.03% graduated in 1965 or 
earlier.  Approximately sixty percent, (57.55%) of the physicians indicated their primary practice site 
was private-based, as opposed to hospital-based.  The geographic region of the physicians’ primary 
practice site varied: 29.29% practice in the South, 26.63% practice in the Midwest, 23.08% practice 
in the Northeast, 20.41% practice in the West, and only 0.59% practice in the Pacific.  The 
population of the primary practice area varied as 34.40% have primary practice sites in areas with 
50,000 – 249,999 people, 25.36% practice in areas with a population of 1 million or more people, 
24.78% practice in areas with 250,000 – 999,999 people, and 15.45% practice in areas with 50,000 
people or less.  The majority (70.74%) of the physicians indicated specialties of both adult and child 
psychiatry, and the majority (54.89%) are board certified as both adult psychiatrists and child 
psychiatrists.  The practice volume also varied somewhat, however the majority of physicians 
indicated they treat both, 10 or less children (72.01%) and 10 or less adolescents (56.85%) per week.  
Approximately three-fourths, (75.57%) of physicians, indicated they have treated adolescents for 
greater than 10 years.  The demographics of physicians who treat adolescents with major depressive 
disorder are shown below in Table 4.43.       
 
 
 
 
 
 
 
 
 
 121 
Table 4.43:  Demographics of Physicians Who Treat Adolescents for Major Depressive 
Disorder 
Variable N (%) 
Type of Physician: 
Pediatricians 
Child Psychiatrists 
 
57 (16.06%) 
298 (83.94%) 
Gender: 
Male  
Female 
 
215 (61.25%) 
136 (38.75%) 
Age: 
40 years or younger 
41 years – 60 years 
61 years or older 
 
45 (12.82%) 
232 (66.10%) 
74 (21.08%) 
Year Graduated from Medical School: 
1965 or Before 
1966 – 1975 
1976 - 1985 
1986 - 1995 
1996 – 2003 
 
23 (7.03%) 
66 (20.18%) 
91 (27.83%) 
108 (33.03%) 
39 (11.93%) 
Primary Practice Site: 
Private Based Practice 
Hospital Based Practice 
Other (ex. hospital and private) 
 
202 (57.55%) 
67 (19.09%) 
82 (23.36%) 
Geographic Location of Practice: 
Northeast 
South 
Midwest 
West 
Pacific 
 
78 (23.08%) 
99 (29.29%) 
90 (26.63%) 
69 (20.41%) 
2 (0.59%) 
Population of Practice Area: 
Less than 50,000 
50,000 – 249,999 
250,000 – 999,999 
1 million or more 
 
53 (15.45%) 
118 (34.40%) 
85 (24.78%) 
87(25.35%) 
Physician Specialty: 
Child Psychiatrist 
Pediatrics 
Adult and Child Psychiatrist 
Other (ex. adult and child psychiatry and general practice) 
 
36 (10.23%) 
52 (14.77%) 
249 (70.74%) 
15 (4.26%) 
Board Certification: 
Adult Psychiatrist 
Child Psychiatrist 
General Practitioner 
Pediatrician 
Adult and Child Psychiatrist 
Other (ex. adult and child psychiatry and pediatrics)  
Not Board Certified 
 
59 (16.95%) 
1 (0.29%) 
1 (0.29%) 
56 (16.09%) 
191(54.89%) 
18 (5.17%) 
22 (6.32%) 
Child Patient Volume Per Week: 
10 or less 
11 – 40 
41 – 80 
81 or greater 
 
247(72.01%) 
79 (23.03%) 
14 (4.08%) 
3 (0.87%) 
Adolescent Patient Volume Per Week: 
10 or less 
11 – 40 
41 – 80 
81 greater 
 
195 (56.85%) 
126 (36.73%) 
16 (4.66%) 
6 (1.75%) 
Number of Years Treating Children and/or Adolescents: 
Greater than 1 to 5 years 
Greater than 5 to 10 years 
Greater than 10 years 
 
 
25 (7.18%) 
60(17.24%) 
263(75.57%) 
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Objective 15:  To determine physicians’ first line of treatment for newly diagnosed adolescents with 
major depressive disorder by: a) type of treatment, b) drug category, and c) specific antidepressant 
prescribed.   
 
     A majority of physicians, both pediatricians (87.72%) and child psychiatrists (76.95%) indicated 
their preferred first-line of treatment for adolescents with major depressive disorder is a combination 
treatment of antidepressants and counseling.  Counseling only was the next most frequently 
preferred choice as a first-line of treatment of both pediatricians (8.77%) and child psychiatrists 
(15.93%).  Few pediatricians (3.51%) and child psychiatrists (0.68%) indicated they use 
antidepressants only as a first-line of treatment for adolescents.  These results are shown in Table 
4.44.       
Table 4.44:  First-Line of Treatment for Adolescents with Major Depressive Disorder  
Type of Treatment All 
Physicians 
N (%) 
Pediatricians 
N (%) 
Child 
Psychiatrists 
N (%) 
Antidepressants Only 4 (1.14%) 2 (3.51%) 2 (0.68%) 
Counseling/Psychotherapy Only 52 (14.77%) 5 (8.77%) 47 (15.93%) 
Both Antidepressants and Counseling 277 
(78.69%) 
50 (87.72%) 227 
(76.95%) 
Other Treatment 19 (5.40%) 0 (0.00%) 19 (6.44%) 
 
     In the event the physicians utilized antidepressants as a first-line of treatment, all pediatricians 
(100.00%) indicated their first-line of treatment would include an SSRI type antidepressant.  Over 
ninety percent (94.67%) of the child psychiatrists also indicated they would utilize an SSRI type 
antidepressant.  The results per antidepressant class, associated with the first-line treatment, for 
adolescents are displayed in Table 4.45.     
     The specific type of antidepressant varied somewhat for both pediatricians and child psychiatrists.  
Similar to the findings in the child population, the majority of pediatricians and child psychiatrists 
indicated they would utilize either Prozac® or Zoloft® in their first-line of treatment for adolescents 
with major depressive disorder.  For first-line treatment, 44.23% of pediatricians indicated they 
would utilize Prozac® and 50.21% indicated they would utilize Zoloft®.  For first-line treatment 
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38.46% of the child psychiatrists indicated they would utilize Prozac® and 19.84% indicated they 
would utilize Zoloft® as part of their first-line of treatment for adolescents with major depressive 
disorder.  The specific antidepressants utilized by physicians as a first-line of treatment for 
adolescents can be found in Table 4.46.         
Table 4.45:  Therapeutic Category of Antidepressant Used as First-Line of Treatment for 
Adolescents  
Drug Class All 
Physicians 
N (%) 
Pediatricians 
N (%) 
Child 
Psychiatrists 
N (%) 
Tricyclic Antidepressants (TCAs) 1 (0.34%) 0 (0.00%) 1 (0.41%) 
Tetracyclic Antidepressants 1 (0.34%) 0 (0.00%) 1 (0.41%) 
Selective Serotonin Reuptake Inhibitors 
(SSRIs) 
281 (95.58%) 50 (100.00%) 231 (94.67%) 
Selective-norepinephrine Reuptake 
Inhibitors (SNRIs) 
1 (0.34%) 0 (0.00%) 1 (0.41%) 
Norepinephrine and Dopamine 
Reuptake Inhibitors (NDRIs) 
10 (3.40%) 0 (0.00%) 10 (4.10%) 
 
Table 4.46:  Specific Antidepressant Used as First-Line of Treatment for Adolescents  
Antidepressant All 
Physicians 
N (%) 
Pediatricians 
N (%) 
Child 
Psychiatrists 
N (%) 
Prozac® 147 (49.16%) 23 (44.23%) 124 (50.21%) 
Zoloft® 69 (23.08%) 20 (38.46%) 49 (19.84%) 
Celexa® 31 (10.37%) 5 (9.61%) 26 (10.53%) 
Lexapro® 33 (11.04%) 2 (3.85%) 31 (12.55%) 
Wellbutrin® 10 (3.35%) 0 (0.00%) 10 (4.05%) 
Tofranil® 1 (0.33%) 0 (0.00%) 1 (0.40%) 
Cymbalta® 1 (0.33%) 0 (0.00%) 1 (0.40%) 
Remeron® 1 (0.33%) 0 (0.00%) 1 (0.40%) 
Listed multiple 
antidepressants 
6 (2.01%) 2 (3.85%) 4 (1.62%) 
 
 
Objective 16:  To determine physicians’ second and third lines of treatment for newly diagnosed 
adolescents with major depressive disorder by:  a) drug category, and b) specific antidepressant 
prescribed.  
 
     In the event the first-line of treatment is not successful, the majority of pediatricians, 68.43%, 
indicated they would switch an adolescent patient to a different antidepressant.  Also, approximately 
seventy percent (72.73%) of child psychiatrists reported switching an adolescent patient to a 
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different antidepressant.  The results for physicians’ second-line of treatment for adolescents are 
shown in Table 4.47.        
Table 4.47:  Second-Line of Treatment for Adolescents with Major Depressive Disorder 
Type of Treatment All 
Physicians 
N (%) 
Pediatricians 
N (%) 
Child 
Psychiatrists 
N (%) 
Augment with Antidepressants  63 (17.80%) 5 (8.77%) 58 (19.53%) 
Switch to a Different Antidepressant 255 
(72.03%) 
39 (68.43%) 216 
(72.73%) 
Augment with Counseling\Psychotherapy 15 (4.24%) 7 (12.28%) 8 (2.69%) 
Switch or Augment with Antidepressant 4 (1.13%) 1 (1.75%) 3 (1.01%) 
Other Treatment 17 (4.80%) 5 (8.77%) 12 (4.04%) 
 
     As was the case for the first-line of treatment, the majority of pediatricians (86.37%) and child 
psychiatrists (74.00%) indicated they utilize SSRIs a part of the second-line of treatment for 
adolescents with major depressive disorder.  The SSRIs most often utilized as part of the second-line 
of treatment by pediatricians are Prozac® (30.43%), Zoloft® (19.57%), and Celexa® (15.22%).  
Whereas, the SSRIs most often utilized as part of the second-line of treatment by child psychiatrists 
are Prozac® (18.73%), Zoloft® (23.97%), and Celexa® (8.99%).  The antidepressant drug categories 
and specific antidepressants utilized by physicians as part of their second-line of treatment for 
adolescents with major depressive disorder are listed in Tables 4.48 and 4.49.         
 
Table 4.48:  Therapeutic Category of Antidepressant used as Second-Line of Treatment for 
Adolescents  
Drug Class All 
Physicians 
N (%) 
Pediatricians 
N (%) 
Child 
Psychiatrists 
N (%) 
Tricyclic Antidepressants 
(TCAs) 
2 (0.68%) 0 (0.00%) 2 (0.80%) 
Tetracyclic Antidepressants 1 (0.34%) 0 (0.00%) 1 (0.40%) 
Selective Serotonin Reuptake 
Inhibitors (SSRIs) 
223 (75.85%) 38 (86.37%) 185 (74.00%) 
Selective-norepinephrine 
Reuptake Inhibitors (SNRIs) 
27 (9.18%) 1 (2.27%) 26 (10.40%) 
Norepinephrine and 
Dopamine Reuptake 
Inhibitors (NDRIs) 
41 (13.95%) 5 (11.36%) 36 (14.40%) 
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Table 4.49:  Specific Antidepressant Used as Second-Line of Treatment for Adolescents  
Antidepressant All 
Physicians 
N (%) 
Pediatricians 
N (%) 
Child 
Psychiatrists 
N (%) 
Prozac® 64 (20.45%) 14 (30.43%) 50 (18.73%) 
Zoloft® 73 (23.32%) 9 (19.57%) 64 (23.97%) 
Celexa® 31 (9.90%) 7 (15.22%) 24 (8.99%) 
Lexapro® 28 (8.95%) 4 (8.70%) 24 (8.99%) 
Wellbutrin® 41 (13.10%) 5 (10.87%) 36 (13.48%) 
Cymbalta® 13 (4.15%) 0 (0.00%) 13 (4.87%) 
Effexor® 13 (4.15%) 1 (2.17%) 12 (4.50%) 
Remeron® 1 (0.32%) 0 (0.00%) 1 (0.37%) 
Pamelor® 2 (0.64%) 0 (0.00%) 2 (0.75%) 
Paxil® 3 (0.96%) 2 (4.34%) 1 (0.37%) 
Listed multiple 
antidepressants 
44 (14.06%) 4 (8.70%) 40 (14.98%) 
 
 
     In the event the second-line of treatment for major depressive disorder in adolescents is not 
successful, pediatricians (52.00%) indicated using some “other’ type of treatment for adolescents.  In 
contrast, the majority (66.43%) of child psychiatrists indicated they would switch another type of 
antidepressant and 20.00% of the child psychiatrists reported they would try some “other” type of 
treatment.  Table 4.50 shows the results for physicians’ third-line of treatment for adolescents with 
major depressive disorder.       
Table 4.50:  Third-Line of Treatment for Adolescents with Major Depressive Disorder  
Type of Treatment All 
Physicians 
N (%) 
Pediatricians 
N (%) 
Child 
Psychiatrists 
N (%) 
Augment with Antidepressants  28 (8.26%) 1 (2.00%) 27 (9.34%) 
Switch to a Different Antidepressant 172 
(50.74%) 
8 (16.00%) 164 
(56.75%) 
Augment with Counseling\Psychotherapy 32 (9.44%) 11 (22.00%) 21 (7.27%) 
Switch or Augment with Antidepressant 5 (1.47%) 2 (4.00%) 3 (1.04%) 
Switch or Refer Patient 2 (0.59%) 2 (4.00%) 0 (0.00%) 
Switch or Other Treatment 4 (1.18%) 0 (0.00%) 4 (1.38%) 
Other Treatment 96 (28.32%) 26 (52.00%) 70 (24.22%) 
 
     The majority of the pediatricians (96.15%), who indicated they would use some “other” treatment 
as the third-line for adolescents, specified they would refer these patients to psychiatry.  In 
comparison, the majority of the child psychiatrists (84.29%) who indicated they would utilize some 
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“other” treatment reported the use of some other type of medication.  These child psychiatrists 
indicated they would use antipsychotics, mood stabilizers, anticonvulsants, thyroid medications, or a 
combination of these medications.  The results for the “other” treatment may be found in Tables 4.51 
and 4.52.       
Table 4.51: Pediatricians’ “Other 3rd Line of Treatment” for Adolescents    
Type of Treatment Pediatricians N (%) 
Refer to Psychiatry 25 (96.15%) 
Antipsychotic 1 (3.85%) 
 
Table 4.52:  Child Psychiatrists’ “Other 3rd Line Treatment” for Adolescents  
Type of Treatment Child Psychiatrists N (%) 
Antipsychotic 14 (20.00%) 
Mood Stabilizer 13 (18.57%) 
Anticonvulsant 10 (14.29%) 
Lithium 11 (15.71%) 
Combination of Antidepressants  5 (7.14%) 
Lithium or Thyroid 2 (2.86%) 
Antipsychotic or Anticonvulsant 1 (1.43%) 
Mood Stabilizer or Antipsychotic 1 (1.43%) 
Thyroid or Anticonvulsant 1 (1.43%) 
Benzodiazepine 1 (1.43%) 
Other: Re-evaluate environment, 
hospitalization, other counseling, etc 
11 (15.71%) 
 
     Of those reporting, the third-line of treatment for adolescents included the use of either an SSRI 
or NDRI for the majority of pediatricians and child psychiatrists.  Pediatricians utilized either SSRIs 
(46.15%) or NDRIs (38.46%).  In contrast, child psychiatrists reported using NDRIs (41.81%) more 
often than SSRIs (33.33%).  Results for physicians’ third-line of treatment for adolescents with 
major depressive disorder by drug category can found in Table 4.54.  
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Table 4.53:  Therapeutic Category of Antidepressant Used as Third-Line of Treatment for 
Adolescents  
Drug Class All 
Physicians N 
(%) 
Pediatricians 
N (%) 
Child 
Psychiatrists 
N (%) 
Tricyclic Antidepressants 
(TCAs) 
1 (0.53%) 0 (0.00%) 1 (0.56%) 
Tetracyclic Antidepressants 1 (0.53%) 0 (0.00%) 1 (0.56%) 
Selective Serotonin Reuptake 
Inhibitors (SSRIs) 
65 (34.21%) 6 (46.15%) 59 (33.33%) 
Selective-norepinephrine 
Reuptake Inhibitors (SNRIs) 
43 (22.63%) 2 (15.39%) 41 (23.16%) 
Norepinephrine and 
Dopamine Reuptake 
Inhibitors (NDRIs) 
79 (41.57%) 5 (38.46%) 74 (41.81%) 
Other Antidepressants 1 (0.53%) 0 (0.00%) 1 (0.56%) 
   
     Of those reporting, approximately one-third of pediatricians (31.25%) and child psychiatrists 
(37.76%) indicated they would utilize Wellbutrin®, as part of their third-line treatment for 
adolescents.  Although many physicians indicated the use of SSRIs the choice of the specific SSRI 
was varied.  The most preferred antidepressant for third-line treatment by both pediatricians 
(18.75%) and child psychiatrists (37.76%) is Lexapro®.  The next most preferred antidepressant by 
child psychiatrists (10.20%) was Zoloft®.  All other antidepressants were preferred by less than ten 
percent of both pediatricians and child psychiatrists.  The results of the physicians’ choice of 
antidepressant for the third-line of treatment for adolescents with major depressive disorder are listed 
in Table 4.54.   
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 Table 4.54:  Specific Antidepressant Used as Third-Line Treatment for Adolescents  
Antidepressant All 
Physicians 
N (%) 
Pediatricians 
N (%) 
Child 
Psychiatrists 
N (%) 
Prozac® 8 (3.77%) 1 (6.25%) 7 (3.57%) 
Zoloft® 21 (9.91%) 1 (6.25%) 20 (10.20%) 
Celexa® 11 (5.19%) 0 (0.00%) 11 (5.61%) 
Lexapro® 11 (5.19%) 3 (18.75%) 8 (4.08%) 
Wellbutrin® 79 (37.26%) 5 (31.25%) 74 (37.76%) 
Cymbalta® 10 (4.72%) 0 (0.00%) 10 (5.10%) 
Effexor® 29 (13.68%) 2 (12.50%) 27 (13.78%) 
Tofranil® 1 (0.47%) 0 (0.00%) 1 (0.51%) 
Remeron® 1 (0.47%) 0 (0.00%) 1 (0.51%) 
Desyrel® 1 (0.47%) 0 (0.00%) 1 (0.51%) 
Paxil® 5 (2.36%) 1 (6.25%) 4 (2.04%) 
Luvox® 1 (0.47%) 0 (0.00%) 1 (0.51%) 
Listed multiple 
antidepressants 
34 (16.04%) 3 (18.75%) 31 (15.82%) 
 
 
Objective 17: To determine the difference in first, second, and third lines of antidepressant treatment 
prescribed by physicians to newly diagnosed adolescents with major depressive disorder by a) the 
pharmacotherapy category and b) specific antidepressant prescribed. 
 
Null Hypothesis 17.a:  There is no difference in the pharmacotherapy category prescribed by 
physicians for first, second, and third lines of antidepressant treatment for newly diagnosed 
adolescents with major depressive disorder. 
 
Null Hypothesis 17.b:  There is no difference in the specific antidepressant prescribed by physicians 
for first, second, and third lines of treatment for newly diagnosed adolescents with major depressive 
disorder.  
 
     In order to determine whether there is an association between the first, second, and third lines of 
antidepressant treatment and physician type several steps were required for the statistical analysis. 
First, a series of χ2 tests, examined the association between two sets of variables:  physician type 
(pediatrician versus child psychiatrist) and pharmacotherapy category (TCAs, Tetracyclics, SSRIs, 
SNRIs, NDRIs, and Other Antidepressants).  Separate χ2 tests examined the association between the 
first-line of pharmacotherapy class and physician type, second-line of pharmacotherapy class and 
physician type, and third-line of pharmacotherapy class and physician type.  Each of these three χ2 
tests indicated no significance between the variables.  Furthermore, over 20% of the cell counts for 
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each of the tests were less than five.  When this is the case the χ2 test is probably not a valid 
statistical test.  Researchers can manage small expected values by collapsing or combining cells.  In 
this study, groups of antidepressant categories were collapsed or combined.  Since the majority of 
the scientific research has focused on utilizing SSRIs in treating adoelscents, it was decided to 
combine antidepressant categories into SSRIs and Non-SSRIs.  After recoding the data into these 
two groups, χ2 tests were run to determine whether there was a relationship between physician type 
(pediatrician versus child psychiatrist) and the new antidepressant categories (SSRIs versus Non-
SSRIs) for first, second, and third-lines of treatment.  Even after collapsing the antidepressant drugs 
by drug category the χ2 tests still resulted in small expected values.  If this occurs, however, another 
statistic may be used to examine the associations between physician type and antidepressant 
categories.  This statistic is the Fisher’s exact test.  The Fisher’s exact test may be utilized when a 
researcher wants to make a comparison between two binomial variables.  This test is especially 
useful when small sample sizes because the assumption of normal approximation to the binomial 
distribution is relaxed.   
     Table 4.55 shows no statistically significant (p=0.871 to p=0.3733) association between physician 
type and the antidepressant category prescribed for first, second, or third-lines of treatment for 
adolescents with major depressive disorder.  On the basis of these tests, the Null Hypothesis 17.a:  
There is no difference in the pharmacotherapy category prescribed by physicians (pediatricians 
versus child psychiatrists) for first, second, and third lines of antidepressant treatment for newly 
diagnosed adolescents with major depressive disorder is not rejected. 
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Table 4.55:   Association of Physician Type and Antidepressant Category 
Association Two-sided Probability 
Adolescent’s First-line of Antidepressant: 
    Physician Type * Antidepressant Type  
 
 
0.1349 
Adolescent’s Second-line of 
Antidepressant: 
    Physician Type * Antidepressant Type  
 
 
0.0871 
Adolescent’s Third-line of Antidepressant: 
    Physician Type * Antidepressant Type  
 
 
0.3733 
 
     As was the case with the first part of Objective 17 several steps were necessary to determined 
whether there is an association between the first, second, and third lines of specific antidepressant 
treatment and physician type.  Three χ2 tests, one for each line of treatment (first, second, and third-
line) were conducted and examined the association between two variables:  physician type 
(pediatrician versus child psychiatrist) and specific antidepressant prescribed.  However, the specific 
type of antidepressant medication varied so that for the first-line of treatment there were 12 different 
groups of antidepressants, for the second-line of treatment there were 30 different groups of 
antidepressants, and for the third-line there were 34 different antidepressant groups.  Since the 
number of groups were so large, it was necessary to collapse the antidepressant categories.  Prozac® 
is the only antidepressant, U.S. FDA approved to treat major depressive disorder in adolescents, 
therefore, it was decided to collapse the antidepressants into two categories, either Prozac® or non- 
Prozac® type antidepressants.  Therefore, for each line of treatment (first, second, and third) the χ2 
statistic tested whether or not there is an association between physician type (pediatrician versus 
child psychiatrist) and specific antidepressant (Prozac® versus non- Prozac®).  The results of these 
analyses are in Table 4.56 below.    
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Table 4.56:  Association of Physician Type and Specific Antidepressant 
 Pediatrician 
(N) 
Child 
Psychiatrist 
(N) 
Test Statistic p-value 
1
st
-Line of Antidepressant  
Treatment: 
Non-Prozac® 
Prozac® 
 
 
34 
23 
 
 
170 
124 
 
 
χ2=0.5338 
 
 
0.4650 
2nd-Line of Antidepressant 
Treatment: 
Non-Prozac® 
Prozac®  
 
 
42 
14 
 
 
232 
50 
 
 
χ2=3.2576 
 
 
0.0711 
3
rd
-Line of Antidepressant 
Treatment: 
Non-Prozac® 
Prozac® 
 
 
53 
1 
 
 
279 
7 
 
Fisher’s 
Exact Test 
 
 
0.4721 
 
     Based on the χ2 tests and the fisher’s exact test there is not statistically significant association 
between physician type and the specific antidepressant prescribed to adolescents.  Hence, we must 
fail to reject the Null Hypothesis 17.b:  There is no difference in the specific antidepressant 
prescribed by physicians (pediatricians versus child psychiatrists) for first, second, and third lines of 
treatment for newly diagnosed adolescents with major depressive disorder.  
 
Objective 18:  To predict which physician characteristics affect the treatment prescribed for 
adolescents with major depressive disorder. 
 
     Logistic regression was utilized to estimate the probability that a physician would prescribe 
antidepressant medication versus counseling to adolescents with major depressive disorder.  The 
explanatory or independent variables utilized in this model were physician characteristics (specialty 
of physician, gender of physician, age of physician, physicians’ primary practice site, geographic 
location of physician, population of community of physicians’ primary practice site, physicians’ 
board certification, patient volume per week, and length of time physician has treated the child and 
adolescent population).  The pre-specified criterion of p = 0.15 was utilized and a stepwise logistic 
regression model was estimated using SAS®, just as was conducted for the child population.   
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     However, in this model convergence was not achieved.  Estimation of the logistic model is an 
iterative process involving many approximations.  This process ceases when the change in the 
coefficients become very small, at this point the model is said to have converged (Allison, 1999).  
Two reasons convergence may not be achieved.  These two reasons are complete separation and 
quasi-complete separation of the data.  Complete separation occurs when the dependent variable is 
perfectly predicted by some linear combination of the independent variables (Allison, 1999).  The 
other reason, quasi-complete separation, is what occurred in the data for this model.  Quasi-complete 
separation is similar to complete separation except for there being a value for the predictor (or 
independent variable) for which both values of the dependent variable occur (Allison, 1999).  Quasi-
complete separation can occur when all of the cases at one level of the independent variable fall into 
one of the two levels of the dependent variable.  This can be seen if cross-tabs of the independent 
and dependents variables are examined.  Examination of the cross-tabs for the data in this model 
reveals the independent variable, number of adolescents treated per week, has this property.  This is 
shown below in Table 4.57.  One way to manage quasi-complete separation is to recode and collapse 
categories of the independent variable (Allison, 1999).  In the current data set, the independent 
variable has only two levels already.  Therefore, collapsing these variables is not possible.  Another 
method and most common method to manage quasi-separation is to delete the cases(s) causing the 
problem (Allison, 1999).  In this case, the cases were deleted and the stepwise logistic procedure re-
calculated.   
Table 4.57:  Crosstabs of Treatment by Number of Adolescents Seen Per Week 
 
Treatment: 
40 Patients or Less 41 Patients or Greater 
Antidepressants         248 21 
Counseling 51 0 
 
     Based on our pre-specified criterion, two variables, type of physician and age of physician were 
retained in the stepwise model.  The final logistic regression model resulted in no independent 
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variables being retained, based on a p < 0.05 criterion.  However, it should be noted that age of the 
physician approached statistical significance (χ2=3.2178, p=0.0728).  These results are listed in 
Table 4.58.  Therefore, it can be concluded from this model that none of our independent variables 
are significantly associated with the probability of a physician prescribing antidepressant treatment 
for an adolescent patient.      
 
Table 4.58:  Logistic Regression Analysis of Physicians’ Antidepressant Prescribing to 
Adolescents with Major Depressive Disorder   
Variable Estimate 
β 
SE β Wald’s 
χ2 
df p-value Point 
Estimate 
95% CI 
Intercept 2.2345 0.4708 22.5219 1 <0.0001 NA NA 
Child Psychiatrist  -0.8114 0.4972 2.6632 1 0.1027 0.444 0.168 – 
1.177 
Age of Physician 
Greater than 60 years 
0.8238 0.4592 3.2178 1 0.0728 2.279 0.927 – 
5.606 
SE=Standard Error, df=degrees of freedom, CI=Confidence Interval 
 
Objective 19:  To determine the average length of antidepressant treatment for newly diagnosed 
adolescents with major depressive disorder. 
 
 
     Physicians were asked to indicate how long on average an antidepressant be prescribed to an 
adolescent, if the treatment was successful in terms of decreasing depressive symptoms.  The 
majority of the physicians, both pediatricians (25.00+38.46=63.46%) and child psychiatrists 
(46.59+24.90=71.49%) indicated they would prescribe the antidepressant medication to an 
adolescent for at least ten months.  These frequencies are listed in Table 4.59.    
Table 4.59:  Frequencies of Average Length of Antidepressant Treatment for Adolescents    
Length of 
Antidepressant 
Treatment  
All Physicians 
 N (%) 
Pediatricians   
 N (%) 
Child Psychiatrists 
N (%) 
1-3 months  1(0.33)  0(0.00)  1(0.40) 
4-6 months  36(11.96) 10(19.23)  26(10.44) 
7-9 months 53(17.61)  9(17.31)  44(17.67) 
10-12 months  129(42.86)  13(25.00)  116(46.59) 
Greater than 12 
months 
 82(27.24) 20(38.46) 62(24.90) 
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     The American Academy of Child and Adolescent Psychiatry has recently recommended 
adolescents be treated for a minimum of six months (American Academy of Child and Adolescent 
Psychiatry, 2007).  The categorical variable, length of treatment, was then transformed into a 
continuous variable so comparisons could be made to the six month minimum.  The categorical 
variable was re-coded by computing the average number of months the physician treats the 
adolescent with an antidepressant.   The variable was re-coded as follows:  1-3 months was 
transformed into 2 months, 4-6 months was transformed into 5 months, 7-9 months was transformed 
into 8 months, 10-12 months was transformed into 11 months, and greater than 12 months was 
transformed into 12 months.  The average length of time pediatricians and child psychiatrists 
prescribed antidepressant treatment for adolescents was then compared to the minimum length of 
time.  It was found that both pediatricians and child psychiatrists treat adolescents significantly 
longer than the six month minimum.  These results are listed in Table 4.60.   
Table 4.60:  Length of Antidepressant Treatment Compared to the AACAP Recommendations  
Physician 
Type 
Length of 
Antidepressant 
Treatment 
(Mean + SD)  
Minimum Length 
of AACAP 
Recommendations 
(months) 
Test Statistic Significance p 
Pediatrician 9.712 + 2.710 6 t=9.874 0.000* 
Child 
Psychiatrist 
10.056 + 2.248 6 t=28.473 0.000* 
*Significant at p<0.05, SD=Standard Deviation 
 
Objective 20:  To determine the types of pharmacotherapy monitoring in newly diagnosed 
adolescents with major depressive disorder. 
 
 
     Physicians were asked several questions related to the monitoring they conduct, in the event they 
utilize antidepressant treatment for adolescents with major depressive disorder.  More specifically 
physicians were asked the mode of monitoring (e.g., how is the monitoring done), who conducts the 
monitoring, the type of monitoring they conduct, and the frequency with which they monitor.  The 
physicians’ responses to the mode of monitoring, who conducts the monitoring, and the type of 
 
 
 135 
monitoring conducted are listed in Table 4.61, Table 4.62, and Table 4.63, respectively.  The 
majority of pediatricians (89.10%) and child psychiatrists (96.48%) indicated they would conduct 
monitoring through an individual office visit with the adolescent.  Both pediatricians (96.36%) and 
child psychiatrists (95.41%) indicated, almost exclusively, they would conduct the monitoring 
themselves.  Greater than ninety-five percent of pediatricians and child psychiatrists reported they 
monitor for adverse events, suicidality, and monitor clinical symptoms.  Some pediatricians 
(27.78%) and three-fourths of the child psychiatrists (74.65 %) indicated they would conduct some 
type of labwork to monitor medication therapy.   
Some pediatricians (%) and child psychiatrists (%) indicated they conduct some other type of 
monitoring for adolescents.  Other types of monitoring physicians listed included monitoring 
ongoing psychotherapy progress, monitoring school, social, family, or interpersonal functioning, and 
monitoring depressive symptoms through the use of scales (ex. Beck’s Depression Inventory).           
 
Table 4.61:  Mode of Antidepressant Monitoring for Adolescents 
Mode of 
Monitoring 
All Physicians 
N(%) 
Pediatricians 
 N(%) 
Child Psychiatrists 
N(%) 
Individual Office 
Visit 
323 (95.28) 49 (89.10) 274 (96.48) 
Telephone 6 (1.77) 3 (5.45) 3 (1.06) 
Other 10 (2.95) 3 (5.45) 7 (2.46) 
 
 
Table 4.62:  Healthcare Provider Conducting Antidepressant Monitoring for Adolescents 
Healthcare Provider All Physicians 
N(%) 
Pediatricians N(%) Child Psychiatrists 
N(%) 
Physician 323 (95.56) 53 (96.36) 270 (95.41) 
Nurse/Nurse Practitioner 5 (1.48) 1 (1.82) 5 (1.77) 
Counselor/Psychotherapist 4 (1.18) 1 (1.82) 3 (1.06) 
Other 6 (1.78) 0 (0.00) 5 (1.77) 
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Table 4.63:  Type of Antidepressant Monitoring for Adolescents 
Type of 
Monitoring 
All Physicians  
(N=340) 
Pediatricians  
(N=54) 
Child Psychiatrists 
(N=284) 
Adverse Events 337 (99.12) 54 (100.00) 283 (99.65) 
Suicidality 335 (98.53) 52 (96.30) 283 (99.65) 
Conduct Labwork 227 (66.76) 15 (27.78) 212 (74.65) 
Clinical Symptoms 334 (98.24) 53 (98.15) 281 (98.94) 
Other 78 (22.94) 4 (7.41) 74 (26.06) 
 
     Physicians were also asked to indicate how frequently they monitor adolescents treated with 
antidepressants during the first three months of treatment.  During the first month of treatment over 
half of the pediatricians (53.70%) indicated they monitor children every two weeks, with another 
38.89% pediatricians reported monitoring once a week.  In comparison, approximately the same 
percentage of child psychiatrists reported, monitoring adolescents either once a week (38.95%) or 
every two weeks (32.98%) during the first month of antidepressant treatment.  The findings for 
monitoring frequency during the first month of treatment are listed in Table 4.64.  
 Table 4.64:  Frequency of Antidepressant Monitoring: Month One 
 All Physicians 
(N) 
Pediatricians 
(N) 
Child Psychiatrists 
(N) 
Frequency of Monitoring:    
Two Times per Week  2(0.59%) 0(0.00%) 2(0.70%) 
Once a Week 132(38.94%) 21(38.89%) 111(38.95%) 
Every Two Weeks 123(36.28%) 29(53.70%) 94(32.98%) 
Every Three Weeks 14(4.13%) 0(0.00%) 14(4.91%) 
Once a Month 40(11.80%) 3(5.56%) 37(12.98%) 
Greater than Once a Month 0(0.00%) 0(0.00%) 0(0.00%) 
Other 28(8.26%) 1(1.85%) 27(9.47%) 
 
 
     For the second month of antidepressant treatment about two-thirds of pediatricians (62.97%) 
monitor adolescents once a month, while another one-fourth (24.07%) monitor adolescents every 
two weeks.  The majority of child psychiatrists indicated they monitor adolescents either once a 
month (45.77%) or every two weeks (30.28%).  Results for the frequency of monitoring, by these 
physicians, during the second month of treatment are listed in Table 4.65.   
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Table 4.65:  Frequency of Antidepressant Monitoring: Month Two 
 All Physicians 
(N) 
Pediatricians 
(N) 
Child Psychiatrists 
(N) 
Frequency of Monitoring:    
Two Times per Week  2(0.59%) 0(0.00%) 2(0.70%) 
Once a Week 15(4.44%) 1(1.85%) 14(4.93%) 
Every Two Weeks 99(29.29%) 13(24.07%) 86(30.28%) 
Every Three Weeks 29(8.58%) 1(1.85%) 28(9.86%) 
Once a Month 164(48.52%) 34(62.97%) 130(45.77%) 
Greater than Once a Month 16(4.73%) 4(7.41%) 12(4.23%) 
Other 13(3.85%) 1(1.85%) 12(4.23%) 
 
     During month three, over ninety percent of the pediatricians reported they monitor adolescents 
either once a month (42.60%) or at some time interval greater than one month (50.00%).  The 
majority of child psychiatrists (62.68%) indicated they monitor adolescents once a month.  Another 
21.48% of the child psychiatrists reported they monitor adolescents at some interval greater than 
once a month.  Table 4.66 shows the results of the frequency of monitoring by physicians during the 
third month of treatment.   
Table 4.66:  Frequency of Antidepressant Monitoring: Month Three 
 All Physicians 
(N) 
Pediatricians 
(N) 
Child Psychiatrists 
(N) 
Frequency of Monitoring:    
Two Times per Week  2(0.59%) 0(0.00%) 2(0.70%) 
Once a Week 9(2.66%) 0(0.00%) 9(3.17%) 
Every Two Weeks 10(2.96%) 1(1.85%) 9(3.17%) 
Every Three Weeks 12(3.55%) 2(3.70%) 10(3.52%) 
Once a Month 201(59.47%) 23(42.60%) 178(62.68%) 
Greater than Once a Month 88(26.04%) 27(50.00%) 61(21.48%) 
Other 16(4.73%) 1(1.85%) 15(5.28%) 
 
 
Objective 21:  To determine differences in antidepressant monitoring for newly diagnosed 
adolescents with major depressive disorder and the U.S. FDA recommendations for monitoring 
adolescents treated with antidepressants. 
 
Null Hypothesis 21.0:  There is no difference in pharmacotherapy monitoring for newly diagnosed 
adolescents with major depressive disorder and the U.S. FDA recommendations for monitoring 
adolescents treated with antidepressants.   
  
     The frequencies associated with physician monitoring of adolescents treated with antidepressant 
medication was provided in the above objective, and listed in Tables 4.64 4.65, and 4.66.  Physicians 
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answered the monitoring frequency question by selecting one of the following categories: “two times 
per week”, “once a week”, “every two weeks’, “every three weeks”, “once a month”, greater than 
once a month”, or “other”.  These variables are categorical in nature.  Therefore, to compute an 
average number of times per month a physician monitors adolescents on antidepressants these 
categories were re-coded.  This was accomplished as follows:  “two times per week” was 
transformed into eight times per month, “once a week” was transformed into four times a month, 
“every two weeks” was transformed into two times per month, “every three weeks” was transformed 
into 1.4 times per month, “once a month” was transformed into 1 time per month, and “greater than 
once a month” was transformed into .5 times per month.  For this analysis the “other” category was 
eliminated.  The frequencies of the recoded variables are provided below in Tables 4.67, 4.68, and 
4.69.   
Table 4.67:  Recoded Frequency of Antidepressant Monitoring: Month One 
Frequency of Monitoring 
(Number of Times per 
Month) : 
All Physicians 
(N) 
Pediatricians 
(N) 
Child Psychiatrists 
(N) 
0.5 0 0 0 
1 40 3 37 
1.4 14 0 14 
2 123 29 94 
4 132 21 111 
8 2 0 2 
 
Table 4.68:  Recoded Frequency of Antidepressant Monitoring: Month Two 
Frequency of Monitoring 
(Number of Times per 
Month): 
All Physicians 
(N) 
Pediatricians 
(N) 
Child Psychiatrists 
(N) 
0.5 16 4 12 
1 164 34 130 
1.4 29 1 28 
2 99 13 86 
4 15 1 14 
8 2 0 2 
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Table 4.69:  Recoded Frequency of Antidepressant Monitoring: Month Three 
Frequency of Monitoring 
(Number of Times per 
Month): 
All Physicians 
(N) 
Pediatricians 
(N) 
Child Psychiatrists 
(N) 
0.5 88 27 61 
1 201 23 178 
1.4 12 2 10 
2 10 1 9 
4 9 0 9 
8 2 0 2 
 
     The U.S. FDA recommendation, for physician monitoring of antidepressant treatment is one time 
per week for the first four weeks of treatment (U.S.FDA, 2005).  During the second month of 
treatment the patient should be seen biweekly, and at week 12, during the third month (U.S.FDA, 
2005).  These recommendations were compared to the number of times per month the physicians 
reported they monitor adolescents, during the first three months of antidepressant treatment.  For the 
first month of treatment pediatricians (t=-7.967, p=0.000) and child psychiatrists (t=-15.941, 
p=0.000) monitor adolescents significantly less than the U.S. FDA recommended four times.  During 
the second month of treatment, both pediatricians (t=-8.715, p=0.000) and child psychiatrists (t=-
8.078, p=0.000) monitor significantly less than the U.S. FDA recommended two times per month.  
During the third month of treatment pediatricians (t=-4.947, p=0.000) still monitor significantly less 
than the U.S. FDA recommendations.  However, child psychiatrists’ (t=1.847, p=0.101) monitoring 
does not differ significantly from the U.S. FDA recommendations of one time during month three.  
These comparisons are listed in Table 4.70.     
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Table 4.70: Comparisons of Physician Monitoring to U.S. FDA Recommendations 
 Mean +  SD Test Statistic Significance 
Month One: 
All Physicians 
Pediatricians 
Child Psychiatrists 
 
2.732 + 1.242 
2.736 + 1.059 
2.731 + 1.277 
 
t=-18.001 
t=-7.967 
t=-15.941 
 
0.000* 
0.000* 
0.000* 
Month Two: 
All Physicians 
Pediatricians 
Child Psychiatrists 
 
1.497 + 0.896 
1.272 + 0.608 
1.541 + 0.937 
 
t=-8.130 
t=-8.715 
t=-8.078 
 
0.000* 
0.000* 
0.000* 
Month Three: 
All Physicians 
Pediatricians 
Child Psychiatrists 
 
1.037 + 0.814 
0.779 + 0.325 
1.087 + 0.870 
 
t=0.893 
t=-4.947 
t=1.847 
 
0.372 
  0.000* 
0.101 
*Significant at p<0.05, SD=Standard Deviation, U.S. FDA=United States Food and Drug Administration  
 
 
Objective 22:  To determine whether there are differences, by physician type, in the average number 
of times per month physicians monitor adolescents with major depressive disorder. 
 
Null Hypothesis 22.0:  There is no difference, by physician type, in the average number of times per 
month physicians monitor adolescents with major depressive disorder.  
 
     The hypothesis that there is no difference by physician type (pediatricians versus child 
psychiatrists) in the average number of times per month physicians monitor adolescents was tested.  
The recoded data from Objective #21 was utilized to analyze this objective.  This data was used to 
compare the average number of times per month pediatricians monitor adolescents to the average 
number of times child psychiatrists monitor adolescents on antidepressant therapy.  The Levene’s 
test for equality of variances was first conducted on each of the comparisons.  If the Levene’s test for 
equality was significant then equal variances could not be assumed.  If the Levene’s test for equality 
was not significant then equal variances were assumed.  Next, the appropriate two sample t-test, 
either for the assumption of equal variances or unequal variances was conducted.  The results are 
listed below in Table 4.71.   
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Table 4.71:  Comparison of Pediatricians and Child Psychiatrists Monitoring  
of Adolescents   
 Mean + SD Test Statistic p-value 
Month One: 
Pediatricians 
Child Psychiatrists 
 
2.74  + 1.06 
2.73  +  1.28 
 
 
t = 0.029 
 
 
0.977 
Month Two: 
Pediatricians 
Child Psychiatrists 
 
1.27 +  0.61 
1.54 +  0.94 
 
t = -2.667 
 
0.009* 
Month Three: 
Pediatricians 
Child Psychiatrists 
 
0.78  +  0.32 
1.09  +  0.87 
 
t = -2.541 
 
0.012* 
* Significant at p <0.05 
 
 
     The average number of times physicians (pediatricians versus child psychiatrists) monitored 
adolescents did not significantly differ during the first (p=0.977) month of antidepressant treatment.  
Child psychiatrists monitored significantly more than pediatricians during the second (p=0.009) and 
third (p=0.012) months of treatment.  Therefore, Null Hypothesis 13.0:  There is no difference, by 
physician type, in the average number of times per month physicians monitor adolescents with major 
depressive disorder, will fail to be rejected for month one and will be rejected for months two and 
three of treatment.      
 
Phase II Results for Exploratory Factor Analysis 
 
Objective 23:   To determine the relative importance which physicians place on each factor prior to 
prescribing antidepressants to newly diagnosed children and adolescents with major depressive 
disorder. 
 
Objective 24:  To determine the factors associated with physicians’ antidepressant prescribing 
behavior for children and adolescents newly diagnosed with major depressive disorder.   
 
 
     Section seven of the phase II survey asked physicians to rate the extent to which 28 variables 
influenced their decisions to prescribe or not to prescribe an antidepressant to a newly diagnosed 
child or adolescent with major depressive disorder.  The physicians rated the influence of these 28 
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variables on a scale of 1-4, where 1= not influential, 2= somewhat influential, 3= influential, and 4= 
extremely influential.   
     The physicians’ ratings of these 28 variables are listed in Table 4.68.  Both pediatricians and 
child psychiatrists on average rated clinical experience with prescribing antidepressants, co-existing 
conditions of patient (e.g. obsessive compulsive disorder), comfort in managing MDD in youth, drug 
safety, drug efficacy, familiarity with an antidepressant being prescribed, severity of MDD 
symptoms, and suicidal thinking as being “influential” or “extremely influential”.  
     Pediatricians and child psychiatrists rated advertisements to physicians via journals and/or mail, 
availability of patient education materials, direct-to-consumer advertising, face-to-face detailing by 
medical sciences liaison and/or pharmaceutical representatives, FDA approved, formulary inclusion, 
frequency of dosing, generic form of drug available, manufacturer provides free drugs to indigent 
patients, medication cost, monitoring requirements, parents’ education level, parental use of 
antidepressants, patient's ability to perform daily activities, patient's age, patient's family income, 
patient's gender, patient's insurance, and sample drugs available as being either “not influential” or 
only “somewhat influential”.  
     Pediatricians rated potential adverse effects as being “not influential” or only “somewhat 
influential”, while child psychiatrists rated potential adverse effects as being either “influential” or 
“extremely influential”.    
 
 
 
 
 
 
 
 
 143 
Table 4.72:  Means and Standard Deviations of Variables/Factors Which Influence 
Antidepressant Prescribing Decisions for Child Psychiatrists and Pediatricians  
Factor 
Child Psychiatrists 
(Mean ± S.D.) 
Pediatricians 
(Mean ± S.D.) t-test 
Significance 
(p) 
Advertisements to physicians via 
journals and/or mail 1.2 ±0.5 1.1 ±0.4 -2.009 0.048 
Availability of patient education 
materials  1.4 ±0.7 1.3 ±0.5 -1.881 0.063 
Clinical experience with prescribing 
antidepressants 3.8 ±0.4 3.5 ±0.6 -3.535   0.001* 
Co-existing conditions of patient (e.g. 
obsessive compulsive disorder) 3.7 ±0.6 3.5 ±0.6 -2.583   0.012* 
Comfort in managing MDD in youth 
3.5 ±0.8 3.3 ±0.6 -1.226 0.221 
Direct-to-consumer advertising   1.3 ±0.5 1.0 ±0.2 -5.309   0.000* 
Drug efficacy  3.8 ±0.4 3.5 ±0.6 -4.017   0.000* 
Drug safety  3.8 ±0.4 3.7 ±0.5 -1.520 0.133 
Face-to-face detailing by medical 
sciences liaison and/or pharmaceutical 
representatives  1.5 ±0.6 1.3 ±0.5 -2.188   0.032* 
Familiarity with an antidepressant being 
prescribed  3.7 ±0.5 3.6 ±0.5 -1.864 0.063 
FDA approved  2.5 ±1.0 2.9 ±1.0 2.783   0.006* 
Formulary inclusion  2.4 ±0.9 2.6 ±0.9 1.883 0.061 
Frequency of dosing  2.8 ±0.8 2.6 ±0.8 -1.029 0.304 
Generic form of drug available  2.4 ±0.9 2.5 ±0.8 0.850 0.396 
Manufacturer provides free drugs to 
indigent patients  2.0 ±0.9 1.5 ±0.7 -4.366  0.000* 
Medication cost  2.5 ±0.8 2.5 ±0.6 0.018 0.985 
Monitoring requirements 2.4 ±0.9 2.3 ±0.8 -0.582 0.561 
Parents’ education level  
1.9 ±0.9 1.9 ±0.8 0.071 0.943 
Parental use of antidepressants  2.6 ±0.9 2.1 ±0.9 -3.683  0.000* 
Patient's ability to perform daily 
activities  2.9 ±0.9 2.8 ±0.9 -0.638 0.524 
Patient's age  2.9 ±0.8 2.8 ±0.7 -0.384 0.701 
Patient's family income  1.5 ±0.8 1.4 ±0.6 -1.748 0.084 
Patient's gender 1.3 ±0.6 1.2 ±0.4 -1.487 0.140 
Patient's insurance  1.7 ±0.9 1.7 ±0.8 0.109 0.913 
Potential adverse effects  
3.3 ±0.7 3.0 ±0.7 -3.139   0.002* 
Sample drugs available  1.8 ±0.8 1.4 ±0.7 -2.854   0.005* 
Severity of MDD symptoms  
3.7 ±0.6 3.3 ±0.9 -3.301   0.002* 
Suicidal thinking  3.6 ±0.7 3.5 ±0.8 -1.451 0.148 
* Significant at p < 0.05, S.D. =Standard Deviation 
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     Comparisons of the pediatricians’ ratings of the factors and child psychiatrists’ ratings of the 
factors were made.  The Levene’s test for equality of variances was first conducted on each of the 28 
comparisons.  If this test was significant then equal variances were not assumed, if the Levene’s test 
was not significant then equal variances could be assumed.  Next, the appropriate two-sample t-test, 
either for equal variances or unequal variances was conducted.  The results are listed in the Table 
4.72.   Mean ratings were significantly different for pediatricians and child psychiatrists for the 
following factors:  clinical experience with prescribing antidepressants, co-existing conditions of 
patient (e.g. obsessive compulsive disorder),  direct-to-consumer advertising, drug efficacy, face-to-
face detailing by medical sciences liaison and/or pharmaceutical representatives, FDA approved,  
manufacturer provides free drugs to indigent patients, parental use of antidepressants,  potential 
adverse effects, sample drugs available, and severity of MDD symptoms.   
     Next, an exploratory factor analysis was conducted on the physicians’ responses to the 28 
variables.  Exploratory factor analysis is appropriate when the researcher has obtained measures on a 
number of variables (in this study the variables are the 28 factors or variables association with the 
decision to prescribe or not prescribe an antidepressant) and wants to identify the factor structure or 
underlying factors or constructs in the set of data (Hatcher, 1994).  A factor “is an unobserved 
variable (or latent variable)” or a “hypothetical construct” that you believe exists and influences 
certain “manifest or observed variables” (Hatcher, 1994).  Some variables will correlate strongly/are 
intercorrelated with each other because these variables are all “caused by the same latent factor” or 
construct (Hatcher, 1994).    
        There are guidelines to choose the sample size that is adequate for a factor analysis (Hatcher, 
1994).  The minimal number of subjects should be at least 100 or five times the number of variables 
being analyzed (Hatcher, 1994).  In the current study physicians were asked to rate how influential 
28 variables are when deciding whether or not to prescribe an antidepressant medication to children 
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or adolescent patients.  Therefore, 28*5 or a minimum of 140 subjects are required to conduct a 
factor analysis in the current study.  A factor analysis was not conducted for the pediatrician group 
because only 57 useable surveys were obtained from pediatricians.  For the child psychiatrist group 
there were 299 returned and usable surveys.  If a subject fails to answer even one item they will not 
provide usable data for a factor analysis and SAS will drop these subjects from the final sample 
(Hatcher, 1994).  The final sample consisted of 259 subjects.  This number is more than the 140 
subjects minimally required for a factor analysis.     
     There are three decisions points or steps in conducting an exploratory factor analysis. The 
researcher must decide which extraction method to utilize, the number of factors to be retained in the 
analysis for rotation, and choose a rotation method.     
        There are several extraction methods that can be utilized when conducting a factor analysis.  
However, information regarding the strengths and weaknesses of these methods is limited (Osborne 
& Costello, 2005).  The most common methods utilized are principal components analysis and 
principal axis factoring (Hatcher, 1994; Osborne & Costello, 2005; Thompson, 2004).  There is 
much debate regarding whether or not principal components analysis should be utilized in as an 
extraction method in exploratory factor analysis (Osborne & Costello, 2005; Thompson, 2004).  
Additionally, principal axis factoring is more robust and does not even assume that data is normally 
distributed.  For these reasons the researcher took a conservative approach and utilized the principal 
axis method for this study.     
     The researcher also needs to determine the number of factors to retain (Hatcher, 1994; Osborne & 
Costello, 2005).  In other words the researcher must decide how many factors are meaningful factors 
and should be retained for rotation and interpretation.  Usually it can be expected that the first few 
factors in the model account for the large majority of the common variance and are therefore more 
meaningful (Hatcher, 1994).  There are several guidelines to follow in order to determine the number 
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of factors to retain for interpretation (Hatcher, 1994).  Since these are guidelines and are rather 
subjective, it has been recommended that these guidelines be used in combination, in order for the 
researcher maximize his/her chances of identifying the correct factor structure for the data (Hatcher, 
1994).  The four guidelines utilized to determine the number of factors to be retained are as follows:  
1)  Kaiser Criterion, 2)  Scree Test, 3)  Proportion of Variance , and 4)  Interpretability Criterion 
(Hatcher, 1994).        
     The Kaiser Criterion calls for factors to be retained if they have an eigenvalue equal to 1.0 or 
greater (Hatcher, 1994).  In this study, the first four factors (4.66, 2.04, 1.30, and 1.00 respectively) 
produced rounded eigenvalues equal to or greater than 1.0.  Therefore, based on this criterion four 
factors should be retained.       
     The scree test plots the eigenvalues for each factor against the number of each factor.  The 
researcher looks for “breaks” in the scree plot to determine how many factors should be retained 
(Cattell, 1966; Hatcher, 1994).  In this study, the scree plot showed four breaks after factor 1, factor 
2, factor 3, and factor 4.    Therefore, based on this criterion four factors should be retained.     
     The proportion of variance criteria can also be utilized to determine the number of factors to 
retain for rotation.  According to this criterion, a factor is retained if it accounts for a certain 
percentage of the variance in a set of data (Hatcher, 1994).  This method has been criticized for 
being subjective (Hatcher, 1994).  If applied to this study the proportion of variance criteria yields 
the slightly different results as the other methods.  For example, if any factor that accounts for at 
least 10% of the common variance is retained, as suggested by Hatcher (1994) only three factors 
would be retained.  The fourth factor having a proportion of variance equal to 0.0922, would not be 
retained.  Although subjective this criterion can serve as a check for the other criterion, especially if 
the results are in agreement.   
 
 
 147 
     The last guideline is the interpretability criterion.  This guideline is not empirical in nature, but 
involves the researcher examining the variables that load on any given factor and determining 
whether or not they seem to share some common conceptual meaning (Hatcher, 1994).  Table 4.73 
lists the variables which loaded on each of the three factors. 
Table 4.73:  Initial Factor Pattern 
Variable Factor 
 
Face-to-face detailing by medical sciences liaison and/or 
pharmaceutical representatives 
Formulary inclusion 
Frequency of dosing 
Generic form of drug available 
Manufacturer provides free drugs to indigent patients 
Medication cost 
Monitoring requirements 
Parents’ education level 
Parental use of antidepressants 
Patient's ability to perform daily activities 
Patient's age 
Patient's family income 
Patient's insurance 
Potential adverse effects  
Sample drugs available  
 
Factor 1 
Patient's ability to perform daily activities 
Severity of MDD symptoms 
Suicidal thinking 
Factor 2 
Drug efficacy 
Drug safety 
Factor 3 
Formulary inclusion Factor 4 
     
 
     According to the interpretable criterion the variables which load on each of the three factors 
should have something in common or seem to group together.  On the first factor the variables face-
to-face detailing by medical sciences liaison and/or pharmaceutical representatives, formulary 
inclusion, frequency of dosing, generic form of drug available, manufacturer provides free drugs to 
indigent patients, medication cost, monitoring requirements, parents’ education level, parental use of 
antidepressants, patient's ability to perform daily activities, patient's age, patient's family income,  
patient's insurance, potential adverse effects, and  sample drugs available load.  These variables seem 
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to relate to the concepts of “drug cost and socio-economic status of the patient”.  Patient’s ability to 
perform daily activities, severity of major depressive disorder symptoms, and suicidal thinking all 
seem to correspond to the idea of “disease presentation or severity of disease”.  The drug efficacy 
and drug safety variables which load on factor 3 could both be related to the concept of “drug 
profile”.  In this initial factor pattern matrix, the variable formulary inclusion loads by itself on factor 
4.  If this factor continued to load only one variable, it should probably be dropped from the analysis, 
as it would be considered a weak or unstable factor.  However, this is not the case as seen in the 
remaining analysis.               
     The next step in factor analysis is rotation of the data.  There are two main types of rotation that 
may be utilized.  These rotation methods are orthogonal rotation or oblique rotation (Hatcher, 1994; 
Osborne & Costello, 2005).  Orthogonal rotation seems to be easier to interpret.  However oblique 
rotation seems to provide better results for many types of variables, as it allows factors to correlate 
with one another.  If the factors are correlated and orthogonal rotation is used this information is lost.  
Oblique rotation is more appropriate in social sciences because behavior is rarely placed in neat 
packages and variables tend to correlate (Hatcher, 1994; Osborne & Costello, 2005).  Therefore, this 
study utilized oblique rotation.    
     The goal of rotation is to simplify the structure of the data.  Simple structure of the data is said to 
be achieved when the variables have “relatively high factor loadings” on one factor and low factor 
loadings (near zero) on the other factors (Hatcher, 1994).  In other words, maximize high factor 
loadings while minimizing low factor loadings. 
Factor loadings are the coefficients that result in the factor pattern matrix or factor structure matrix 
in the results of the factor analysis or the coefficients of the variable on each of the factors (Hatcher, 
1994).     
 
 
 149 
     For analysis utilizing oblique rotation the researcher must interpret at least two matrices in order 
to understand the results.  These are the “Rotated Factor Pattern” and the Factor Structure Matrix” 
(Hatcher, 1994).  In order to understand the results the researcher reviewed the “Rotated Factor 
Pattern” first.  The variables which have meaningful loadings on the factors are identified.  For the 
social sciences factor loadings/ communalities are considered meaningful if they are greater than 
0.40 (Osborne & Costello, 2005; Stevens, 1986).  Second if variables have meaningful loadings on 
two or more factors they are said to crossload and researchers tend to drop these variables, as they do 
not represent a “pure” measure of any one factor or construct (Hatcher, 1994).  The other matrix that 
should be examined is the “Factor Structure Matrix”.  This matrix is less likely to demonstrate 
simple structure, and for this reason it is recommended that researchers rely more on the 
interpretation gained from the rotated factor pattern (Hatcher, 1994).  The results for these matrices 
are listed below in Table 4.74.     
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Table 4.74:  Results of Rotated Factor Pattern and Factor Structure Matrix   
 Factor Loadings 
Factor 1: Rotated Factor Pattern Factor Structure Matrix 
1.  Direct-to-consumer 
advertising 
0.47 0.46 
2.  Face-to-fact detailing by 
medical sciences liaison 
and/or pharmaceutical 
representative 
0.46 0.48 
3.  Monitoring requirements 0.42 CL 
4.  Parents’ education level 0.55 0.58 
5.  Parental use of 
antidepressants 
0.48 0.50 
6.  Patient’s family income 0.67 0.67 
7.  Patient’s gender 0.59 0.51 
8.  Availability of patient 
education materials 
DNL 0.43 
9.  Patient’s age DNL CL 
Factor 2:   
1.  Patient’s ability to perform 
daily activities 
0.59 0.63 
2.  Severity of MDD 
symptoms 
0.77 0.73 
3.  Suicidal thinking 0.80 0.76 
4.  Patient’s age DNL CL 
Factor 3:   
1.  Formulary inclusion   0.66 0.60 
2.  Frequency of dosing 0.43 0.50 
3.  Generic form of drug 
available 
0.69 0.66 
4.  Manufacturer provides free 
drugs to indigent patients 
0.51 0.56 
5.  Medication cost 0.62 CL 
6.  Monitoring requirements DNL CL 
7.  Patient’s insurance DNL 0.42 
8.  Sample drugs to patients DNL CL 
Factor 4:   
1.  Drug efficacy 0.68 0.67 
2.  Drug safety 0.64 0.65 
3.  Co-existing conditions of 
patient 
DNL 0.41 
4.  Potential adverse effects DNL 0.44 
DNL= variable did not achieve a factor loading greater than 0.40 on the matrix 
CL=variable had a meaningful factor loading on two factors under the matrix structure  
 
     The next step is to determine whether or not the variables which load on each factor in the rotated 
factor matrix have anything in common or seem to measure a similar construct.  In reviewing the 
 
 
 151 
variables which loaded on Factor 1 (Direct-to-consumer advertising, Face-to-face detailing by 
medical sciences liaison and/or pharmaceutical representatives, Monitoring requirements, Parents’ 
education level, Parental use of antidepressants, Patient's family income, and Patient's gender) these 
variables have a theme of drug marketing or patient socio-economics.  The variables which loaded 
on Factor 2 (Patient’s ability to perform daily activities, Severity of major depressive disorder 
symptoms, and Suicidal thinking) all seem to measure the construct of disease severity.  The 
variables (Formulary inclusion, Frequency of dosing, Generic form of dug available, Manufacturer 
provides free drugs to indigent patients, and Medication cost) that loaded on Factor 3 all measure 
treatment or antidepressant cost to the patient.  The variables (Drug efficacy and Drug safety) loaded 
on Factor 4 and both measure antidepressant drug profile.           
     The “Reference Structure Matrix” can be reviewed in the case where variables do not 
demonstrate simple structure in the “Rotated Factor Pattern”.  This can result if the factors are 
correlated with one another.  The analysis indicated that Factor 1 and Factor 3 have an inter-factor 
correlation coefficient of 0.50.  This is not a strong correlation, but does show that these two factors 
are correlated.  Conceptually, this does make sense as the variables which load on Factor 1 are 
related to the patient’s socio-economic status and the variable which load on Factor 3 are related to 
the cost of the medication.  Socio-economic status and the ability to pay for the medication are 
related concepts or constructs.  Since some of the variables have meaningful loadings on one of the 
four factors identified above, but do not have zero or near-zero loadings on the other factors, the 
“Reference Structure Matrix”, will be reviewed.  Factor loadings on the “Reference Structure 
Matrix” are listed below in Table 4.75. 
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Table 4.75:  Factor Loadings on the Reference Structure Matrix 
 Factor Loading 
Factor 1:  Socio-economic Status of 
Patient 
 
1.  Parents’ education level 0.47 
2.  Parental use of antidepressants 0.41 
3.  Patient’s family income 0.57 
4.  Patient’s gender 0.50 
Factor 2:  Disease Severity  
1.  Patient’s ability to perform daily 
activities 
0.57 
2.  Severity of MDD symptoms 0.75 
3.  Suicidal thinking 0.77 
Factor 3:  Medication Cost  
1.  Formulary inclusion 0.57 
2.  Generic form of drug available 0.59 
3.  Manufacturer provides free drugs to 
indigent patients 
0.44 
4.  Medication cost 0.53 
Factor 4:  Drug Profile  
1.  Drug efficacy 0.66 
2.  Drug safety 0.62 
 
 
     Conceptually, the evaluation of this matrix provides a cleaner split of the variables.  The variables 
that load on Factor 1 all measure patients’ socio-economic status, the variables on Factor 2 measure 
disease severity, the variables on Factor 3 measure drug cost to the patient, and the variables on 
Factor 4 measure drug profile.  No variables crossloaded on two factors on this matrix and simple 
structure was achieved for most variables.  The drawback to the interpretation of this matrix is that 
only two variable loaded on factor 4.  The number of variables, however, was not increased in the 
rotated factor pattern in this study.  This analysis shows this matrix is most useful for our in 
interpretation of the four factors underlying our variables.  Therefore, it can be concluded that four 
factors labeled socio-economic status of the patient, disease severity, medication cost, and drug 
profile influence child psychiatrists’ decision to prescribe or not to prescribe antidepressant 
medication to a child or adolescent who has been newly diagnosed with major depressive disorder.       
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CHAPTER FIVE:  DISSCUSION & CONCLUSIONS 
 
     This chapter contains the discussion and the conclusions of this study.  The results are discussed 
in the context of their significance and relation to the current published literature.  This discussion is 
followed by study limitations, conclusions, and directions for future research.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 154 
Discussion and Conclusions for Phase I 
     The purpose of Phase I of this study was to determine whether pediatricians treat children and/or 
adolescents with major depressive disorder.  It has been documented in the literature that children 
and adolescents receive antidepressant treatment from primary care physicians (Olfson, 2008; 
Rushton et al., 2000).  Due to resource limitations, the present study surveyed only one group of 
primary care providers, pediatricians.  The current study found 60% of the pediatricians surveyed did 
not treat children or adolescents for major depressive disorder.  None of the pediatricians surveyed 
treated children only, while 11.80% treated only adolescents.  Additionally, 28.20% of the 
pediatricians reported treating both children and adolescents for major depressive disorder.  A study 
conducted after the 2004 United States (U.S.) FDA black box warning on antidepressants, reported a 
shift away from primary health care providers to specialists treating children and adolescents with 
depression (Nemeroff et al., 2007).  Nemeroff et al. (2007) found before the warning, psychiatrists 
accounted for 44% of the patient care for these depressed children and adolescents, however after the 
warning psychiatrists cared for 63% of the depressed children and adolescents (Nemeroff et al., 
2007).  If the current study had been conducted before the 2004 “black box” warning the results may 
have indicated more pediatricians willing to treat children and adolescents with major depressive 
disorder, however, this is not known to be a fact.    
     Even before the 2004 U.S. FDA warning, many pediatricians referred children and adolescents to 
other mental health care professionals for treatment.  One such study   conducted by Olfson (2008) 
found that pediatricians referred 78-79% of cases to other professionals.  This was consistent with 
the findings of the current study which showed that over 80 % of the pediatricians reported they 
refer children and adolescents to some other type of health care provider.  Results also showed that 
pediatricians’ decision to refer or treat was not necessarily a mutually exclusive decision.  
Psychiatrists were the primary health care provider to whom pediatricians most often refer children 
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(67.60%) and adolescents (67.30%).  The second most commonly cited health care professional was 
a psychologist for both children (13.70%) and adolescents (14.00%).  Although the previously 
conducted studies did not focus specifically on major depressive disorder in children and 
adolescents, as did the current study, the results represent a consistent trend and hesitation of 
pediatricians to treat any form of depression in children and adolescents, including major depressive 
disorder.         
     The reason for pediatricians’ hesitation to treat these patients may be due to their lack of 
confidence in their ability and training regarding the diagnosis and management of this disorder.   A 
2001 study found that 90% of pediatricians feel a responsibility to recognize depression in children 
and adolescents, but only 26-27% feels responsible for treating these patients (Olfson, 2008).  Few 
pediatricians (10-14%) felt confident in treating children and adolescents with depression, however, 
35% of these physicians indicated they felt motivated to enhance skills to recognize and manage 
these patients (Olfson, 2008).  This implies a readiness for education and training in the assessment 
and treatment of children and adolescents with major depressive disorder.  This also implies a need 
for the creation of educational resources for pediatricians related to the management and treatment of 
childhood and adolescent major depressive disorder.        
     From Phase I, it can be concluded that the proportion of pediatricians who treat children (χ2 = 
6.532, p = 0.088) and adolescents (χ2 = 4.019, p = 0.259) across the U.S. does not significantly vary 
according to geographic region.  However, pediatricians in the Midwest are somewhat more likely to 
treat children, while pediatricians in the Northeast are somewhat less likely to treat children for 
major depressive disorder.  Geographic variation in physician prescribing has been documented in 
other studies, so the trend toward statistical significance is not surprising (Cox, Motheral, 
Henderson, & Mager, 2003; Hull, Aquino, & Cotter, 2005).  The current study like the previous 
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ones, however, did not reveal the reasons behind the geographic variation (Cox et al., 2003; Hull et 
al., 2005).   
     The other purpose of Phase I was to identify pediatricians who treat children and/or adolescents 
for major depressive disorder and who were willing to participate in the larger Phase II survey, 
regarding specific treatment practices.  Only 39.95% of the pediatricians who returned surveys 
indicated they treat children and/or adolescents.  Of those 163 pediatricians who treat children and/or 
adolescents, only 67.48% (n=110) were willing to participate in the Phase II survey.  This 
information is useful by providing a basis for calculating future sample sizes when surveying 
pediatricians who treat children and/or adolescents with major depressive disorder.                    
Discussion and Conclusions for Phase II 
Choice of Treatment for Children and Adolescents 
    The American Academy of Child and Adolescent Psychiatry (AACAP) recently published 
Practice Parameters for the treatment of depression in children and adolescents (AACAP, 2007).  
According to the Practice Parameters, children and adolescents with mild depression may benefit 
from education, supportive counseling, and case management (AACAP, 2007).  More severe cases 
of depression, such as the population investigated in the current study, generally require treatment 
with antidepressants (AACAP, 2007).  According to the AACAP the child or adolescent may be 
treated with antidepressants, either alone or in combination with counseling/psychotherapy 
(AACAP, 2007).  It should be noted the Practice Parameters outline treatments shown to be effective 
in the treatment of depression but do not specify how physicians should treat children and 
adolescents with any type of depression, including major depressive disorder.  The treatment of 
depression remains an individualized physician’s decision.       
     One purpose of the Phase II study was to determine physicians’ first, second, and third-lines of 
treatment for children and adolescents with major depressive disorder.  The preponderance of child 
 
 
 157 
psychiatrists indicated they would first attempt to use a combination of antidepressants and 
counseling to treat children (52.19%) and adolescents (76.95%) with major depressive disorder.  The 
same finding was reported by the majority of the pediatricians that they utilize a combination of 
antidepressants and counseling to treat children (63.46 %) and adolescents (87.72 %) with major 
depressive disorder.  However, many other physicians indicated they would first attempt to treat the 
child or adolescent with counseling only.  Child psychiatrists and pediatricians reported they use this 
approach more for children (40.07%; 28.85%) than adolescents (15.93%; 8.77%).  
     In the event the first-line of treatment is not successful the majority of child psychiatrists 
(93.71%) and pediatricians (74.00%) would switch the child to a different antidepressant medication 
or augment the counseling therapy, as the second-line of treatment.  For adolescents, the majority of 
child psychiatrists (72.73%) and pediatricians (68.43%) reported switching the patient to a different 
antidepressant medication.   
      In the event the second-line of treatment was not successful, two-thirds of the child psychiatrists 
(66.43%) reported switching the child to another antidepressant medication.  While another 20% of 
the child psychiatrists indicated they would use some “other” type of treatment.  For the child 
psychiatrists this “other” treatment consisted of treating the child with some other type of 
medication.  These medications included antipsychotics (17.86%), mood stabilizers (17.86%), 
anticonvulsants (8.93%), or lithium (8.93%).  The majority of pediatricians (51.28%) reported 
attempting some “other treatment” for children.  This “other treatment” consisted of pediatricians 
referring these children for psychiatric care.  In the event the second-line of treatment was not 
successful for adolescents most of the child psychiatrists (56.75%) reported switching these patients 
to another type of antidepressant medication.  Over one-half of the pediatricians (52.00%) reported 
they would attempt some “other” treatment.  That treatment consists of referring the adolescent to a 
psychiatrist.  Twenty four (24.22%) percent of the child psychiatrists also indicated attempting some 
 
 
 158 
“other” treatment for these adolescents.  For the child psychiatrists this “other” treatment consisted 
of treating the adolescent with some other type of medication.  These medications included 
antipsychotics (20.00%), mood stabilizers (18.57%), anticonvulsants (14.29%), or lithium (15.71%).   
     The findings of this study indicate the preponderance of child psychiatrists and pediatricians 
utilize a combination of antidepressant treatment and counseling/psychotherapy for children and 
adolescents with major depressive disorder.  This treatment is consistent with the American 
Academy of Child and Adolescent Psychiatry’s recommendations for the treatment of children and 
adolescents with major depressive disorder (AACAP, 2007).  The current study also found that many 
child psychiatrists and pediatricians try counseling/psychotherapy only as a first-line treatment for 
children.  This seemingly more conservative approach should not be interpreted as an inadequate 
treatment, as this therapy is also supported by the AACAP for the treatment of depression.  This 
approach may be related back to the pediatricians’ lack of confidence in diagnosing and managing 
this disorder (Olfson, 2008).  The child psychiatrists’ desire to treat children with counseling only 
could be a function of their training, education, and expertise in counseling and psychotherapeutic 
techniques (AACAP, 2004).  More investigation is necessary to draw valid conclusions on the 
reason for these treatment choices.  Additionally, more examination is necessary to explore the 
timelines associated with switching treatments.  Presently there are no guidelines on switching 
treatment in children and adolescents.  Based on the adult literature, however, it is understood that 
treatment response to antidepressants is not immediate and requires several weeks (AACAP, 2004).  
The purpose of this study did not include investigating how long physicians wait for a treatment 
response until they switch to a new treatment for a child or adolescent with major depressive 
disorder.  This could be investigated in future research.             
     In the event physicians utilize an antidepressant medication for the first-line of treatment for 
children or adolescents, they indicated they most commonly prescribe either Prozac® or Zoloft®.  
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This result was found for both child psychiatrists and pediatricians.  For the first-line of treatment, 
the majority of child psychiatrists (51.98%) and pediatricians (56.76%) indicated they utilize 
Prozac® to treat children.  Other child psychiatrists (27.12%) and pediatricians (24.33%) indicated 
the use of Zoloft® to treat children.  The findings were similar for physicians treating adolescents.  
For the first-line of treatment the majority of the child psychiatrists indicated they would utilize 
either Prozac® (50.21%) or Zoloft® (19.84%) to treat adolescents.  This was also true for most of the 
pediatricians who indicated they would utilize either Prozac® (44.23%) or Zoloft® (38.46%).        
     For the second-line of treatment the majority of the physicians still reported utilizing Prozac® or 
Zoloft® to treat children.  The choice of antidepressant for the treatment of adolescents, however, 
varied somewhat for both child psychiatrists and pediatricians.  The second-line of treatment choice 
was varied for the child psychiatrists. They utilized Zoloft®  (23.97%), Prozac®, (18.73%), 
Wellbutrin (13.48%), and Celexa® (8.99%) and Lexapro®  (8.99%). In comparison to pediatricians 
who reported utilizing Prozac® (36.85%), Zoloft® (28.95%), or Celexa® (15.22%).   
     For the third-line of treatment physicians’ choice of antidepressant treatment for children and 
adolescents was more varied than for the first and second-lines of treatment.  Child psychiatrists 
primarily reported utilizing one of the SSRI type antidepressants, but thirty percent (30.24%) noted a 
preference for Wellbutrin® as a third-line of treatment for children.  In comparison, the majority 
(55.56%) of the pediatricians indicated they would try the child on Wellbutrin®.  Another one-third, 
of the pediatricians (33.33%) indicated the use of Zoloft® as a third-line of treatment.     
     When treating adolescents, the choice of antidepressants was even more varied.  Approximately 
40% of child psychiatrists reported using Wellbutrin®.  However, many indicated they would utilize 
some type of SSRI (most frequently Zoloft®) or Effexor® (SNRI).  In contrast, pediatricians 
(31.25%) utilized Wellbutrin® or some type of SSRI.  Of those reporting, Lexapro® was the most 
frequent SSRI chosen.  The specific antidepressant most commonly used as first-line treatment for 
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both children and adolescents by child psychiatrists and pediatricians was Prozac®.  The second most 
commonly used antidepressant by both specialties is Zoloft®.  As a second line of antidepressant 
treatment child psychiatrists and pediatricians and still utilized Prozac® and Zoloft® more commonly 
than other antidepressants for both children and adolescents.       
     The reasons for the popularity of these antidepressants may be related to the fact Prozac® is the 
only U.S. FDA approved antidepressant treatment for children and adolescents with major 
depressive disorder (U.S. FDA, 2004).  The 2004 U. S. FDA warning highlighted a possible increase 
in suicidality in child and adolescents who are treated with antidepressants.  Because of this risk, 
physicians may view Prozac® as a safer or more conservative treatment option and be hesitant to 
prescribe off-label antidepressants to children and adolescents.  Although Zoloft® is not approved for 
the treatment of depression in children and adolescents; it is indicated for the treatment of obsessive-
compulsive disorder in the pediatric population (U.S.FDA, 2007).  Since this medication is indicated 
for the treatment of another disorder in this population, physicians may feel more comfortable 
prescribing it to this age group.  The current study, however, did not investigate the specific rationale 
for prescribing one antidepressant over another.     
Association of Physician Type and Antidepressant Category 
     The relationship between physician type and antidepressant category was assessed for the first, 
second, and third-lines of treatment for children and then for adolescents treated for major 
depressive disorder.  It was concluded there was no significant difference in the antidepressant 
category prescribed by physicians (child psychiatrists versus pediatricians) for children or 
adolescents for either the first, second, or third-line of treatment.  This result may have been due to 
the fact there was a small sample size of pediatricians and there was not enough power to detect a 
statistical difference between the two physician groups.  These comparisons have not been reported 
in the literature to date.        
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Association of Physician Type and Specific Antidepressant 
     The relationship between physician type and the specific antidepressant prescribed was also 
assessed for the first, second, and third-lines of treatment for children and then for adolescents 
treated for major depressive disorder.  It was concluded there was no significant difference in the 
specific antidepressant prescribed by physicians (child psychiatrists versus pediatricians) for children 
or adolescents for the first, second, and third-lines of treatment.  This result may have been due to 
the fact there was a small sample size of pediatricians and there was not enough power to detect a 
statistical difference between the two physician groups. Again, these comparisons have not been 
reported in the literature.       
Association of Physician Characteristics and Type of Treatment Prescribed for Children and 
Adolescents with Major Depressive Disorder 
 
     The association between physician characteristics and type of treatment (antidepressant treatment 
versus counseling) prescribed for children, was assessed by the use of logistic regression.  It was 
found that the type of physician, age of the physician, and geographic region in which the physician 
practiced was associated with prescribing antidepressant medication for a child with major 
depressive disorder.   
     The odds in favor of a physician prescribing an antidepressant is 0.402 times greater for a child 
psychiatrist as compared to a pediatrician.  At first this finding may seem counterintuitive; however, 
this study found that many child psychiatrists use counseling only as a first-line approach to treat 
children and adolescents.  This association of physician type and probability of prescribing an 
antidepressant medication for treatment may be related, at least in part, to the fact that child 
psychiatrists receive more training in conducting counseling/psychotherapy and are more confident 
in their abilities to treat the child or adolescent with counseling/psychotherapy (AACAP, 2004).   
     The odds in favor of a physician prescribing an antidepressant medication is greater for 
physicians older than 60 years of age.  This finding may be related to the idea that many physicians 
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rely on their own clinical experience to guide treatment choices.  The current study found that a 
majority of the physicians surveyed utilize their own clinical experience or that of their colleagues to 
help guide their treatment choices.  Perhaps even with the U.S. FDA “black box” warning many of 
these physicians have successfully utilized antidepressants in children and adolescents for many 
years in their own practices.     
     The odds in favor of physicians prescribing antidepressant medication whose practices are 
located in the South, Midwest, or Pacific/West are respectively, 2.625, 2.694, and 2.421, times 
greater as compared to physicians who practice in the Northeast.  Geographic variation in 
prescribing psychotropic medications has been documented (Cox et al., 2003; Hull et al., 2005; 
Webster, Cifuentes, Verma, & Pransky, 2008).  This variation has been related to the demographics 
of the physicians.  For example, Hull et al. (2005) reported, Asian-trained physicians were less likely 
to prescribe antidepressants to adults patients.  Another study attributed geographic variation to 
differential training of physicians (Cox et al., 2003).  The current study found that specialty of 
physician (p=0.0249), physician age (p=0.0551), and geographic location (p=0.0040 to p=0.0168) 
were significantly associated with physicians prescribing antidepressants as treatment.  The findings 
of the current study suggest an association between these variables and not causation.  Therefore, to 
better understand the relationships between geographic variation, physician characteristics, and the 
treatment prescribed for children and adolescents with major depressive disorder, further study of 
these associations is warranted.     
Average Length of Treatment for Children and Adolescents        
     The current study found approximately two-thirds (65.15%) of child psychiatrists and one-half 
(51.35%) of pediatricians continue to prescribe antidepressant medication to both children and 
adolescents for a period of at least ten months.    Additionally, it was found the majority of child 
psychiatrists (71.49%) and pediatrician (63.46%) prescribe antidepressant medication for 
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adolescents for at least ten months.  The average length of time the physicians treat children and 
adolescents with antidepressant therapy was compared to the recent recommendations published by 
the AACAP.  These recommendations are to continue treatment for depression for at least six 
months.  This time frame has been associated with a lower rate of relapse of depressive symptoms.  
A randomized controlled trial compared children and adolescents with major depressive disorder on 
Prozac® to patients on placebo.  The objective of this trial was to determine whether treatment for six 
months could prevent relapse.  It was concluded that the mean time to relapse was significantly 
longer (p=0.046) in the patients taking Prozac® than those given placebo treatment (Emslie et al., 
2004).  Therefore, based on the findings of the current study, both child psychiatrists and 
pediatricians are prescribing antidepressant medications to children and adolescents in accordance 
with the recently published recommendations of the AACAP (AACAP, 2207).  The significance of 
this finding is that both children and adolescents, who are treated by pediatricians and child 
psychiatrists are receiving antidepressant medication for a sufficient length of time in order to 
prevent disease relapse.            
Pharmacotherapy Monitoring for Children and Adolescents 
     Both child psychiatrists and pediatricians reported they conduct monitoring as part of an office 
visit with the child or adolescent.  Furthermore, child psychiatrists and pediatricians indicated they 
would conduct the monitoring themselves.  Over 90% of the pediatricians and child psychiatrists 
reported monitoring for adverse events, suicidality, and clinical symptoms.  Some child psychiatrists 
and pediatricians also indicated they conduct some type of labwork for children and adolescents 
treated with an antidepressant. 
            Physicians were asked to indicate how frequently they monitored child and adolescent 
patients during the first three months of antidepressant treatment.  For the first month of treatment, 
the majority of child psychiatrists monitor either once a week (41.43%) or every two weeks 
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(30.71%) while pediatricians (54.35%) reported monitoring children every two weeks. During the 
second month, the majority of child psychiatrists indicated they monitor either once a month 
(42.65%) or every two weeks (34.05%) compared to most pediatricians (65.23%), who indicated 
they monitor once a month.  Throughout the third month, the preponderance of child psychiatrists 
(62.72%) monitor children once a month, whereas most of pediatricians (52.18%) monitor children 
at some interval greater than once a month.  For adolescents, during the first month, child 
psychiatrists monitor either once a week (38.95%) or every two weeks (32.98%) in comparison to 
most of the pediatricians (53.70%) who monitor adolescents every two weeks. During the second 
month of treatment, child psychiatrists continue to monitor once (45.77%) or twice a month 
(30.28%), whereas pediatricians (62.97%) reported that they did more frequent monitoring during 
the second month of treatment (once a month) than in the first month.  During the third month of 
treatment, child psychiatrists (62.68%) continue to monitor adolescents on antidepressant therapy 
once a month. In contrast, pediatricians monitor adolescents either once a month (42.60%) or 
interval greater than once a month (50.00%).  The fact that physicians monitor more frequently early 
in treatment may be related to the idea that antidepressants can trigger agitation in some patients, and 
this agitation has been linked to an increase in suicidality (NIMH, 2009).         
     The frequency with, which physicians monitor children and adolescents, while they are on 
antidepressant treatment, was compared to the U.S. FDA recommendations.  It was concluded that 
child psychiatrists and pediatricians monitor, both children and adolescents significantly less than 
the U.S. FDA recommendations during the first and second month of antidepressant therapy.  During 
month three pediatricians still monitor children and adolescents significantly less than the U.S. FDA 
recommendations.  However, the frequency with which child psychiatrists monitor children and 
adolescents, who are on antidepressant treatment, during the third month of treatment, does not 
differ significantly from the U.S. FDA recommendations.   
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     A recent study compared the frequency of physician monitoring before and after the U.S. FDA 
black box warning and found that less than 5% of all patients met the U.S. FDA monitoring 
recommendations before or after the 2004 warning (Morrato et al., 2008).  Another recent study 
found that only 7.5% of “prescribing physicians” met the U.S. FDA recommendations for 
monitoring frequency (Bhatia et al., 2008).  The results of the current study seem to be in agreement 
with other, similar studies in that physicians are not monitoring as frequently as the U.S. FDA 
recommended in 2004.  The rationale for the monitoring frequency, however, was not explored in 
the current study.       
     The U.S. FDA recommends children and adolescents on antidepressant medication be monitored 
as follows:  one time per week for the first month of treatment, biweekly during the second month of 
treatment, and at week twelve (U.S. FDA, 2004).  Therefore, if child psychiatrists and pediatricians 
wish to monitor according to the U.S. FDA recommendations, they need to increase the frequency of 
monitoring during the first and second months of treatment.  Pediatricians also need to increase 
monitoring frequency for children and adolescents during the third month of antidepressant 
treatment.       
Variables Influencing Physicians’ Decision to Prescribe Antidepressants 
     Physicians were asked to rate the extent to which 28 variables influenced their decisions of 
whether or not to prescribe an antidepressant to a child or adolescent with major depressive disorder.  
Both child psychiatrists and pediatricians on average rated clinical experience with prescribing 
antidepressants, co-existing conditions of patient (e.g. obsessive compulsive disorder), comfort in 
managing major depressive disorder in youth, drug safety, drug efficacy, familiarity with an 
antidepressant being prescribed, severity of major depressive disorder symptoms, and suicidal 
thinking as being “influential” or “extremely influential”.  Child psychiatrists also, rated potential 
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adverse effects as being either “influential” or “extremely influential”, while pediatricians rated 
potential adverse effects as being “not influential” or only “somewhat influential”.    
     Exploratory factor analysis revealed four underlying factors socio-economic status of patient, 
disease severity, medication cost, and drug profile.  Based on this analysis it was concluded that 
these four factors influence child psychiatrists’ decision of whether or not to prescribe antidepressant 
medication to a child or adolescent who had been newly diagnosed with major depressive disorder.   
     This was the first study to examine these relationships for children and adolescents with major 
depressive disorder.  However, other studies have examined the relationships between variables and 
physician prescribing behavior.  Patient characteristics have been found to be related to physicians 
prescribing of antidepressants and medication for the treatment of panic disorder (Freeman et al., 
1993; Sleath & Shih, 2003).  Disease severity and physical impairment have been shown to be 
related to physicians prescribing of antidepressants and antipsychotics to adults (Benson, 1983; 
Sleath & Shih, 2003).  Medication cost has been found to be related to physicians prescribing 
antidepressants to adults (Cates, 2001).  Drug safety and efficacy have been found to influence 
physicians prescribing of antidepressants and medications to treat panic disorder in adults (Cates, 
2001; Freeman et al., 1993).   The results of this study also show associations similar to those in the 
aforementioned studies conducted for various disorders in the adult population.          
Study Limitations 
     The limitations to the current study are related to the survey methodology employed.   
Surveys can be prone to sampling error, non-response bias, measurement error, and self-report.  
Steps were taken in this study to help mitigate the impact of these factors.  The sample utilized in 
this survey was a national random sample of pediatricians and child psychiatrists.  This was done in 
order to increase the generalizability of the results of the survey.  The degree to which the returned 
surveys were geographically representative to the original sample was not assessed in this study.  
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The reason for this was that the researcher did not have access to an electronic database of the 
original sample of pediatricians and child psychiatrists and data analysis was not feasible.  Also, two 
mailings of each survey were completed in order to increase the response rate.  The length of the 
survey, at eight pages was long and may have impacted the response rates to some extent.  
Physicians are busy people especially, child psychiatrists, in light of the current shortage of child 
psychiatrists in the United States (AACAP, 2004).  Incentives have been shown to increase response 
rates, however due to limited resources, offering an incentive was not feasible for this study 
(Kellerman, 2001).         
     Non-response bias can be a problem with survey research if the respondents differ from the non-
responders.  A non-response analysis was conducted, which compared early responders of the Phase 
II survey to late responders (who served as a proxy for non-responders).  The non-response analysis 
found no statistical significant difference between early responders and non-responders.  Based on 
this analysis, it appears that non-response bias was not a factor in this survey.     
     Measurement error occurs when respondents do not understand the survey questions or surveys 
instructions, and will impact the accuracy of the inferences drawn from the survey responses.  A 
pilot study was done in order to assess the survey instrument for Phase II.  Based on the findings 
from the pilot study it was concluded some of the questions and instructions regarding treatment 
choices (first, second, and third-line of treatment) for children and adolescents were unclear and 
were misunderstood.  These questions were revised and the instructions were re-written.  The 
changes to the survey seemed to help clarify these issues somewhat when the final survey was sent 
to the larger sample of child psychiatrists and pediatricians.  Some of the child psychiatrists 
(20.25%) still indicated their first-line of treatment was “counseling only”, but also listed the use of 
an antidepressant for the first-line of treatment.  Since the majority of these physicians also listed the 
same antidepressant in the second-line of treatment, the researchers made the assumption that 
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“counseling only” was truly their first-line of treatment and the antidepressant chosen was their  
second-line of treatment.  This is a reasonable assumption; however, if a similar survey is conducted 
in the future the wording of these questions should be re-examined and pilot tested to further ensure 
clarity.           
     This study surveyed a national sample of both pediatricians and child psychiatrists.  Thus, the 
results from the study should be generalizable.  A response rate of 22.9% was obtained for Phase I of 
the study and a response rate of 15.1% was obtained for the surveyed child psychiatrists (Phase II).  
However, only 57 pediatricians’ surveys were usable out of the 110 mailed in Phase II.  This was a 
function of the finding that 60% of the pediatricians in Phase I do not treat children or adolescents 
for major depressive disorder.  Unfortunately, this impacted some of the planned analyses for this 
population.  For instance, factor analysis requires at a very minimum five subjects for every variable 
(Hatcher, 1994).  In this study, there were 28 variables and a minimum of 140 subjects needed to 
conduct factor analysis.  The 57 pediatricians did not meet these minimum standards.  The small 
sample size of pediatricians in Phase II is also a cause for concern in comparisons between 
pediatricians and child psychiatrists.  Post hoc power analyses failed to demonstrate adequate power 
to conduct many of these comparisons.  The associations between physician type and class of 
antidepressant (SSRIs versus Non-SSRIs) and then specific type of antidepressant (Prozac® versus 
Non-Prozac®) were tested.  None of these comparisons resulted in statistically significant 
associations.  For these comparisons, the actual sample sizes for the pediatricians ranged from 9 to 
57, and for the child psychiatrists ranged from 175 to 294.  The significance level was α =0.05 and 
the post hoc power for these comparisons resulted in 0.51 or less power for all comparisons (Cohen, 
1988).  For other objectives the t-test statistic was utilized to test for differences between the average 
number of times pediatricians and child psychiatrists monitor patients during months one, two, and 
three of antidepressant treatment.  The sample sizes for the pediatricians ranged from 45-53, and 
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ranged from 251-272 for child psychiatrists.  The observed power for these comparisons ranged 
from 0.05 – 0.88 power.  The sample size of 53 pediatricians and 269 child psychiatrists, achieved 
0.88 power to detect an effect size of d=0.47 (d=0.50 represents a “medium” effect size) using a t-
test with a significance level of α =0.05 (Cohen, 1988).  Power analyses were conducted using the 
computer programs PASS® or G*Power 3 (Erdfelder, 1996).  In summary, the number of 
pediatricians was not adequate to conduct all of the comparisons, with adequate power, between 
pediatricians and child psychiatrists for this study.  Additionally, because of the limited number of 
pediatricians in Phase II, caution should be exercised when extrapolating the findings from this 
survey to the entire population of pediatricians in the U.S.   
Overall Conclusions 
     In the absence of empirical research to guide the selection of antidepressant treatment, research 
was necessary to examine: what physicians consider to be the most appropriate antidepressant 
treatment, physicians’ recommended course of treatment (i.e., length of treatment, monitoring), and 
the factors which impact physicians’ decisions to treat major depressive disorder in children and 
adolescents with antidepressants.  
     In achieving these goals some preliminary information needed to be collected on pediatricians, in 
Phase I.  The findings from this phase provide a basis for calculating a sample size for future surveys 
of pediatricians who treat children and/or adolescents with major depressive disorder and allowed 
for the identification of pediatricians eligible for Phase II of this study. 
     The treatment of depression is an individualized choice and therefore strict guidelines for 
treatment choices do not exist.  The AACAP has published Practice Parameters to outline the 
treatments that have been shown, through randomized clinical trials, to be effective in the treatment 
of major depressive disorder in children and adolescents.  These parameters are meant to help direct 
physicians in treating children and adolescents with major depressive disorder, but in no way dictate 
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proper treatment of these patients.  The current study gathered information on pediatricians’ and 
child psychiatrists’ preferred treatment choices for children and adolescents with major depressive 
disorder and these preferences are in line with the current AACAP Practice Parameters.      
     The current study gathered information on the frequency with which physicians monitor children 
and adolescents who are prescribed antidepressant medication.  These findings indicate pediatricians 
and child psychiatrists are not monitoring as frequently as the U.S. FDA recommends.  The reasons 
for this are not known.    
     Exploratory factor analysis did reveal four underlying factors (socio-economic status of patient, 
disease severity, medication cost, and drug profile) related to the physicians’ decision of whether or 
not to prescribe antidepressant treatment.  The associations between physician characteristics 
(specialty of physician, geographic location of practice, and physician age) and the treatment 
prescribed were also found in this study and concur with similar studies in other patient populations.      
Future Research 
     Four areas of future research were identified.  First, the study gathered preliminary information 
regarding pediatricians’ treatment of children and adolescents with major depressive disorder.   
Since this information is now available, it will be possible to conduct a larger, more representative 
study regarding pediatricians’ treatment choices for treating children and adolescents with major 
depressive disorder.  Additionally, a larger study of pediatricians can investigate in more detail areas 
why pediatricians lack training and skills to diagnose and treat major depressive disorder.       
     Second, the study collected information on pediatricians’ and child psychiatrists’ treatment 
choices for children and adolescents with major depressive disorder.  However, it did not investigate 
the rationale behind these choices.  For example, although the majority of physicians treat patients 
with a combination of antidepressants and counseling, some physicians opt to treat with counseling 
only as a fist-line of therapy.  Additionally, as a third-line of treatment, many physicians treat with 
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other type of medications such as, antipsychotics or mood stabilizers.  Also, the most popular 
choices for antidepressant treatment were Prozac® and Zoloft®.  Future studies should also explore 
why these were the choices of the physicians surveyed.    
     Third, according to the findings of this study and other recent studies (Bhatia et al., 2008; 
Morrato et al., 2008), pediatricians and child psychiatrists do not monitor as frequently as the U.S. 
FDA recommendations.  The reasons for this could not be determined from this study and should be 
an area for further research.       
     Fourth, the researcher found that the socio-economic status of the patient, disease severity, 
medication cost, and drug profile are related to the physicians’ decision of whether or not to 
prescribe antidepressant treatment.  Also, associations between physician characteristics (specialty, 
age, and geographic location) and the treatment prescribed were found in this study.  In order to 
better understand these relationships, these associations warrant further investigation.                         
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APPENDIX A 
 
Identification of Physicians Treating Children and Adolescents with Major Depressive 
Disorder (MDD) 
 
 
Instructions:  This survey is designed to identify physicians who treat children and adolescents 
with MDD and who are willing to participate in a larger study related to MDD in children and 
adolescents.   
 
 
 
1.  Please check all age group(s) whom you treat in an outpatient setting for MDD. 
      
        Children (5 – 12 years old) 
        Adolescents  (13 – 18 years old)  
        Do not treat 
 
2.  Please check all age group(s) whom you refer for the treatment of MDD and  
     indicate the type of health care provider to whom you refer these patients. 
      
        Refer children (5 - 12 years) to  ___________________________________. 
        Refer adolescents (13 - 18 years) to  _______________________________. 
        Do not refer 
 
3.  If you treat children and/or adolescents with MDD, are you willing to participate 
     in a more in-depth questionnaire designed to gain information about physicians’ 
     prescribing habits in treating those patients?  
 
        Yes 
        No 
      
 
 
Comments:  Please use this space to provide additional comments. 
 
 
 
 
 
 
 
 
 
THANK YOU FOR YOUR TIME AND ASSISTANCE! 
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APPENDIX B 
Physician Prescribing Behavior and Factors Related to Antidepressant Prescribing to 
Children and Adolescents with Major Depressive Disorder (MDD) 
 
Instructions:  This survey is designed to determine 1) your first, second, and third-lines of 
outpatient treatment for children and/or adolescents who have been diagnosed with MDD, 2) the 
type and length of pharmacotherapy monitoring you conduct, and 3) the factors that influence your 
decision to prescribe an antidepressant.  The survey is divided into eight sections.   
For this survey, the definition of major depressive disorder is a condition that is “manifested by 
a combination of symptoms that interfere with the ability to work, study, sleep, eat, and enjoy once 
pleasurable activities“(NIMH, 2007).  MDD can be diagnosed using the criteria set forth by the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR).  In the scientific literature, 
children are typically defined as being 5 through 12 years of age while adolescents are 13 through 
18 years old.  This survey will utilize these definitions of age for both children and adolescents.  
 
Reference: National Institute of Mental Health. (2007). Retrieved October 15, 2007, from  
http://www.nimh.nih.gov/health/publications/depression/what-is-a-depressive-disorder.shtml. 
 
Section 1:  Outpatient Treatment versus Referral of Children and Adolescents 
 with Major Depressive Disorder (MDD)   
 
1.  Please check all age group(s) whom you treat for MDD. 
        Children (5 – 12 years old) 
        Adolescents (13 – 18 years old)  
        Do not treat  (please skip to Section 8, Question #23) 
 
2.  Please check the age group(s) of patients you refer for the treatment of MDD and indicate the type of   
     health care provider to whom you refer these patients. 
        Refer children (5 - 12 years) to  ___________________________________. 
        Refer adolescents (13 - 18 years) to  _______________________________. 
        Do not refer 
 
3.  Please indicate the youngest patient (under 13 years of age) with MDD to whom you would consider  
     prescribing an antidepressant medication.  
        1 – 4 years 
        5 – 7 years 
        8 – 10 years 
        11 – 12 years 
        Do not prescribe for children less than 13 years  
 
Section 2:  Preferred First-Line Outpatient Treatment  
 
4. Check your first-line of outpatient treatment, for children and/or adolescents who have been newly 
    diagnosed with MDD. 
 
Children (5-12 years) Adolescents (13-18 years) 
   Antidepressants only    Antidepressants only 
   Counseling/psychotherapy only    Counseling/psychotherapy only 
   Both antidepressant and   
     counseling/psychotherapy 
   Both antidepressant and  
     counseling/psychotherapy 
   Other, please specify    Other, please specify 
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If your first-line of treatment (in Question #4) included antidepressants (either alone or  
in combination with counseling/psychotherapy), for EITHER children or adolescents 
please answer Questions #5 - #8, otherwise skip to Section 3, Question #9. 
 
5.  As indicated in Question #4, check the ONE antidepressant (either alone or in combination with  
     counseling/psychotherapy) you would most commonly select as a typical first-line treatment for that  
     child (5-12 years old) and/or adolescent (13-18 years old) newly diagnosed with MDD.  
 
Child (5-12 years) Adolescent (13-18 years) 
   Celexa
®
   (citalopram HBr)    Celexa
®
   (citalopram HBr)
   Cymbalta
®
  (duloxetine HCl)     Cymbalta
®
  (duloxetine HCl) 
   Effexor
®
  (venlafaxine HCl)       Effexor
®
  (venlafaxine HCl)   
   Elavil
®
  (amitriptyline HCl)       Elavil
®
  (amitriptyline HCl)   
   Desyrel
®
  (trazodone HCl)              Desyrel
®
  (trazodone HCl)          
   Lexapro
®
  (escitalopram oxalate)    Lexapro
®
  (escitalopram oxalate)
   Luvox 
®
 (fluvoxamine maleate)        Luvox 
®
 (fluvoxamine maleate)  
   Nardil
®
  (phenelzine sulfate)      Nardil
®
  (phenelzine sulfate)  
   Norpramin
®
  (desipramine HCl)      Norpramin
®
  (desipramine HCl)  
   Pamelor
®
  (nortriptyline HCl)          Pamelor
®
  (nortriptyline HCl)      
   Paxil
®
  (paroxetine HCl)               Paxil
®
  (paroxetine HCl)           
   Parnate
®
  (tranlcypromine sulfate)     Parnate
®
  (tranlcypromine sulfate) 
   Prozac
®
  (fluoxetine HCl)             Prozac
®
  (fluoxetine HCl)         
   Remeron
®
  (mirtazpine)                 Remeron
®
  (mirtazpine)             
   Serzone
®
  (nefazodone HCl)           Serzone
®
  (nefazodone HCl)       
   Tofranil
®
  (imipramine HCl)           Tofranil
®
  (imipramine HCl)       
   Wellbutrin
®
  (buproprion HCl)               Wellbutrin®  (buproprion HCl)           
   Zoloft
®
  (sertraline HCl)                  Zoloft
®
  (sertraline HCl)              
   Other, please specify 
 
   Other, please specify
 
6.  For the first-line antidepressant(s) selected above, please indicate the standard total daily starting dosage  
     and the standard maximum total daily dosage you use for an outpatient child and/or adolescent with MDD.  
  
Drug Dosage Child (5-12 years) Adolescent (13-18 years) 
Starting dosage 
(mg/day) _______________mg              _______________mg     
Maximum dosage 
(mg/day) _______________mg              _______________mg 
 
7.  If antidepressant therapy is successful, how long do you continue prescribing the antidepressant(s) 
     to the newly diagnosed outpatient child and/or adolescent? (Check one) 
  
Child (5-12 years) Adolescent (13-18 years)  
    1-3  months     1-3  months
    4-6  months     4-6  months
    7-9  months     7-9  months
10-12 months 10-12 months
    > 12 months     > 12 months
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8.  If there is no improvement in the depressive symptoms of the child and/or adolescent, after reaching the  
    antidepressant’s tolerated maximum prescribed dosage (assuming no adverse events), how long do you 
    continue to prescribe the drug before considering another treatment approach? (Check one) 
 
Child (5-12 years) Adolescent (13-18 years) 
   < 2  weeks    < 2  weeks
2 – 4  weeks 2 – 4  weeks
5 – 6  weeks 5 – 6  weeks
7 – 8  weeks 7 – 8  weeks
9 –10 weeks 9 –10 weeks
> 10 weeks > 10 weeks
 
Section 3:  Preferred Second-Line Outpatient Treatment  
 9.  Assuming you have re-evaluated and confirmed the diagnosis of MDD, if there are no improvements in 
     depressive symptoms with the first-line treatment, what would you typically recommend as your next step 
     in outpatient treatment for this child and/or adolescent? (Check one) 
 
Child (5-12 years) Adolescent (13-18 years)  
Augment with antidepressant therapy Augment with antidepressant therapy
Switch to a different antidepressant Switch to a different antidepressant
Augment with counseling/psychotherapy Augment with counseling/psychotherapy
Other treatment, please specify 

Other treatment, please specify 

 
10.  If you indicated above (Question # 9) you would augment with antidepressant therapy or switch to a 
different antidepressant, what would you typically prescribe as your second-line of treatment for this 
child and/or adolescent (otherwise please skip to Question #11)?  
 
 Child (5-12 years) Adolescent (13-18 years) 
 Antidepressant 
_______________              _______________     
 
Section 4:  Preferred Third-Line Outpatient Treatment  
 
11.  If there are no improvements in depressive symptoms with the second-line treatment, what would you        
       typically recommend as your next step in outpatient treatment for this child and/or adolescent? 
       (Check one) 
 
Child (5-12 years) Adolescent (13-18 years)  
Augment with antidepressant therapy Augment with antidepressant therapy
Switch to a different antidepressant Switch to a different antidepressant
Augment with counseling/psychotherapy Augment with counseling/psychotherapy
Other treatment, please specify 

Other treatment, please specify 

 
12.  If you indicated above (Question # 11) you would augment with antidepressant therapy or switch to a 
      different antidepressant, what would you typically prescribe as your third-line of treatment for this  
      child and/or adolescent (otherwise please skip to Question #13)?  
  
 Child (5-12 years) Adolescent (13-18 years) 
Antidepressant 
_______________              _______________     
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Section 5:  Counseling/Psychotherapy   
 
         13.  If you believe the child and/or adolescent should have counseling/psychotherapy, would you refer to a 
                counselor or psychotherapist or conduct the counseling/psychotherapy yourself? (Check one)   
         Refer the child and/or adolescent to ________________________________ 
         Conduct my own therapy (please skip to Question # 15)  
         Do not utilize counseling/psychotherapy (please skip to Section #6, Question #16) 
 
14.  If you refer a child and/or adolescent with MDD for counseling/psychotherapy treatment, please 
       indicate how far, in approximate miles, the patient would have to travel, from their residence, to visit a  
       counselor/psychotherapist.   ____________________ Miles (please skip to Section 6, Question #16)                  
 
15.  If you conduct your own counseling/psychotherapy, please rank the following types of 
counseling/psychotherapy based on how likely you would be to utilize them when treating a child and/or 
adolescent, newly diagnosed with MDD.  Rank the following types from 1 – 7, where 1 = the type you 
would most likely recommend or utilize and 7 = the type you would least likely recommend or 
utilize.     
 
Rank                    Children (5-12 years) Rank                  Adolescents (13-18 years) 
                    Cognitive behavioral therapy                     Cognitive behavioral therapy 
                    Family therapy                              Family therapy          
                    Interpersonal therapy                     Interpersonal therapy 
                    Patient education                     Patient education 
                    Play therapy                     Play therapy 
                    Psychodynamic therapy                     Psychodynamic therapy 
                    Supportive counseling                         Supportive counseling 
 
Section 6:  Pharmacotherapy Monitoring of Outpatient Children and Adolescents 
 
If you do not utilize pharmacotherapy, please skip to Section 7, Question #22 
 
16.  Check the primary mode of monitoring outpatient children and/or adolescents who are receiving an 
       antidepressant for MDD? (Check one)  
 
Children (5-12 years) Adolescents (13-18 years) 
Individual patient office visit Individual patient office visit
Telephone contact Telephone contact
Patient medication group Patient medication group
Other, please specify 

Other, please specify 

 
17. Check the primary type of health care provider who conducts the monitoring?  (Check one)  
  
Children (5-12 years) Adolescents (13-18 years) 
Physician Physician
Nurse/Nurse Practitioner Nurse/Nurse Practitioner
Counselor/Psychotherapist Counselor/Psychotherapist
Pharmacist Pharmacist
Physician Assistant Physician Assistant 
Other, please specify Other, please specify 
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18.  Check all types of monitoring conducted for outpatient children and/or adolescents taking an 
       antidepressant for MDD? 
 
Children (5-12 years) Adolescents (13-18 years) 
Monitor for adverse events Monitor for adverse events
Monitor for suicidality Monitor for suicidality
Conduct labwork related to treatment  Conduct labwork related to treatment 
Monitor clinical symptoms (e.g. sleep, 
    appetite, energy, activities) 
Monitor clinical symptoms (e.g. sleep, 
    appetite, energy, activities) 
Other, please specify Other, please specify
 
19.  During the first month of treatment, check the most appropriate timeline you use, on average, to 
monitor outpatient children and/or adolescents taking an antidepressant for MDD? 
 
Children (5-12 years) Adolescents (13-18 years) 
Two times per week Two times per week
Once a week Once a week
Every 2 weeks Every 2 weeks
Every 3 weeks Every 3 weeks
Once a month Once a month
Greater than 1 month Greater than 1 month 
Other, please specify 

Other, please specify 

 
20.  During the second month of treatment, check the most appropriate timeline you use, on average, to 
monitor outpatient children and/or adolescents taking an antidepressant for MDD? 
 
Children (5-12 years) Adolescents (13-18 years) 
Two times per week Two times per week
Once a week Once a week
Every 2 weeks Every 2 weeks
Every 3 weeks Every 3 weeks
Once a month Once a month
Greater than 1 month Greater than 1 month
Other, please specify

Other, please specify 

 
21.  During the third month of treatment, check the most appropriate timeline you use, on average, to 
monitor outpatient children and/or adolescents taking an antidepressant for MDD? 
 
Children (5-12 years) Adolescents (13-18 years) 
Two times per week Two times per week
Once a week Once a week
Every 2 weeks Every 2 weeks
Every 3 weeks Every 3 weeks
Once a month Once a month
Greater than 1 month Greater than 1 month
Other, please specify 

Other, please specify 

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Section 7:  Factors Influencing Whether or Not to Prescribe an Antidepressant  
 
22.  Please circle the number that best represents the extent to which the following factors influence your 
       decision of whether or not to prescribe an antidepressant to a newly diagnosed child or adolescent with    
       MDD, in an outpatient setting  (e.g. selecting an antidepressant versus some other type of treatment).    
Factor 
Not 
Influential  
Somewhat 
Influential  Influential  
Extremely 
Influential 
Advertisements to physicians via journals 
and/or mail 1 2 3 4 
Availability of patient education materials  1 2 3 4 
Clinical experience with prescribing 
antidepressants 1 2 3 4 
Co-existing conditions of patient (e.g. 
obsessive compulsive disorder) 1 2 3 4 
Comfort in managing MDD in youth 
1 2 3 4 
Direct-to-consumer advertising   1 2 3 4 
Drug efficacy  1 2 3 4 
Drug safety  1 2 3 4 
Face-to-face detailing by medical 
sciences liaison and/or pharmaceutical 
representatives  1 2 3 4 
Familiarity with an antidepressant being 
prescribed  1 2 3 4 
FDA approved  1 2 3 4 
Formulary inclusion  1 2 3 4 
Frequency of dosing  1 2 3 4 
Generic form of drug available  1 2 3 4 
Manufacturer provides free drugs to 
indigent patients  1 2 3 4 
Medication cost  1 2 3 4 
Monitoring requirements 1 2 3 4 
Parents’ education level  
1 2 3 4 
Parental use of antidepressants  1 2 3 4 
Patient's ability to perform daily activities  1 2 3 4 
Patient's age  1 2 3 4 
Patient's family income  1 2 3 4 
Patient's gender 1 2 3 4 
Patient's insurance  1 2 3 4 
Potential adverse effects  1 2 3 4 
Sample drugs available  1 2 3 4 
Severity of MDD symptoms  1 2 3 4 
Suicidal thinking  1 2 3 4 
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Section 8:  Demographic Information 
 
23. Please indicate your gender:      
        Male   
        Female  
 
24.  Please indicate your age-group:  
        30 years or younger 
        31 to 40 years  
        41 to 50 years 
        51 to 60 years 
        61 years and older 
 
25. Year of graduation from medical school:  __________ 
 
26. Your primary practice site: 
       Hospital based: non-university-affiliated 
       Hospital based: university-affiliated  
       Private practice: solo, office-based 
       Private practice: group, office-based 
       Other, please specify _______________ 
 
27.  In which state is your primary practice site located?     __________  
 
28.  Check the population of the community where your primary practice site is located? 
          Less than 10,000   
           10,000 -   24,999   
           25,000 -   49,999   
           50,000 -.  99,999   
         100,000 - 249,999 
         250,000 - 499,999 
         500,000 - 999,999      
           1 million or more                 
 
29.  Please check all of your practice specialties: 
         Adult psychiatry 
         Child & adolescent psychiatry 
         Family practice  
         General practice 
         Pediatrics 
         Other, please specify _____________  
 
30.  Please check all of your board certifications: 
         Adult psychiatry 
         Child & adolescent psychiatry 
         Family practice  
         General practice 
         Pediatrics 
         Not board certified 
         Other, please specify _____________  
 
31.  Average number of children (5 – 12 years) with MDD seen in your office.  _________ per week 
 
32.  Average number of adolescents (13 – 18 years) with MDD seen in your office. ______ per week 
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33.  How long have you treated children and/or adolescents? 
         One year or less 
         Greater than one year to five years  
         Greater than five years to 10 years 
         Greater than 10 years 
 
34. Check all reasons that influence your choice of treatment for children and/or adolescents with MDD.   
       Results of randomized clinical trials 
       Results of pilot studies, chart reviews, case studies, letters to the editor 
       Own clinical experience  
       Clinical experience of colleagues 
       Other, please specify ____________________ 
 
35.  Are you aware of the U.S. FDA black box warning for antidepressant medication for children and/or 
       adolescents?    
          Yes                                  
           No 
 
36.  Has the U.S. FDA black box warning had any impact on your decision-making about treatment of 
       children and/or adolescents with MDD? 
          Yes (Go to Question 37)        
           No 
 
                                                                                               
 
 
 
 
 
 
 
 
 
 
 
 
Comments :  Please use this space to provide additional comments. 
 
 
 
 
 
 
 
 
 
 
 
 
THANK YOU FOR YOUR TIME AND ASSISTANCE!  
 
 
37.  Please describe any major changes you have made in 
the treatment of MDD in children and/or adolescents as a 
result of the FDA black box warning.   
______________________________________________________
______________________________________________________
______________________________________________________ 
______________________________________________________
______________________________________________________ 
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APPENDIX C 
Physician Prescribing Behavior and Factors Related to Antidepressant Prescribing to 
Children and Adolescents with Major Depressive Disorder (MDD) 
 
Instructions:  This survey is designed to determine 1) your first, second, and third-lines of 
treatment for outpatient children and/or adolescents who have been diagnosed with MDD, 2) the 
type and length of pharmacotherapy monitoring you conduct, and 3) the factors that influence your 
decision to prescribe an antidepressant.  The survey is divided into six sections.   
For this survey, the definition of major depressive disorder is a condition that is “manifested by 
a combination of symptoms that interfere with the ability to work, study, sleep, eat, and enjoy once 
pleasurable activities“(NIMH, 2007).  MDD can be diagnosed using the criteria set forth by the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR).  In the scientific literature, 
children are typically defined as being 5 through 12 years of age while adolescents are 13 through 
18 years old.  This survey will utilize these definitions of age for both children and adolescents.  
 
Reference: National Institute of Mental Health. (2007). Retrieved October 15, 2007, from  
http://www.nimh.nih.gov/health/publications/depression/what-is-a-depressive-disorder.shtml. 
 
Section 1:  Treatment versus Referral of Outpatient Children and Adolescents 
 with Major Depressive Disorder (MDD)   
 
 
1.  Please check all age group(s) whom you treat for MDD. 
        Children (5 – 12 years old) 
        Adolescents  (13 – 18 years old)  
        Do not treat 
 
2.  Please check the age group(s) of patients you refer for the treatment of MDD and indicate the type of   
     health care provider to whom you refer these patients. 
        Refer children (5 - 12 years) to  ___________________________________. 
        Refer adolescents (13 - 18 years) to  _______________________________. 
        Do not refer 
 
3.  Please indicate the youngest patient (under 13 years of age) with MDD to whom you would consider  
     prescribing an antidepressant medication.  
        1 – 4 years 
        5 – 7 years 
        8 – 10 years 
        11 – 12 years 
        Do not prescribe for children less than 13 years  
 
 
Section 2:  Preferred Outpatient Treatment  
 
4. Check your first-line of outpatient treatment, for children and/or adolescents who have been newly 
    diagnosed with MDD. 
Children (5-12 years) Adolescents (13-18 years) 
   Do not treat    Do not treat 
   Antidepressants    Antidepressants 
   Counseling/psychotherapy    Counseling/psychotherapy 
   Both antidepressant and   
     Counseling/psychotherapy 
   Both antidepressant and  
     counseling/psychotherapy 
   Other, please specify 
 
   Other, please specify  
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5. Check ALL reasons, why this would be your first choice for treatment   
 Results of randomized clinical trials 
 Results of pilot studies, chart reviews, case studies, letters to the editor 
 Own clinical experience  
 Clinical experience of colleagues 
 Other, please specify ____________________ 
 
6. Check the ONE antidepressant (either alone or in combination with counseling/psychotherapy) you would     
      most commonly select as a typical first-line outpatient antidepressant treatment for a child (5-12 years old)  
      and/or adolescent (13-18 years old) newly diagnosed with MDD?  
 
Child (5-12 years) Adolescent (13-18 years) 
   Celexa
®
   (citalopram HBr)    Celexa
®
   (citalopram HBr)
   Cymbalta
®
  (duloxetine HCl)     Cymbalta
®
  (duloxetine HCl) 
   Effexor
®
  (venlafaxine HCl)       Effexor
®
  (venlafaxine HCl)   
   Elavil
®
  (amitriptyline HCl)       Elavil
®
  (amitriptyline HCl)   
   Desyrel
®
  (trazodone HCl)              Desyrel
®
  (trazodone HCl)          
   Lexapro
®
  (escitalopram oxalate)    Lexapro
®
  (escitalopram oxalate)
   Luvox 
®
 (fluvoxamine maleate)        Luvox 
®
 (fluvoxamine maleate)  
   Nardil
®
  (phenelzine sulfate)      Nardil
®
  (phenelzine sulfate)  
   Norpramin
®
  (desipramine HCl)      Norpramin
®
  (desipramine HCl)  
   Pamelor
®
  (nortriptyline HCl)          Pamelor
®
  (nortriptyline HCl)      
   Paxil
®
  (paroxetine HCl)               Paxil
®
  (paroxetine HCl)           
   Parnate
®
  (tranlcypromine sulfate)     Parnate
®
  (tranlcypromine sulfate) 
   Prozac
®
  (fluoxetine HCl)             Prozac
®
  (fluoxetine HCl)         
   Remeron
®
  (mirtazpine)                 Remeron
®
  (mirtazpine)             
   Serzone
®
  (nefazodone HCl)           Serzone
®
  (nefazodone HCl)       
   Tofranil
®
  (imipramine HCl)           Tofranil
®
  (imipramine HCl)       
   Wellbutrin
®
  (buproprion HCl)               Wellbutrin®  (buproprion HCl)           
   Zoloft
®
  (sertraline HCl)                  Zoloft
®
  (sertraline HCl)              
   Other, please specify 
 
   Other, please specify
 
7.  For the first-line antidepressant(s) selected above, please indicate the standard total daily starting dosage  
     and the standard maximum total daily dosage you use for an outpatient child and/or adolescent with MDD.  
  
Drug Dosage Child (5-12 years) Adolescent (13-18 years) 
Starting dosage 
(mg/day) _______________mg              _______________mg     
Maximum dosage 
(mg/day) _______________mg              _______________mg 
 
8.  If antidepressant therapy is successful, how long do you continue prescribing the antidepressant(s) 
     to the newly diagnosed outpatient child and/or adolescent? (Check one) 
 Child (5-12 years) Adolescent (13-18 years)  
       1-3  months        1-3  months
       4-6  months        4-6  months
       7-9  months        7-9  months
10-12 months 10-12 months
      > 12 months       > 12 months
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9.  If there is no improvement in the depressive symptoms of the child and/or adolescent, after reaching the  
     antidepressant’s tolerated maximum prescribed dosage (assuming no adverse events), how long do you 
     continue to prescribe the drug before considering another treatment approach? (Check one) 
 
Child (5-12 years) Adolescent (13-18 years) 
   < 2  weeks    < 2  weeks
2 – 4  weeks 2 – 4  weeks
5 – 6  weeks 5 – 6  weeks
7 – 8  weeks 7 – 8  weeks
9 –10 weeks 9 –10 weeks
> 10 weeks > 10 weeks
 
10.  If there is no improvement in depressive symptoms with the first-line antidepressant, what would you 
typically prescribe as your next step in outpatient treatment for this child and/or adolescent? (Check one) 
 
Child (5-12 years) Adolescent (13-18 years)  
Augment antidepressant therapy Augment antidepressant therapy
Switch to a different antidepressant Switch to a different antidepressant
Augment with counseling/psychotherapy Augment with counseling/psychotherapy
Other treatment, please specify 

Other treatment, please specify 

 
11.  If you indicated above that you would augment antidepressant therapy or switch to a different 
antidepressant, what would you typically prescribe as your second-line of antidepressant treatment for 
this child and/or adolescent?  
 
 Child (5-12 years) Adolescent (13-18 years) 
2
nd
-Line 
Antidepressant _______________              _______________     
 
12.  If there is no improvement in depressive symptoms with the second-line antidepressant, what would you 
       typically prescribe as your third-line of antidepressant treatment for this child and/or adolescent?  
  
 Child (5-12 years) Adolescent (13-18 years) 
3
rd
-Line 
Antidepressant _______________              _______________     
 
 
Section 3:  Counseling/Psychotherapy   
 
         13.  If you believe the child and/or adolescent should have counseling/psychotherapy, would you refer to a 
               counselor or psychotherapist or conduct the counseling/psychotherapy yourself? (Check one)   
        Refer the child and/or adolescent to ________________________________ 
        Conduct my own therapy  
        Do not utilize counseling/psychotherapy 
 
14.  If you refer a child and/or adolescent with MDD for counseling/psychotherapy treatment, please 
       indicate how far, in approximate miles, the patient would have to travel to visit a  
       counselor/psychotherapist.   ____________________ Miles                  
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15.  What type of counseling/psychotherapy, would you most likely recommend/utilize? (Check all that  
apply)    
 
Children (5-12 years) Adolescents (13-18 years) 
Cognitive behavioral therapy Cognitive behavioral therapy
Family therapy Family therapy
Interpersonal therapy Interpersonal therapy
Patient education Patient education
Play therapy Play therapy
Supportive counseling Supportive counseling
Do not utilize counseling/psychotherapy Do not utilize counseling/psychotherapy 
Other, Please Specify 
 
Other, Please Specify 
 
 
Section 4:  Pharmacotherapy Monitoring of Outpatient Children and Adolescents 
 
16.  Check the primary mode of monitoring outpatient children and/or adolescents who are receiving an 
       antidepressant for MDD?  
 
Children (5-12 years) Adolescents (13-18 years) 
Individual patient office visit Individual patient office visit
Telephone contact Telephone contact
Patient medication group Patient medication group
Other, please specify 

Other, please specify 

 
17. Check the primary type of health care provider who conducts the monitoring?  
  
Children (5-12 years) Adolescents (13-18 years) 
Physician Physician
Nurse Nurse
Counselor/Psychotherapist  Counselor/Psychotherapist 
Pharmacist Pharmacist
Other, please specify 

Other, please specify 

 
18.  Check ALL types of monitoring conducted for outpatient children and/or adolescents taking an 
       antidepressant for MDD? 
 
Children (5-12 years) Adolescents (13-18 years) 
Monitor for adverse events Monitor for adverse events
Monitor for suicidality Monitor for suicidality
Conduct labwork  Conduct labwork 
Monitor clinical symptoms (e.g. sleep, 
       appetite, energy, activities) 
Monitor clinical symptoms (e.g. sleep, 
      appetite, energy, activities) 
Other, please specify Other, please specify
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19.  During the first month of treatment, check the most appropriate timeline you use, on average, to 
monitor outpatient children and/or adolescents taking an antidepressant for MDD? 
 
Children (5-12 years) Adolescents (13-18 years) 
Two times per week Two times per week
Once a week Once a week
Every 2 weeks Every 2 weeks
Every 3 weeks Every 3 weeks
Once a month Once a month
Greater than 1 month Greater than 1 month 
Other, please specify 

Other, please specify 

 
20.  During the second month of treatment, check the most appropriate timeline you use, on average, to 
monitor outpatient children and/or adolescents taking an antidepressant for MDD? 
 
Children (5-12 years) Adolescents (13-18 years) 
Two times per week Two times per week
Once a week Once a week
Every 2 weeks Every 2 weeks
Every 3 weeks Every 3 weeks
Once a month Once a month
Greater than 1 month Greater than 1 month
Other, please specify

Other, please specify 

 
21.  During the third month of treatment, check the most appropriate timeline you use, on average, to 
monitor outpatient children and/or adolescents taking an antidepressant for MDD? 
 
Children (5-12 years) Adolescents (13-18 years) 
Two times per week Two times per week
Once a week Once a week
Every 2 weeks Every 2 weeks
Every 3 weeks Every 3 weeks
Once a month Once a month
Greater than 1 month Greater than 1 month
Other, please specify 

Other, please specify 

 
 
 
 
 
 
 
 
Please continue to the next page
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Section 5:  Factors Influencing Your Decisions to Prescribe  
 
22.  Please circle the number that best represents the extent to which the following factors influence your 
      decision of whether or not to prescribe an antidepressant to a newly diagnosed child or adolescent with 
MDD, in an outpatient setting  (e.g. selecting an antidepressant versus some other type of treatment).    
  
 
Factor 
Not 
Influential  
Somewhat 
Influential  Influential  
Extremely 
Influential 
Advertisements to physicians via journals 
and/or mail 1 2 3 4 
Availability of patient education materials  1 2 3 4 
Clinical experience with prescribing 
antidepressants 1 2 3 4 
Co-existing conditions of patient (e.g. 
obsessive compulsive disorder) 1 2 3 4 
Comfort in managing MDD in youth 1 2 3 4 
Direct-to-consumer advertising   1 2 3 4 
Drug efficacy  1 2 3 4 
Drug safety  1 2 3 4 
Face-to-face detailing by medical 
sciences liaison and/or pharmaceutical 
representatives  1 2 3 4 
Familiarity with an antidepressant being 
prescribed  1 2 3 4 
FDA approved  1 2 3 4 
Formulary inclusion  1 2 3 4 
Frequency of dosing  1 2 3 4 
Generic form of drug available  1 2 3 4 
Manufacturer provides free drugs to 
indigent patients  1 2 3 4 
Medication cost  1 2 3 4 
Monitoring requirements 1 2 3 4 
Parents’ education level  1 2 3 4 
Parental use of antidepressants  1 2 3 4 
Patient's ability to perform daily activities  1 2 3 4 
Patient's age  1 2 3 4 
Patient's family income  1 2 3 4 
Patient's gender 1 2 3 4 
Patient's insurance  1 2 3 4 
Potential adverse effects  1 2 3 4 
Sample drugs available  1 2 3 4 
Severity of MDD symptoms  1 2 3 4 
Suicidal thinking  1 2 3 4 
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Section 6:  Demographic Information 
 
23. Please indicate your gender:      
        Male   
        Female  
 
24.  Please indicate your age-group:  
        30 years or younger 
        31 to 40 years  
        41 to 50 years 
        51 to 60 years 
        61 years and older 
 
25. Year of graduation from medical school:  __________ 
 
26. Your primary practice site: 
       Hospital based: non-university-affiliated 
       Hospital based: university-affiliated  
       Private practice: solo, office-based 
       Private practice: group, office-based 
       Other, please specify _______________ 
 
27.  In which state is your primary practice site located?     __________  
 
28.  Check the population of the community where your primary practice site is located? 
          Less than 10,000   
           10,000 -   24,999   
           25,000 -   49,999   
           50,000 -.  99,999   
         100,000 - 249,999 
         250,000 - 500,000 
         500,000 - 999,999      
           1 million or more                 
 
29.  Please check all of your practice specialties: 
         Adult psychiatry 
         Child & adolescent psychiatry 
         Family practice  
         General practice 
         Pediatrics 
         Other, please specify _____________  
 
30.  Please check all of your board certifications: 
         Adult psychiatry 
         Child & adolescent psychiatry 
         Family practice  
         General practice 
         Pediatrics 
         Not board certified 
         Other, please specify _____________  
 
31.  Average number of children (5 – 12 years) with MDD seen in your office.  _________ per week 
 
32.  Average number of adolescents (13 – 18 years) with MDD seen in your office. ______ per week 
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33.  How long have you treated children and/or adolescents? 
         One year or less 
         Greater than one year to five years  
         Greater than five years to 10 years 
         Greater than 10 years 
 
34.  Are you aware of the U.S. FDA black box warning for antidepressant medication for children and/or 
       adolescents?    
          Yes                                  
           No 
 
35.  Has the U.S. FDA black box warning had any impact on your decision-making about treatment of 
       children and/or adolescents with MDD? 
          Yes (Go to Question 36)        
           No 
 
                                                                                               
 
 
 
 
 
 
 
 
 
 
 
 
Comments :  Please use this space to provide additional comments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THANK YOU FOR YOUR TIME AND ASSISTANCE!  
 
 
 
36.  Please describe any major changes you have made in 
the treatment of MDD in children and/or adolescents as a 
result of the FDA black box warning.   
______________________________________________________
______________________________________________________
______________________________________________________ 
______________________________________________________
______________________________________________________ 
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APPENDIX D 
                                                                                                                   November 26, 2007 
     
                                                                                                                      
Dear Physician: 
 
     My name is Andrea Pfalzgraf, a Doctoral Candidate in the Department of Pharmaceutical 
Systems and Policy at West Virginia University (WVU) School of Pharmacy.  My dissertation 
consists of conducting a national survey of pediatricians and child psychiatrists who may be 
involved in treating children and/or adolescents with major depressive disorder in an outpatient 
setting.  This research study is designed to examine the prescribing behavior and the factors that 
influence the prescribing behavior of antidepressant medication to children and adolescents with 
major depressive disorder.  The enclosed survey is designed to identify physicians who treat children 
and adolescents with major depressive disorder and who would be willing to participate in the study.     
     The enclosed questionnaire will take only a few minutes to complete.  Your participation is 
voluntary and you are not required to answer every question in the survey.  Your responses will be 
kept as confidential as legally possible and will be analyzed and reported in aggregate form.  .   
     If you choose to participate, please complete the survey and mail in the enclosed business reply 
envelope.  Any questions related to the questionnaire may be directed to Andrea Pfalzgraf, 412-225-
6845 or Dr. Ginger Scott at 304-293-1553.  Thank you in advance for your valuable time and 
information.  
 
 
Sincerely, 
 
 
 
Andrea Pfalzgraf, MPH                                                      Virginia (Ginger) Scott, PhD, MS, RPh 
Doctoral Candidate                                                              Professor and Advisor 
 
 
 
                                                                                                WVU IRB reviewed and acknowledged
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APPENDIX E 
 
                                                                                                                             January 10, 2008 
     
                                                                                                                      
Dear Physician: 
 
     My name is Andrea Pfalzgraf, a Doctoral Candidate in the Department of Pharmaceutical 
Systems and Policy at West Virginia University (WVU) School of Pharmacy.  My dissertation 
consists of conducting a national survey of pediatricians and child psychiatrists who may be 
involved in treating children and/or adolescents with major depressive disorder in an outpatient 
setting.  This research study is designed to examine the prescribing behavior and the factors that 
influence the prescribing behavior of antidepressant medication to children and adolescents with 
major depressive disorder.   
     The enclosed questionnaire will take less than ten minutes to complete.  Your participation is 
voluntary and you are not required to answer every question in the survey.  However, your input is 
essential to determine antidepressant prescribing behavior of physicians and the factors that 
influence the prescribing behavior of physicians in children and adolescents with major depressive 
disorder in an outpatient setting.  Your responses will be kept as confidential as legally possible and 
will be analyzed and reported in aggregate form.   
     If you choose to participate, please complete the survey and mail in the enclosed business reply 
envelope.  Any questions related to the questionnaire may be directed to Andrea Pfalzgraf, 412-225-
6845 or Dr. Ginger Scott at 304-293-1553.  Thank you in advance for your valuable time and 
information.     
 
Sincerely, 
 
 
 
Andrea Pfalzgraf, MPH                                                       Virginia (Ginger) Scott, PhD, MS, RPh 
Doctoral Candidate                                                              Professor and Advisor 
 
 
                                                                                        WVU IRB reviewed and acknowledged
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APPENDIX F 
 
 
                                                                                                                               January 10, 2008 
     
                                                                                                                      
Dear Physician: 
 
     Recently you indicated you would be willing to participate in a survey that is an integral part of 
my dissertation, as a Doctoral Candidate in the Department of Pharmaceutical Systems and Policy at 
West Virginia University (WVU) School of Pharmacy.  My dissertation consists of conducting a 
national survey of pediatricians and child psychiatrists who may be involved in treating children 
and/or adolescents with major depressive disorder in an outpatient setting.  This research study is 
designed to examine the prescribing behavior and the factors that influence the prescribing behavior 
of antidepressant medication to children and adolescents with major depressive disorder.   
     The enclosed questionnaire will take less than ten minutes to complete.  Your participation is 
voluntary and you are not required to answer every question in the survey.  However, your input is 
essential to determine antidepressant prescribing behavior of physicians and the factors that 
influence the prescribing behavior of physicians in children and adolescents with major depressive 
disorder in an outpatient setting.  Your responses will be kept as confidential as legally possible and 
will be analyzed and reported in aggregate form.   
     Thank you for volunteering to participate in this study.  Please complete the survey and mail in 
the enclosed business reply envelope.  Any questions related to the questionnaire may be directed to 
Andrea Pfalzgraf, 412-225-6845 or Dr. Ginger Scott at 304-293-1553.  Thank you in advance for 
your valuable time and information.     
 
 
Sincerely, 
 
 
 
Andrea Pfalzgraf, MPH                                                  Virginia (Ginger) Scott, PhD, MS, RPh 
Doctoral Candidate                                                          Professor and Advisor 
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